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Microglia are the innate immune cells of the central nervous system (CNS). They are capable of sens-
ing infection and damage through various receptors and consequently trigger an appropriate immune
response. This includes the production of several cytokines and chemokines that modulate immune
functions and can lead to the recruitment of peripheral immune cells into the CNS. Among these, the
neutrophil chemoattractant CXCL1 and the monocyte chemoattractant CCL2 are released in response
to activation of Toll-like receptors (TLRs) as sensors of highly conserved structures on foreign as well
as host molecules. Apart from that, microglia have been demonstrated to secrete interferons (IFNs),
which are crucial cytokines for fighting viral and also bacterial infections.
Here we show that the production of type I interferons can be induced by activation of microglial TLRs. In
response to double-stranded RNA associated with viral infections detected by TLR3, microglia are able
to produce IFNα as well as IFNβ. Furthermore, activation of TLR4 by bacterial ligands and damage-
related factors triggers IFNβ release. In contrast to that, bacterial ligands of TLR2 fail to induce any type
I interferon. These differences in interferon production can be attributed to the differential involvement
of the major TLR signaling routes. We demonstrate that the release of IFNβ exclusively depends on
the presence of the TIR-domain-containing adapter-inducing IFNβ (TRIF), which is only recruited upon
activation of TLR3 and TLR4. Within the TLR4 system, TRIF-dependent signaling further requires the
TLR4 co-receptor CD14 and accordingly, we could show that CD14 enables IFNβ production.
Following their release, type I interferons exert a variety of functions. In addition to their role in host
defenses against infections, several immunomodulatory effects have been identified, which can be ei-
ther beneficial or detrimental depending on the disease context. Here we show, how IFNβ differentially
regulates microglial responses to CNS infection and damage. We demonstrate that the production of
CXCL1 and CCL2 in response to TLR activation is controlled by an IFNβ-mediated feedback mecha-
nism. While CCL2 is positively regulated, CXCL1 is under negative control of type I interferon signaling.
This mechanism is individually organized within different TLR systems. In response to TLR4 activation,
both subunits of the interferon-α/β receptor (IFNAR) cooperatively regulate chemokine production. This
effect is mediated by the canonical type I interferon signaling pathway, which includes janus kinases and
the signal transducer and activator of transcription (STAT)1 and STAT2. In contrast to that, only IFNAR1
and IFNAR2 regulate TLR2-induced chemokine production independent of downstream components of
the canonical type I interferon signaling pathway.
These different regulatory mechanisms of chemokine production also translate into in vivo control of
immune cell infiltration during CNS infection. In a model of gram-negative meningitis, we demonstrate
protective effects of IFNAR1 by prevention of excessive neutrophil infiltration into the brain. This cor-
relates with the IFNβ-mediated negative control of microglial CXCL1 production. In contrast to that,
neutrophil infiltration in models of gram-positive meningitis and the autoimmune disease neuromyelitis
optica is not controlled by type I interferon signaling. This underlines that immunomodulatory effects of
type I interferons are very specific and highlights the importance of understanding their mode of action.
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1. Introduction
1.1 Inflammation and innate immunity
The immune system is a complex biological system that exists to protect the host against a large variety
of different diseases. In vertebrates, it can be classified into innate and adaptive immunity. The innate
immunity enables a rapid response to several pathogens in a generic way. However, it lacks the ability of
the adaptive immunity to specifically recognize a particular pathogen and provide long-lasting, protective
memory for preventing reinfection. In response to harmful threats, such as infectious agents or tissue
damage, inflammation is one of the first reactions of the immune system. The major functions of this
complex process are elimination of the threat, clearance of the damaged tissue and initiation of tissue
repair. It is part of the non-specific immune response mounted by the innate immune system.
The first line of defense against pathogens are anatomical barriers that protect from invading bacteria,
viruses or parasites. Pathogens that overcome these barriers, immediately face tissue macrophages,
which act as sentinel cells that initiate an inflammatory response. This is accompanied by the pro-
duction of several soluble mediators of inflammation, such as vasoactive proteins, complement factors,
cytokines, chemokines and lipid inflammatory mediators. As a first step, the diameter of surrounding
blood vessels is increased leading to a slower blood flow. In combination with the induced expression
of adhesion molecules this allows the attachment of leukocytes to the endothelium and their migration
into the tissue. The last major change is an increase in blood vessel permeability resulting in exudation
of fluid and plasma proteins into the tissue (Janeway et al. 2001).
Once inflammation has begun, neutrophils are the first cells rapidly attracted to the site of infection or
damage. Neutrophils are the most abundant immune cell type and have a very short lifespan (Summers
et al. 2010). They are produced in the bone marrow and released into the blood stream in response
to inflammation. Their egress from the bone marrow and migration towards the site of inflammation is
controlled by the granulocyte-colony stimulating factor (G-CSF) (Semerad et al. 2002) and chemokine
(C-X-C motif) ligand (CXCL) 1 and CXCL2, the two ligands of chemokine (C-X-C motif) receptor (CXCR)
2 (Burdon et al. 2008; Wengner et al. 2008). The subsequent recruitment into the inflamed tissue
involves the following steps: tethering, slow rolling, adhesion strengthening and spreading, intravascular
crawling and paracellular or transcellular transmigration (Ley et al. 2007). Once neutrophils passed
through the endothelium, they migrate towards the inflammatory site along chemotactic gradients and
directly attack pathogens.
Neutrophils have different methods for pathogen elimination. After they encounter microorganisms, neu-
trophils phagocytose and destroy them intracellularly by NADPH oxygenase-dependent mechanisms or
different antibacterial proteins, such as cathepsins, defensins, lactoferrin and lysozyme. These antibac-
terial proteins can also be released into the extracellular milieu in a process called degranulation in order
to target the pathogens directly (Kolaczkowska and Kubes 2013). Furthermore, neutrophils can cause
the release of neutrophil extracellular traps (NETs), which contain DNA and several proteins, such as
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neutrophil elastase, cathepsin G or lactoferrin. NETs associate with pathogens, preventing them from
spreading and enabling their degradation through antimicrobial agents (Brinkmann et al. 2004).
In addition to fighting pathogens themselves, neutrophils recruit and activate other immune cells. Fol-
lowing their extravasation to the site of inflammation, they subsequently induce emigration of monocytes
from the bone marrow (Soehnlein et al. 2009). Even though monocytes are also produced in the bone
marrow, they are released as non-differentiated cells that circulate in the blood for 1-3 days (van Furth
and Cohn 1968). Chemotactic gradients of chemokine (C-C motif) ligand (CCL) 2 and CCL7, which are
recognized by the chemokine (C-C motif) receptor (CCR) 2, guide the monocytes to the inflamed tissue
(Tsou et al. 2007). Monocyte extravasation is then realized in the same way as for neutrophils. Once
they reach the tissue, they can differentiate into macrophages or myeloid dendritic cells (Warren and
Vogel 1985; Zhou and Tedder 1996).
Monocytes and their progenies macrophages and dendritic cells serve important functions in fighting
pathogens. They are able to phagocytose various materials and produce a large variety of inflammatory
and immunoregulatory cytokines and chemokines (Kantari et al. 2008). Furthermore, they can present
antigens on major histocompatibility complex (MHC) class II molecules in order initiate a response of
the adaptive immune system specific to the respective antigens by activation of T cells (Randolph et al.
2008).
According to the expression of distinct cell surface receptors, three subtypes of monocytes can be
distinguished. In mice, these are classical Ly6C++ CD43+ monocytes, intermediate Ly6C++ CD43++
monocytes and non-classical Ly6C+ CD43++ monocytes, which can be further characterized by their
expression levels of CCR2 and CX3CR1 (Ziegler-Heitbrock et al. 2010). Classical murine monocytes
are also referred to as inflammatory monocytes, because they are found in inflamed tissue, where
they can trigger immune responses (Geissmann et al. 2003). In contrast to that, non-classical murine
monocytes are also termed patrolling monocytes because of their ability to patrol along blood vessels
in healthy tissue (Auffray et al. 2007) and under inflammatory conditions (Imhof et al. 2016). In humans,
monocyte subtypes are classified according to the expression of CD14 and CD16 (Ziegler-Heitbrock
et al. 2010).
After removal of the infectious agents by the immune cells, the inflammatory reaction needs to be
terminated in order to protect from tissue damage and prevent chronicity. The resolution of inflammation
includes anti-inflammatory and pro-resolving responses (Serhan 2010). Initiation of the termination is
triggered by a switch in secretion of lipid mediators leading to retarded entry of new neutrophils to
sites of inflammation (Serhan et al. 1995) and reduced vascular permeability (Takano et al. 1998).
The neutrophils undergo apoptosis and are then phagocytosed by macrophages (Savill et al. 1989).
Afterwards, macrophages egress from the inflamed tissue to the draining lymph nodes (Bellingan et al.
1996). Although the recruitment of monocytes and neutrophils is essential during infection, they might
also have detrimental effects in unresolved, chronic inflammation. The production of reactive oxygen
species, proteases and growth factors can lead to tissue destruction as well as excessive fibroblast
proliferation and aberrant collagen accumulation resulting in fibrosis (Chen and Nuñez 2010). Therefore,
inflammatory reactions need to be kept under tight control.
1.2 Microglia as innate immune cells of the CNS
Tissue-resident macrophages are an important part of the innate immune system. They serve several
immune sentinel and homeostatic functions according to their specific location. Their diverse phe-
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notypes, which determine their pro- and anti-inflammatory functions, are mainly controlled by the re-
spective tissue environment (Davies and Taylor 2015). There exist a lot of different tissue-resident
macrophages, such as osteoclasts in the bone, Kupffer cells in the liver, alveolar macrophages in the
lung, peritoneal macrophages in serosal tissues or Langerhans cells in the skin (Davies et al. 2013).
Within the central nervous system (CNS), non-parenchymal perivascular, meningeal and choroid plexus
macrophages as well as parenchymal microglia are present (Ransohoff and Cardona 2010).
Microglia are a type of glial cells that are generally considered as the immune cells of the CNS. Ac-
cording to their morphology, they have been first described as microglia by Pı́o del Rı́o-Hortega in 1919
(del Rı́o-Hortega 1919). Within the brain, microglia comprise 5-12% of all cells, depending on their loca-
tion (Lawson et al. 1990). In contrast to other macrophages, microglia do not derive from the definitive
haematopoiesis, but from primitive myeloid progenitors that arise before embryonic day 8 in the yolk sac
of mice (Ginhoux et al. 2010). This process is independent of the transcription factor Myb, which is im-
portant for the definitive haematopoiesis (Schulz et al. 2012), but rather depends on Pu.1 and interferon
regulatory factor (IRF) 8 (Kierdorf et al. 2013). However, a minor non-yolk sac contribution to the origin
of adult microglia was suggested recently (Xu et al. 2015). During adulthood, microglial numbers are
sustained by local self-renewal (Ajami et al. 2007) through proliferation of local progenitor cells (Elmore
et al. 2014).
The role of microglia in inflammatory conditions and neuropathological disorders was for a long time
associated with detrimental actions and failure of protection. However, they also have many beneficial
functions (Hanisch and Kettenmann 2007). Microglia are neuroprotective after ischemic injury (Neu-
mann et al. 2006) and restrict the damage in acute brain injury by attenuating excitotoxicity (Simard and
Rivest 2007). Furthermore, they provide growth factors that positively affect the efficiency of remyelina-
tion in a mouse model of toxic demyelination (Kotter et al. 2005). Most likely, excessive acute, chronic
or maladaptive microglial responses exacerbate damage, while physiological responses are beneficial
and protective (Hanisch and Kettenmann 2007).
Under homeostatic conditions, microglia constantly scan their environment in order to detect even slight
disturbances. This constant tissue surveillance is realized by their extremely motile, highly ramified
processes and protrusions that shape microglial morphology (Nimmerjahn et al. 2005). With their fine
processes, microglia actively participate in remodeling synaptic circuits as they monitor the functional
state of synapses and can lead to their modification or removal (Wake et al. 2009; Tremblay et al.
2010). During postnatal development, microglia also serve important functions in synaptic maturation
as they actively engulf synaptic material and therefore are important for synaptic pruning (Paolicelli
et al. 2011). Defective synaptic pruning has far-reaching consequences as its impairment can lead to
decreased functional brain connectivity and therefore to deficits in social behavior (Zhan et al. 2014).
Apart from affecting behavior (Chen et al. 2010), microglia also influence learning processes (Ziv et al.
2006; Parkhurst et al. 2013) and participate in oligodendrogenesis (Butovsky et al. 2006) and neuroge-
nesis (Walton et al. 2006; Sierra et al. 2010).
Under pathological conditions, microglia can commit to distinct reactive phenotypes depending on the
type of challenge. Sudden encounter or changes in a range of molecules can be interpreted as a sign
of infection or injury (Hanisch and Kettenmann 2007). Shifting to an activated state goes along with
drastic morphological changes that lead to a rounded, amoeboid shape of the cells (Kettenmann et al.
2011). These activated microglia can migrate to the site of infection or injury following chemotactic
gradients of other microglia or immune cells (Yao et al. 1990; Honda et al. 2001). Once at the site
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of the inflammation, microglia execute diverse functions. As the tissue-resident macrophages of the
CNS, they are able to phagocytose various materials. This includes infectious agents and endogenous
material, such as pathological proteins, apoptotic cells and cellular debris (Garden and Möller 2006).
Furthermore, microglia have been shown to participate in clearance of myelin, which plays a role in
damaged CNS tissue and autoimmune diseases, but also as a house-keeping function (Fitzner et al.
2011). In addition to their phagocytic capacity, microglia are able to fight pathogens by generating nitric
oxide and producing a respiratory burst (Banati et al. 1993). Apart from that, they secrete a large variety
of other soluble factors, such as lipid inflammatory mediators (Minghetti and Levi 1998), cytokines and
chemokines (Hanisch 2002). These factors have a broad range of autocrine and paracrine effects. The
release of certain chemokines will attract additional microglia to the site of insult and recruit peripheral
immune cells to the CNS, if necessary (Aloisi 2001). In order to mount an adaptive immune response,
antigens need to be presented to T cells. Therefore, microglia can act as antigen-presenting cells on
demand by up-regulation of MHC class II and co-stimulatory molecules CD80 and CD86 (B7.1 and
B7.2) (Hayes et al. 1987; Xu and Ling 1994). Overall, microglia do not only serve as immune effector
cells themselves, but also coordinate the inflammatory response in the CNS.
1.3 Toll-like receptors
The innate immune system is capable of recognizing and rapidly responding to different types of threats.
For that purpose, a variety of pattern recognition receptors (PRRs) is expressed by cells of the innate
immunity. PRRs are germline-encoded receptors that evolved in order to detect pathogens by rec-
ognizing microbial conserved structural motifs, which are called pathogen-associated molecular pat-
terns (PAMPs) (Takeuchi and Akira 2010). Furthermore, PRRs are also able to sense endogenous
molecules that are linked to cell damage or death, called damage- or danger-associated molecular
patterns (DAMPs) (Matzinger 1994; Matzinger 2002; Kono and Rock 2008).
There exist different classes of PRRs, including Toll-like receptors (TLRs), C-type lectin receptors
(CLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), nucleotide-binding oligomerization
domain-containing protein (NOD)-like receptors (NLRs) and absent in melanoma 2 (AIM2)-like recep-
tors (ALRs) (Brubaker et al. 2015).
Toll-like receptors are named after the Drosophila toll gene, which was discovered in 1985 (Anderson
et al. 1985) and later on found to be involved in antifungal responses (Lemaitre et al. 1996). The human
homologue of the Drosophila toll protein was identified in 1997 and shown to function as a receptor that
controls the expression of several immune genes (Medzhitov et al. 1997).
To date, 10 TLRs have been described in humans (TLR1-10) and 12 in mice (TLR1-9 and TLR11-13)
(Takeuchi and Akira 2010). They recognize distinct molecular patterns of which the most important
ones are summarized in table 1.1. According to their respective ligand, the TLRs are differently local-
ized within the cell (Takeuchi and Akira 2010). TLR1, TLR2, TLR4, TLR5, TLR6, TLR11 can be found
at the cell surface, while TLR3, TLR7, TLR8, TLR9, TLR10, TLR12 (Raetz et al. 2013) and TLR13
(Shi et al. 2011) are located in intracellular compartments, such as endosomes. Upon ligand binding,
the receptors dimerize and mostly form homodimers. However, several heterodimer combinations have
been reported that lead to changes in ligand specificity. This includes TLR1/2 and TLR6/2 as classical




TLR Ligand Origin of ligand
TLR1 triacyl lipoprotein bacteria
TLR2 lipoprotein, HMGB1, HSPs, hyaluronan, bacteria, viruses,
biglycan, versican parasites, self
TLR3 dsRNA viruses
TLR4 LPS, HMGB1, HSPs, hyaluronan, biglycan, bacteria, viruses, self
heparan sulfate, fibrinogen1, fibronectin2
TLR5 flagellin bacteria
TLR6 diacyl lipoprotein bacteria, viruses
TLR7 (human TLR8) ssRNA viruses, bacteria, self
TLR9 CpG-DNA, mitochondrial DNA viruses, bacteria, protozoa, self
TLR10 unknown unknown
TLR11 profilin-like molecule protozoa
TLR12 profilin3 protozoa
TLR13 ribosomal RNA sequence4 virus, bacteria
Table 1.1: TLRs and their ligands adapted from Takeuchi and Akira (2010) and Chen and Nuñez (2010)
1Smiley et al. (2001), 2Okamura et al. (2001), 3Koblansky et al. (2013), 4Oldenburg et al. (2012)
All TLRs are transmembrane glycoproteins that contain an extracellular domain with leucine-rich repeat
motifs that is responsible for ligand binding, a transmembrane domain and an intracellular Toll/IL-1R
homology (TIR) domain that is necessary for signal transduction (Brubaker et al. 2015). Activation
of the receptor by ligand binding initiates the signaling cascade by recruitment of specific TIR domain-
containing adaptor proteins depending on the respective TLR. This family of proteins consists of myeloid
differentiation primary response gene 88 (MyD88), TIR domain-containing adaptor protein (TIRAP), TIR
domain-containing adaptor-inducing interferon-β (TRIF) and TRIF-related adaptor molecule (TRAM) as
well as sterile α- and armadillo-motif-containing protein (SARM) (O’Neill and Bowie 2007). In contrast to
the other four family members, SARM does not activate, but negatively regulates TLR signaling (Carty
et al. 2006).
A signaling pathway initiated by MyD88 is used by all TLRs, except TLR3. Following its association with
the respective TLR, MyD88 recruits interleukin 1 receptor-associated kinase (IRAK) 4, IRAK1, IRAK2
and IRAK-M (Kawai and Akira 2010). While IRAK-M acts only as a negative regulator (Kobayashi et
al. 2002), the other IRAKs participate in initiation of the TLR signaling. After the activation of IRAK4,
IRAK1 and IRAK2 are activated consequently (Li et al. 2002; Kawagoe et al. 2008). The IRAKs then
phosphorylate and thereby activate tumor necrosis factor (TNF) receptor associated factor (TRAF) 6.
TRAF6 is an E3 ubiquitin ligase that together with an E2 ubiquitin-conjugating enzyme complex com-
prising Ubc13 and Uev1A catalyzes polyubiquitination, which activates the transforming growth factor
β-activated kinase 1 (TAK1) complex (Wang et al. 2001). TAK1 then phosphorylates inhibitor of nuclear
factor kappa-B (IκB) kinase β (IKK-β), which results in nuclear factor kappa-B (NF-κB) activation. Fur-
thermore, TAK1 phosphorylates the mitogen activated protein kinase (MAPK) kinases 6 and 7, which
initiates the c-Jun N-terminal kinase (JNK) and p38 kinase pathway, followed by activation of activator
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protein 1 (AP-1) (Bhoj and Chen 2009). Finally, both transcription factors, NF-κB and AP-1, lead to the
induction of inflammatory genes, such as cytokines and chemokines.
In addition to the MyD88-dependent pathway, TLR3 and TLR4 use the adaptor protein TRIF for their
signaling. After recruitment of TRIF to the receptor, it activates the kinases receptor-interacting serine/
threonine-protein kinase 1 (RIPK1), TRAF family member-associated NF-κB activator-binding kinase
1 (TBK1) and IκB kinase ε (IKKε). RIPK1 causes a TRAF6/TAK1-dependent activation of NF-κB gene
transcription as described above (Takeuchi and Akira 2010). Additionally, TBK1 and IKKε phosphorylate
IRF3, which results in the production of type I interferons and chemokines, such as CCL5 (Fitzgerald
et al. 2003).
1.3.1 TLR4
TLR4, the first discovered TLR, was initially identified as the receptor recognizing lipopolysaccharide
(LPS) (Poltorak et al. 1998; Hoshino et al. 1999). LPS is a cell wall component of gram-negative
bacteria and comprises three different parts, lipid A, the core oligosaccharide and the O-antigen (also
O-polysaccharide) (Beutler and Rietschel 2003). Based on their structure, LPS can be classified in
different variants, also called chemotypes. Depending on the complexity of their carbohydrate moieties,
smooth (S) and rough (R) LPS chemotypes can be distinguished (Raetz and Whitfield 2002). If LPS
is liberated from bacteria during an infection, it associates with the LPS binding protein (LBP) in the
plasma and is then transferred to the TLR4 co-receptor CD14 (Wright et al. 1990). CD14 extracts
monomeric LPS molecules and presents them to a complex at the cell surface, consisting of TLR4 and
myeloid differentiation factor-2 (MD-2) (Shimazu et al. 1999). Consequently, a dimeric TLR4/MD-2/LPS
complex is formed (Park and Lee 2013).
Apart from recognizing LPS, TLR4 can respond to several DAMPs. This includes necrotic cell death
related molecules, such as high mobility group box 1 protein (HMGB1) or heat shock proteins (HSPs),
but also extracellular matrix fragments that are released during tissue injury, such as hyaluronan, bigly-
can or heparan sulfate (Kono and Rock 2008; Chen and Nuñez 2010). Extravascular fibrinogen and
plasma fibronectin (FN), indicating vascular leakage, also activate TLR4 (Smiley et al. 2001; Okamura
et al. 2001). These responses to DAMPs also require the co-receptor CD14. CD14 is necessary for
responses to HMGB1 in murine macrophages (Kim et al. 2013) and HSP70 in human monocytes (Asea
et al. 2000) as well as for reactions to tissue damage by murine microglia (Janova et al. 2016).
Following recognition of either PAMP or DAMP, the intracellular signaling cascade is triggered. In this
regard, TLR4 is rather unique within the TLR family as it is the only TLR that uses both, the MyD88-
and the TRIF-dependent signaling pathway. This feature is enabled by the use of the two TIR domain-
containing adaptor proteins TIRAP and TRAM, which serve a sorting function. At first, the TIRAP-
MyD88 pathway is initiated at the plasma membrane and afterwards, the TLR4 complex is internalized
in order to initiate the TRAM-TRIF pathway from endosomes (Kagan et al. 2008). Thereby, TLR4
stimulation leads to the production of MyD88-dependent cytokines and chemokines, but also to the
TRIF-dependent production of type I interferons.
1.3.2 TLR2
TLR2 senses a variety of PAMPs derived from bacteria, fungi, parasites and viruses as well as several
DAMPs (Akira et al. 2006). This ligand diversity is achieved by heterodimerization of TLR2 with TLR1
or TLR6, resulting in recognition of distinct ligands (Ozinsky et al. 2000). TLR1/2 heterodimers are acti-
vated by triacylated lipopeptides from gram-negative bacteria or mycoplasma and TLR6/2 heterodimers
by diacylated lipopeptides from gram-positive bacteria or mycoplasma (Kawai and Akira 2010). As an
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example, TLR1/2 recognizes Pam3-Cys-Ser-Lys4 (Pam3CSK4), a synthetic, triacylated lipopeptide (Jin
et al. 2007), and TLR6/2 recognizes macrophage-activating lipopeptide 2 (MALP-2) from Mycoplasma
fermentans (Takeuchi et al. 2001).
Upon stimulation with one of these ligands, the MyD88-dependent signaling pathway is initiated by
TIRAP as bridging molecule (Yamamoto et al. 2002). This culminates in the production of various pro-
inflammatory cytokines. The TLR2-mediated activity can be enhanced in response to the gram-positive
bacterial cell wall components lipoteichoic acid and peptidoglycan by the use of CD14 as co-receptor
(Yoshimura et al. 1999) and the TLR2-induced NF-κB activation is also regulated by CD14 (Brandt et al.
2013). As the TRIF-dependent pathway is not triggered by TLR2 ligands, type I interferons are basically
not produced in this scenario (Toshchakov et al. 2002). However, TLR2 is able to induce the production
of type I interferons under certain circumstances in response to viruses (Barbalat et al. 2009) and some
bacterial ligands (Dietrich et al. 2010). This signaling depends on MyD88 and requires, in addition to
TIRAP, TRAM as a sorting adaptor protein, which activates IRF7 to induce type I interferon expression
(Stack et al. 2014).
1.4 Type I interferons
Interferons have been discovered in 1957 and were named after their ability to interfere with influenza
virus replication (Isaacs and Lindenmann 1957). These small molecules belong to the large class of
proteins called cytokines (González-Navajas et al. 2012). Interferons are classified in three different
types. The group of type I interferons consists of interferon (IFN)α, IFNβ, IFNε, IFNκ, IFNω, IFNδ, IFNτ
and IFNζ (Pestka 2007). Of these, IFNδ and IFNτ are neither present in humans nor in mice (Owens
et al. 2014) and IFNζ is only present in mice (Hardy et al. 2004). IFNε is expressed only in the placenta
and IFNκ in keratinocytes (Theofilopoulos et al. 2005). Therefore, IFNα and IFNβ are the immuno-
logically most relevant type I interferons. The IFNα family includes 13 subtypes in humans and 14 in
mice, while there is only one IFNβ protein in both species (van Pesch et al. 2004). The group of type
II interferons contains only IFNγ and the group of type III interferons consists of IFNλ1, IFNλ2, IFNλ3,
also called IL-29, IL-28A and IL-28B, respectively (Sheppard et al. 2003; Kotenko et al. 2003).
Interferons are important signaling mediators within the immune system regulating both innate as well
as adaptive immune responses. They are crucial for effectively fighting viral infections as they block
the spread of virus particles by activating an antiviral state in infected and neighboring cells (Sen 2001;
Samuel 2001). Furthermore, they increase the surface expression of MHC class I (David-Watine et al.
1990) and MHC class II molecules (Loughlin et al. 1993). This enhances the efficient recognition of
infected cells by presentation of viral peptides and leads to their rapid elimination by activation of the
immune system. Interferons exert antiproliferative as well as proapoptotic actions (Bekisz et al. 2010)
and also stimulate the cytotoxic activity of different cell types, such as natural killer cells and monocytes
(Ortaldo et al. 1983).
Type I interferons can be produced upon activation of several PRRs. Recognition of nucleic acids from
viruses or bacteria by the intracellular TLRs (TLR3, TLR7 and TLR9) and also activation of TLR4 by LPS
can induce the production of type I interferons (Kawai and Akira 2010). Furthermore, the RLRs RIG-I
and melanoma differentiation-associated protein-5 (MDA-5) that sense viral RNA trigger type I interfer-
ons (Loo and Gale 2011). Apart from these, several other cytosolic PRRs can lead to type I interferon
production. This includes members of the NLR family. NOD1 recognizes bacterial peptidoglycan moi-
eties and triggers type I interferons in response to Helicobacter pylori infection (Watanabe et al. 2010).
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NOD2 is activated by the bacterial cell wall component muramyl dipeptide (Girardin et al. 2003) and is
critical for the type I interferon response to Mycobacterium tuberculosis infections (Pandey et al. 2009).
Additionally, the DNA-dependent activator of IFN (DAI) and the stimulator of interferon genes (STING)
are activated by double-stranded DNA to induce type I interferons (Takaoka et al. 2007; Ishikawa et al.
2009). Furthermore, the ALR IFI16 also serves as intracellular microbial DNA sensor mediating IFNβ
induction (Unterholzner et al. 2010). Alternatively, double-stranded DNA can be transcribed into RNA
by the DNA-dependent RNA-polymerase III and subsequently activate RIG-I (Chiu et al. 2009).
Upon encounter with one of those stimuli, type I interferons can be produced by almost all cell types. The
most potent producers of type I interferons are plasmacytoid dendritic cells (pDCs) (Fitzgerald-Bocarsly
and Feng 2007). pDCs are able to produce up to 1,000-fold more interferons than other types of blood
cells in response to viral infections (Siegal et al. 1999). Within the brain, pDCs are not present under
physiological conditions. However, few numbers of cells can be found in the cerebrospinal fluid (CSF)
from patients with non-inflammatory neurological diseases and these numbers are elevated during CNS
inflammation (Pashenkov et al. 2001).
In the central nervous system, microglia and astrocytes are the main source of IFNβ (Kallfass et al.
2012; Costello and Lynch 2013). This correlates with the fact that both cell types are equipped with the
necessary receptors. Microglia express all relevant TLRs (Kettenmann et al. 2011), RIG-I and MDA-5
(Furr et al. 2008) as well as DAI (Furr et al. 2011). Astrocytes express TLR3 at a high level (Bsibsi et al.
2002), while other TLRs, such as TLR4 and TLR9, are expressed at low levels (Bowman et al. 2003).
Furthermore, astrocytes express RIG-I (Furr et al. 2010), MDA-5 (De Miranda et al. 2009) and DAI (Furr
et al. 2011).
Upon activation of PRRs, e.g. by LPS or poly inosinic:polycytidylic acid (poly I:C), astrocytes are also
able to produce IFNα (Carpentier et al. 2005). Microglial production of IFNα is mostly linked to neu-
ropathological conditions, such as Alzheimer’s disease (Yamada et al. 1994), but can also occur in
response to Theiler’s murine encephalomyelitis virus or LPS (Olson and Miller 2004).
1.5 Type I interferon signaling
All type I interferons share the same receptor, namely the interferon-α/β receptor (IFNAR). IFNAR is a
cell surface receptor that consists of two subunits, IFNAR1 and IFNAR2 (Uzé et al. 1990; Colamonici
and Domanski 1993). The presence of both subunits is required for effective ligand binding (Cohen
et al. 1995). Each subunit is constitutively associated with a non-receptor tyrosine kinase of the janus
kinase family. While IFNAR1 is associated with tyrosine kinase 2 (Tyk2) (Colamonici et al. 1994),
IFNAR2 is associated with janus kinase 1 (Jak1) (Domanski et al. 1997). Upon ligand binding, the
receptor dimerizes at the cell surface and a tyrosine phosphorylation cascade is initiated inside the
cell. Jak1 and Tyk2 transphosphorylation occurs starting with Jak1 phosphorylating Tyk2, which then
cross-phosphorylates Jak1 for further activation (Stark et al. 1998). Subsequently, the activated kinases
phosphorylate conserved tyrosine residues in the cytoplasmic tail of the receptor (Hervas-Stubbs et al.
2011). These serve as docking site for the src homology 2 (SH2) domain of signal transducers and
activators of transcription (STAT) proteins (Heim et al. 1995; Yan et al. 1996). Following their recruitment
to IFNAR, several of these STAT proteins become tyrosine phosphorylated and thereby activated. This
includes STAT1 and STAT2 as the most important mediators of type I interferon responses, but also
STAT3 and STAT5 (Platanias 2005). However, STAT1 needs the presence of already phosphorylated
STAT2 for its phosphorylation, while STAT2 can be phosphorylated on its own (Leung et al. 1995).
In addition to that, IFNα induces the phosphorylation of STAT4 and STAT6 in certain cell types, such
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as endothelial or lymphoid cells (Fasler-Kan et al. 1998; Farrar et al. 2000; Torpey et al. 2004). If
STAT1 and STAT2 become activated, they form a heterodimer, recruit IRF9 and translocate into the
nucleus. This STAT1-STAT2-IRF9 complex is called IFN-stimulated gene factor 3 (ISGF3) complex
(Martinez-Moczygemba et al. 1997). The ISGF3 complex binds to IFN-stimulated response elements
(ISREs) in the promoter of IFN-stimulated genes (ISGs) and thereby regulates transcription (Decker et
al. 2005). Even though ISGF3 is the most important transcription factor for type I interferon responses,
also other activated STATs can either form homodimers (STAT1, STAT3, STAT4, STAT5 and STAT6) or
heterodimers (STAT1/3, STAT1/4, STAT1/5, STAT2/3 and STAT5/6) that translocate into the nucleus and
bind to IFNγ-activated sites (GAS) (Hervas-Stubbs et al. 2011). STAT1/2 heterodimers are also able to
bind to GAS, if they are not associated with IRF9 (Li et al. 1996).
Figure 1.1: The canonical type I interferon signaling pathway Type I interferons, here represented by IFNβ, are recognized
by the cell surface receptor IFNAR. This receptor consist of the two subunits IFNAR1 and IFNAR2 that are both constitutively
associated with a non-receptor tyrosine kinase. While IFNAR1 is associated with Tyk2, IFNAR2 is associated with Jak1. Following
binding of IFNβ, the receptor dimerizes and both tyrosine kinase become activated by transphosphorylation. Subsequently, they
phosphorylate conserved tyrosine residues in the cytoplasmic tail of the receptor, which provides a docking site for STAT1 and
STAT2. These transcription factors become also phosphorylated and are then able to form a heterodimer. This STAT1/STAT2
heterodimer recruits IRF9 to form the ISGF3 complex and then translocates into the nucleus, where it binds to ISREs in the
promoter region of ISGs and thereby regulates transcription. Adapted from Ivashkiv and Donlin (2014).
Apart from the canonical type I interferon signaling, different other signaling pathways can be activated
and contribute to type I interferon responses. This includes the v-crk sarcoma virus CT10 oncogene
homolog (avian)-like (CRKL) pathway, the MAPK pathway, the phosphoinositide 3-kinase (PI3K) path-
way and either the classical or the alternative NF-κB cascade (Hervas-Stubbs et al. 2011).
Type I interferon responses are tightly regulated in order to adjust the biological outcome. In general, the
components of the canonical type I interferon signaling pathway are constitutively expressed in most cell
types meaning that, in principle, they are able to respond to type I interferons. Immune cells can mount
very rapid responses to even low levels of type I interferons. This is based on an autocrine loop initiated
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by small amounts of IFNβ that leads to high basal expression levels of STAT1 and IRF9 (Gough et al.
2012). In general, the regulation of STAT1 and IRF9 expression is an important mechanism to control
type I interferon signaling. Because both proteins are ISGs, they can be induced by type I interferons,
IFNγ and other cytokines that activate STATs. This provides a basal level of antiviral protection even in
the absence of ongoing signaling (Cheon et al. 2013). Apart from its expression, also the transcriptional
activity of STAT1 can be modified. On the one hand, it can be enhanced through STAT1 phosphorylation
at a conserved carboxy-terminal serine by several kinases of the protein kinase C (PKC) and MAPK
family (Uddin et al. 2002; Goh et al. 1999). On the other hand, STAT tyrosine phosphorylation can be
augmented by immunoreceptor tyrosine-based activation motif (ITAM) signaling utilizing spleen tyrosine
kinase (Syk) and protein tyrosine kinase 2 (Pyk2) (Wang et al. 2008). An important mechanism to
suppress type I interferon signaling is the downregulation of IFNAR surface levels. This can be achieved
by several mechanisms, including inflammatory signaling or metabolic stress (Huangfu et al. 2012;
Bhattacharya et al. 2013). Additionally, negative regulators, such as suppressor of cytokine signaling
(SOCS) and ubiquitin specific peptidase 18 (USP18), influence type I interferon signaling (Krebs and
Hilton 2001; Sarasin-Filipowicz et al. 2009). While SOCS proteins compete with STATs for IFNAR
binding and suppress enzymatic activity of janus kinases (Croker et al. 2008), USP18 displaces Jak1
from IFNAR2 (Malakhova et al. 2006). Further suppressive mechanisms include the pausing of RNA
polymerase II at IFN pathway genes and the induction of several microRNAs (Ivashkiv and Donlin 2014).
1.6 Protective and detrimental roles in the CNS
1.6.1 Dual role of TLRs
Within the CNS, TLRs are expressed on various cell types (see table 1.2). They are important for
fighting pathogens and responding to tissue damage. However, as their activation leads to initiation of
inflammatory responses, they are likewise associated with neurotoxicity.
Cell type TLR expression
microglia TLR1, 2, 3, 4, 5, 6, 7, 8, 9, 111, 132
astrocytes TLR1, 2, 3, 4, 5, 6, 9, 111, 132
oligodendrocytes TLR2, 3
neurons TLR3, 111, 122, 132
Table 1.2: TLR expression in the CNS adapted from Hanisch et al. (2008)
1Atmaca et al. (2014), 2Mishra et al. (2008)
Destructive effects of TLRs were shown, for instance, by activation of TLR2 leading to inflammation
and associated neuron loss (Hoffmann et al. 2007). In this case, toxicity appears to be primarily me-
diated by nitric oxide production resulting in neuronal apoptosis (Lehnardt et al. 2006). Furthermore,
TLRs are involved in detrimental outcomes of brain ischemia and ischemic stroke. TLR2 was shown
to propagate stroke-induced CNS injury (Lehnardt et al. 2007) and similar results were obtained for
TLR4 as its absence reduces infarct size and the inflammatory response after an ischemic insult (Caso
et al. 2007). Additionally, LPS-induced TLR4 responses lead to severe axonal and neuronal loss in
a model of a normally subthreshold hypoxic ischemia (Lehnardt et al. 2003). The harmful effects of
TLR4 responses were also shown by local injections of LPS into the CNS, which result in severe loss
of dopamine neurons in the substantia nigra (Castaño et al. 1998) and neurons in the hippocampus
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(Hauss-Wegrzyniak et al. 1998). Apart from causing neuronal apoptosis, activation of TLR4 by LPS
induces loss of oligodendrocytes and therefore hypomyelination (Lehnardt et al. 2002). This could have
implications for demyelinating disorders, such as multiple sclerosis. In the brains of multiple sclerosis
(Bsibsi et al. 2002) as well as Alzheimer’s disease patients (Jackson et al. 2006) elevated TLR3 expres-
sion was detected, indicating an involvement of TLRs in neurodegeneration. Neuropathic pain seems to
be also modulated by TLRs. TLR4 plays an important role in the induction of behavioral hypersensitivity
in rodent models of neuropathy (Tanga et al. 2005) and TLR2 contributes to nerve injury-induced spinal
cord glial cell activation with subsequent pain hypersensitivity (Kim et al. 2007). In addition to that, TLR
activation in response to pathogens is also not always protective in the CNS. Lethality of West Nile virus
and Herpes simplex virus 1 infection that cause encephalitis is mediated by TLR3 (Wang et al. 2004)
and TLR2 (Kurt-Jones et al. 2004), respectively. Therefore, TLRs seem to have a dual role in CNS
inflammation.
In responses to several bacterial infections, the presence of TLRs is beneficial and necessary for
properly fighting the pathogens. In the absence of TLR2, the severity of Streptococcus pneumoniae
(S. pneumoniae) meningitis is enhanced (Echchannaoui et al. 2002; Koedel et al. 2003) and tlr2 -/- mice
were shown to be highly susceptible to Staphylococcus aureus infection (Takeuchi et al. 2000). Further-
more, TLR2 and TLR4 are required for an optimal intracerebral immune response in Staphylococcus
aureus-induced brain abscess (Stenzel et al. 2008). Still, TLR-triggered inflammatory responses need
to be properly controlled in order to limit harmful outcomes. A simple way to terminate TLR signaling
is the clearance and degradation of the activation stimulus. This can be achieved by phagocytosis, a
process that can be enhanced by TLR activity. Bacterial uptake and intracellular killing by microglia
are increased after application of TLR agonists (Ribes et al. 2010). Similar results were obtained for
amyloidβ uptake and clearance, indicating a beneficial role in Alzheimer’s disease (Tahara et al. 2006;
Chen et al. 2006). In addition to removal of infectious and damage-related agents, several neuropro-
tective mechanisms are favored by TLRs. In a model of spinal cord injury, TLR2 and TLR4 positively
affect the functional recovery (Kigerl et al. 2007). Furthermore, TLR4 can protect the brain tissue from
damage by toxic compounds (Glezer et al. 2006). Overall, TLR-mediated responses do not only have
detrimental outcomes, but rather favor neuroprotection.
1.6.2 Dual role of interferons
Type I interferons are tightly linked to TLR signaling. Their production is induced by activation of TLR3,
TLR7, TLR9 and TLR4 as well as, under certain circumstances, by TLR2. In the CNS, glial cells, mostly
microglia and astrocytes, (Owens et al. 2014) as well as neurons (Préhaud et al. 2005; Delhaye et al.
2006) produce type I interferons in response to innate immune stimulation. Although they were mainly
appreciated for their antiviral functions, type I interferons are also involved in other immunological re-
sponses.
In bacterial infections, type I interferons have opposing roles. On the one hand, they participate in
the resistance against bacteria. This includes Chlamydia species (de la Maza et al. 1985; Buss et al.
2010), Legionella pneumophila (Plumlee et al. 2009) as well as group B streptococci, S. pneumoniae
and Escherichia coli (E. coli) (Mancuso et al. 2007). On the other hand, type I interferon production
is associated with suppression of responses to bacterial infections. IFNAR1-deficient mice are more
resistant to Listeria monocytogenes infections (Auerbuch et al. 2004) and have a decreased and late
mortality in Mycobacterium tuberculosis infection (Manca et al. 2005). Connected to that, type I interfer-
ons are essential effectors in gram-negative sepsis leading to LPS-induced lethality by endotoxic shock
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(Karaghiosoff et al. 2003).
However, type I interferons also play a role in non-infectious inflammatory conditions. Several diseases
are associated with high levels of type I interferons. In Aicardi-Goutierès syndrome, which is a rare,
early onset childhood, genetic disease with severe neurological dysfunction, overexpression of IFNα
is present. This is caused by mutations in any one of several genes leading to impaired clearance of
endogenous nucleic acids, which in turn trigger PRRs to overproduce IFNα (Crow and Rehwinkel 2009).
Similar to that, the disease severity of systemic lupus erythematosus is closely linked to IFNα production
(Kirou et al. 2005) and for the pathogenesis of neuropsychiatric systemic lupus erythematosus, IFNα
could be even causative (Campbell et al. 1999; Santer et al. 2009). In HIV-infected patients suffering
from dementia, IFNα levels are also elevated in the CSF compared to patients without dementia or
controls and these increased IFNα levels correlate with neurocognitive dysfunctions (Rho et al. 1995).
Furthermore, a mouse model of amyotrophic lateral sclerosis revealed a link between astrocytic IFNβ
production and pathological changes in motor neurons (Wang et al. 2011).
Interestingly, effects of type I interferons are highly disease-specific. IFNβ is beneficial and used as
therapeutic in multiple sclerosis (The IFNB Multiple Sclerosis Study Group 1993). However, in neu-
romyelitis optica, another demyelinating disease of the CNS, IFNβ treatment is harmful and increases
autoantibody titers (Palace et al. 2010) as well as relapse rates (Kim et al. 2012).
Protective effects of type I interferons refer, at least in part, to their ability to control homeostatic and
pathologic processes. The integrity of the blood-brain barrier is stabilized by IFNβ (Kraus et al. 2004),
which protects against ischemic injury through actions on endothelial cells (Gesuete et al. 2012). Fur-
thermore, type I interferons control immune cell infiltration into the brain, thereby preventing excessive
inflammatory responses in the CNS. In the absence of essential parts of type I interferon signaling,
leukocyte infiltration into the brain is increased in a model of sterile injury (Khorooshi and Owens 2010)
and also a model of multiple sclerosis (Galligan et al. 2010). Thus, type I interferons could prove to be
key regulators of CNS infection and damage.
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2. Aim of the study
Interferons are pleiotropic cytokines that were initially described as crucial mediators of host defense
against viral infections. More recently, they were also recognized for their potential to fight bacterial
infections. Apart from that, increasing evidence demonstrates also regulatory effects of interferons on
innate and adaptive immune responses under physiological and pathological conditions. Especially
these immunomodulatory functions could prove to be crucial for maintaining homeostasis and deter-
mining the outcome of different diseases. Since type I interferons represent the largest subgroup of
these proteins with a huge variety of effects, they are of special interest for shaping immune reactions
in diverse contexts. Indeed, type I interferons were already shown to be involved in the pathogenesis
of several disorders and to even increase disease severity. In contrast to that, they also exert beneficial
effects and are approved as treatment for individual diseases. However, exact mechanisms of their
broad range of immunological activities are still poorly understood.
Within the CNS, microglia are the principle innate immune cells that serve important functions in health
and disease. They are capable of sensing infections and damage through diverse receptors, such as
TLRs, and consequently trigger an appropriate immune response. Upon activation by several stimuli,
they can produce different interferons with distinct effects on other cells. Interestingly, some microglial
functions are also regulated by interferons. This dual relationship of on the one hand being producers
and on the other hand target of interferons makes these cells ideal candidates for investigating functional
mechanisms of these immunomodulatory molecules. According to that, the following questions were
addressed in this thesis:
1. Under which conditions do microglia produce type I interferons?
• Which type I interferons can be produced in response to activation of different TLRs?
• Which signaling pathways control this production?
2. How are microglial responses to CNS infection and damage regulated by type I interferons?
• How is the production of TLR-induced chemokines regulated by type I interferons?
• Does this regulation involve the canonical type I interferon signaling pathway?
• Do type I interferons similarly regulate responses of microglia and extraneural macrophage
populations?
• Are effects of type I interferon signaling on different TLR systems individually organized?
• Is the outcome of selected infectious diseases and autoimmune disorders of the CNS mod-
ulated by type I interferon signaling?
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3. Material and Methods
3.1 Material
3.1.1 Reagents
Table 3.1: Reagents for in vitro stimulation of cells
Reagent Source of supply
E. coli DsRed DH5α Dr. S. Ribes, Institute for Neuropathology, University Medi-
cal Center Göttingen, Germany
IFNβ PBL Assay Science, Piscataway, NJ, USA
MALP-2 Enzo Life Sciences/Alexis, Lörrach, Germany
mouse fibronectin Molecular Innovations, Novi, MI, USA
Pam3CSK4 Enzo Life Sciences/Alexis, Lörrach, Germany
poly I:C Enzo Life Sciences/Alexis, Lörrach, Germany
Re-LPS (rough chemotype LPS,
E. coli, serotype R515)
Enzo Life Sciences/Alexis, Lörrach, Germany
S-LPS (smooth chemotype LPS,
E. coli, serotype O55:B5)
Enzo Life Sciences/Alexis, Lörrach, Germany
Table 3.2: Reagents
Reagent Source of supply
Ampicillin Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Aquamount Thermo Fisher Scientific, Waltham, MA, USA
β-mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Chloralhydrate Merck Millipore, Darmstadt, Germany
DAB Sigma-Aldrich Chemie GmbH, Steinheim, Germany
DePeX medium VWR international, Darmstadt, Germany
DMEM Gibco, Karlsruhe, Germany
DNase CellSystem, St. Katherine, Switzerland
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EDTA Roth, Karlsruhe, Germany
Eosin G Merck Millipore, Darmstadt, Germany
FCS Gibco, Karlsruhe, Germany
Gentamicin Sigma-Aldrich Chemie GmbH, Steinheim, Germany
HBSS Biochrom, Berlin, Germany
Horse serum Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Hydrogen peroxide, 30% solution Merck Millipore, Darmstadt, Germany
Ketamine Medistar, Hannover, Germany
Lysis buffer Cell Signaling Technology, Cambridge, UK
Mayer’s hemalum solution Merck Millipore, Darmstadt, Germany
Monastral Blue Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Paraffin (Paraplast Plus®) Tyco Healthcare, Neustadt, Germany
PBS Gibco, Karlsruhe, Germany
Penicillin Gibco, Karlsruhe, Germany
Percoll GE Healthcare Life Sciences, Freiburg, Germany
PFA Merck Millipore, Darmstadt, Germany
PLL Gibco, Karlsruhe, Germany
PMSF Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Sodium pyruvate Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Streptavidin horseradish peroxidase Sigma-Aldrich Chemie GmbH, Steinheim, Germany
Streptomycin Gibco, Karlsruhe, Germany
Trypsin Biochrom, Berlin, Germany
Trypsin/EDTA Biochrom, Berlin, Germany
WST-1 Roche Applied Science, Mannheim, Germany
Xylazine Riemser Arzneimittel AG, Greifswald, Germany
Table 3.3: Kinase inhibitors
Inhibitor Target IC50 Source of supply
GLPG0634 Jak1 10 nM Hölzel diagnostika, Köln, Germany
Tyk2 116 nM
Jak inhibitor I Jak1 15 nM Calbiochem/Merck Millipore, Nottingham, UK
Tyk2 1 nM
Solcitinib Jak1 N/A Hölzel diagnostika, Köln, Germany
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3.1.2 Buffers, solutions and cell culture media










0.01 M EDTA, pH=8.0
0.1% NaN3
4% PFA solution PBS
4% PFA
pH = 7.4
1% HCl-alcohol 70% ethanol
1% HCl absolute
1% eosin solution 70% isopropylalcohol
1% eosin G
stirred and filtered
0.5% acetic acid added before use
3% hydrogen peroxide solution PBS
3% hydrogen peroxide
Table 3.5: Cell culture media
Solution Composition
Complete culture medium Dulbecco’s modified Eagle medium (DMEM)
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3.1.3 Antibodies
Table 3.6: Blocking antibodies
Specificity Clone Source of supply
IFNAR1 MAR1-5A3 BioLegend, London, UK
IFNAR2 polyclonal goat IgG R&D systems, Wiesbaden, Germany
Table 3.7: Antibodies for flow cytometry
Specificity Fluorochrome Clone Dilution Source of supply
CD11b APC M1/70 1:100 BioLegend, London, UK
CD11b FITC M1/70 1:100 BioLegend, London, UK
CD16/CD32 2.4G2 1:50 / 1:100 BD Biosciences, Franklin Lakes, NJ, USA
CD3 PE 145-2C11 1:100 BioLegend, London, UK
CD45 PerCP-Cy5.5 30-F11 1:100 BioLegend, London, UK
Ly6C APC HK1.4 1:100 BioLegend, London, UK
Ly6G Pacific Blue 1A8 1:67 BioLegend, London, UK
Table 3.8: Antibodies for induction of focal NMO-like lesions
Specificity Clone Source of supply
AQP4 rAB-53 Dr. J. Bennett, Department of Neurology and Oph-
thalmology, University of Colorado, Denver, USA
Measles virus nucleocapsid protein rAb-2B4 Dr. J. Bennett, Department of Neurology and Oph-
thalmology, University of Colorado, Denver, USA
Table 3.9: Immunohistochemistry antibodies
Specificity Species Dilution Source of supply
AQP4 rabbit 1:100 Merck Millipore, Darmstadt, Germany
rabbit IgG biotinylated 1:200 GE Healthcare Life Sciences, Freiburg, Ger-
many
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3.1.4 Applied kits
Table 3.10: Applied kits
Kit Source of supply
DyLightTM 550 Labeling Kit Thermo Fisher Scientific, Waltham, MA, USA
iTaqTM Universal SYBR® Green Supermix Bio-Rad, Hercules, CA, USA
LEGEND MAXTM Mouse IFNβ ELISA Kit BioLegend, London, UK
Mouse CXCL1/KC DuoSet ELISA R&D Systems, Wiesbaden, Germany
Mouse MCP-1 ELISA MAXTM Standard BioLegend, London, UK
Naphthol AS-D chloroacetate (specific es-
terase) kit
Sigma-Aldrich Chemie GmbH, Steinheim,
Germany
Neural Tissue Dissociation Kit (T) Miltenyi Biotec, Bergisch Gladbach, Germany
QuantiTect® Reverse Transcription Kit Qiagen, Hilden, Germany
RNeasy Mini Kit Qiagen, Hilden, Germany
RT2 First Strand Kit Qiagen, Hilden, Germany
RT2 Profiler PCR Array Qiagen, Hilden, Germany
VeriKine Mouse IFNα ELISA Kit PBL Assay Science, Piscataway, NJ, USA
3.1.5 Primer for real-time PCR
Table 3.11: Primer for real-time PCR
Gene Unique assay ID Source of supply
ifnab qMmuCED0004300 Bio-Rad, Hercules, CA, USA
ifnb1 qMmuCED0050444 Bio-Rad, Hercules, CA, USA
stat1 qMmuCED0046088 Bio-Rad, Hercules, CA, USA
stat2 qMmuCED0048821 Bio-Rad, Hercules, CA, USA
stat3 qMmuCED0044698 Bio-Rad, Hercules, CA, USA
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3.1.6 Consumables
Table 3.12: Consumables
Consumable Source of supply
Blaubrand® intraMARK micropipettes, 5 µL Brand GmbH, Wertheim, Germany
Cell culture plate (96-, 12- and 6-well) Greiner bio-one, Kremsmuenster, Austria
Cell culture flask (75 cm2 and 175 cm2) Greiner bio-one, Kremsmuenster, Austria
Cell scraper Sarstedt, Nürnbrecht, Germany
C-Tubes Miltenyi Biotec, Bergisch Gladbach, Germany
FACS tubes Corning, Corning, NY, USA
Falcon 40µM cell strainer Corning, Corning, NY, USA
Insulin syringes (0.5 mL / 50 I.U.) B.Braun, Melsungen, Germany
Microtest plate, flat bottom and u-bottom shape
(96-well)
Sarstedt, Nürnbrecht, Germany
Needles B.Braun, Melsungen, Germany
Nunc MaxiSorp® plates Thermo Fisher Scientific, Waltham, MA, USA
PCR 8-tube strips Biozym Scientific GmbH, Hessisch Oldendorf,
Germany
PCR plate (96-well) Sarstedt, Nürnbrecht, Germany
Petri dish (3 cm) Greiner bio-one, Kremsmuenster, Austria
Petri dish (10 cm) Sarstedt, Nürnbrecht, Germany
Serological pipettes (5, 10 and 25 mL) Sarstedt, Nürnbrecht, Germany
Syringes B.Braun, Melsungen, Germany
Tubes (50, 15, 10, 1.5, 0.5 and 0.2 mL) Sarstedt, Nürnbrecht, Germany
3.1.7 Software and technical devices
Table 3.13: Software
Software Application Source of supply
FlowJo v10 Analysis of flow cytometry data FlowJo, LLC, Ashland, OR, USA




Analysis of real-time PCR data Thermo Fisher Scientific, Waltham,
MA, USA
RT2 Profiler PCR Ar-
ray Data Analysis V4
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Table 3.14: Technical devices
Device Source of supply
BD LSR FortessaTM BD Biosciences, Franklin Lakes, NJ, USA
Centrifuge 5418 R Eppendorf, Hamburg, Germany
Centrifuge 5810 R Eppendorf, Hamburg, Germany
gentleMACSTM Dissociator Miltenyi Biotec, Bergisch Gladbach, Germany
iMarkTM Microplate Absorbance Reader Bio-Rad, Hercules, CA, USA
Incubator CellStar Nunc/Thermo Fisher Scientific, Waltham, MA,
USA
Light microscope BX51 Olympus, Hamburg, Germany
Microtome Leica, Wetzlar, Germany
NanoDrop ND-1000 Peqlab, VWR International GmbH, Erlangen,
Germany
Quant StudioTM 7 Flex Real-Time PCR System Thermo Fisher Scientific, Waltham, MA, USA
Sonicator UW 2070 Bandelin electronic, Berlin, Germany
Stereotactic device Stoelting Co, Wood Dale, IL, USA
Tissue Processor TP 1020 Leica, Wetzlar, Germany
3.2 Animals
C57BL/6 wildtype mice (wt) and IFNAR1- (ifnar1 -/-), Tyk2- (tyk2 E775K), STAT1- (stat1 -/-), STAT2- (B6.129-
Stat2 tm1Shnd/J), CD14- (B6.129S4-Cd14 tm1Frm/J), MyD88- (myd88 -/-) and TRIF-deficient (trif lps2) mice
were bred and obtained from the central animal facility of the University Medicine Göttingen and housed
under standard or specific pathogen-free (SPF) conditions. Tyk2 E775K, stat2 -/- and cd14 -/- mice were
from the Jackson Laboratory. Ifnar1 -/- mice were kindly provided by Prof. Dr. Marco Prinz, Freiburg,
Germany, stat1 -/- mice by Prof. Dr. Thomas Meyer, Göttingen, Germany, myd88 -/- mice by Prof. Dr.
Shizuo Akira, Osaka, Japan and trif lps2 mice by Prof. Dr. Bruce Beutler, La Jolla, USA. All animals were
treated according to the guidelines for animal care of the University Medicine Göttingen.
3.3 Cell culture
3.3.1 Primary mouse microglial cultures
For the preparation of primary microglial cell cultures, whole brains of neonatal (P0) mice were excised.
The meninges were removed and the brains washed three times with HBSS. Afterwards, cells were
incubated for 5 min at 37°C with 2.5% trypsin, vortexed gently and incubated for another 5 min at 37°C.
The digestion was stopped with complete culture medium. Next, the cell suspension was incubated
with 0.4 mg/mL DNase for 2-3 min at 37°C. Remaining cell clumps were removed by careful resuspen-
sion and cells were centrifuged at 200 x g for 10 min at 4°C. After centrifugation, the supernatant was
removed and cells were resuspended in fresh complete culture medium. Cells were seeded into 75 cm2
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culture flasks that were coated beforehand with 100 µg/mL poly-L-lysine (PLL) for at least 30 min fol-
lowed by three times washing with aquabidest and once with culture medium. Cultures were kept in an
incubator adjusted to 37°C and 5% CO2.
The next day, cultures were washed three times with PBS, once with complete culture medium and
afterwards, fresh culture medium was added. On the following day, the culture medium was changed
again. One week later, cells received complete culture medium containing 30% L929-conditioned cell
culture supernatant to stimulate microglial proliferation. Five days later microglia were harvested. For
this purpose microglia were shaked off the astrocytic feeder layer for at least 30 min at 37°C with a
speed of 140 rpm. The supernatant containing microglia was collected, cells were washed and the
cell number was determined. Microglia were plated in complete culture medium in 96-well plates with
15,000 cells/well, in 12-well plates with 200,000 cells/well and in 6-well plates with 800,000 cells/well.
The remaining cells were re-stimulated with complete culture medium containing 30% L929-conditioned
cell culture supernatant. Using this procedure, cells can be harvested again on day 17, 22 and 24.
3.3.2 Bone marrow-derived macrophage cultures
Bone marrow-derived macrophages were isolated from 8-12 week old mice. Therefore, mice were
sacrificed by cervical dislocation and femurs were isolated by using the scissors and forceps. The
bones were cleaned from the muscle tissue and cut on both ends near the joints. Bone marrow was
washed out of the femur by using a 5 mL syringe with a small needle (0.45 mm diameter) filled with
Pluznik medium. The bone marrow from two femurs was placed in a 10 cm Petri dish containing 10 mL
Pluznik medium and kept in an incubator adjusted to 37°C and 5% CO2 overnight. The next day,
the medium containing the cells was collected into a 50 mL Falcon tube and centrifuged at 300 x g for
10 min at 4°C. The supernatant was discarded, cells were resuspended in 40 mL Pluznik medium and
cultured in four new Petri dishes. Medium was changed on day 4 and BMDM were harvested on day
7 by incubation with 5 mL 4 mM EDTA for 15 min at 37°C. Cells were washed, counted and plated in
complete culture medium in 96-well plates with 15,000 cells/well.
3.3.3 Peritoneal macrophage cultures
Peritoneal macrophages were isolated from 8-12 week old mice. Therefore, mice were sacrificed by
cervical dislocation and the peritoneum was exposed by carefully removing the skin above. Through a
small cut in the peritoneum, 1 mL ice-cold PBS was injected into the peritoneal cavitiy by using a 1000 µL
pipette. The abdomen was gently massaged to loosen the macrophages and the fluid was collected
into a pre-cooled 15 mL Falcon tube. This procedure was repeated six to eight times. Afterwards, cells
were washed, counted and plated in complete culture medium in 96-well plates with 25,000 cells/well.
3.3.4 L929 fibroblast cultures
L929 fibroblasts were cultured in order to obtain L929-conditioned cell culture supernatant for stimu-
lation of microglial proliferation. Therefore, L929 fibroblasts were cultured in two 75 cm2 culture flasks
in complete culture medium. After one week, cells were collected and split into two 75 cm2 culture
flasks for further cultivation and three 175 cm2 culture flasks that were cultivated for two weeks without
medium change. Supernatants were collected from the 175 cm2 culture flasks and stored at -20°C until
used for microglial cultures. L929 fibroblasts were cultured for 30 passages and afterwards replaced by
fresh cultures established from a liquid nitrogen stock.
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L929 fibroblasts were also cultured in order to obtain L929-conditioned medium for stimulation of BMDM
proliferation. Therefore, L929 fibroblasts were seeded at a density of 1x107 cells in 100 mL complete
culture medium. After cultivation for one week without medium change, the medium was collected,
sterile filtered and stored at -20°C until used for BMDM cultures.
3.4 In vitro stimulation of cells and determination of cell viability
Microglia, BMDM and peritoneal macrophages from different mouse strains were stimulated with several
TLR agonists or interferons (see Table 3.1). All stimulating agents were diluted to the respective working
concentration in complete culture medium prior to use. The medium, in which the cells were plated
before, was exchanged for the medium containing the stimulating agent. Cells were then incubated for
a certain period of time at 37°C and 5% CO2 depending on the experimental setup. If inhibitors (see
Table 3.3) or blocking antibodies (see Table 3.6) were used, cells were pre-incubated for 1 h with the
respective compound before stimulation.
The cell viability was determined via a WST-1 assay to rule out toxicity of the different stimulating agents,
inhibitors and blocking antibodies. For this purpose cells received fresh complete culture medium sup-
plemented with 10% WST-1 after removal of the different compounds and were incubated for 3 h at
37°C. WST-1 is a tetrazolium salt that is cleaved by the succinyltetrazolium reductase, which is part of
the mitochondrial respiratory chain and therefore indicates metabolic activity of cells. The cleavage re-
sults in formation of the soluble dye formazan. This color reaction was measured in a microplate reader
at 450 nm with 655 nm as reference wavelength.
3.5 Quantification of chemokines and interferons by ELISA
The release of chemokines and interferons was quantified with enzyme-linked immunoabsorbent assay
(ELISA) using different kits. Levels of CXCL1, CCL2, IFNα and IFNβ were determined in cell culture
supernatants or brain lysates. Assays were performed on Nunc MaxiSorp® plates according to the
manufacturer’s instructions. Absorbance was measured in a microplate reader at 450 nm with 540 nm
as reference wavelength.
Cell culture supernatants for measuring the production of chemokines and interferons by cultured mi-
croglia (15,000/well in 96-well plate), BMDM (15,000/well in 96-well plate) and peritoneal macrophages
(25,000/well in 96-well plate) were obtained from in vitro stimulation experiments after 18 h, unless
stated otherwise, and stored at -20°C until assayed.
Brain lysates for measuring intracerebral chemokine production were prepared as follows. One half of
an adult mouse brain was lysed by adding 500 µL lysis buffer containing 2 nM PMSF for 5 min of ice.
Afterwards, cells were disrupted by sonication. Cell debris was removed by centrifugation at 14,000 x g
for 10 min at 4°C. The supernatant was collected and stored at -20°C until assayed.
3.6 Real-time PCR and RT2 ProfilerTM PCR array
Total RNA was isolated from cultured microglia (800,000/well in 6-well plate) 3 h after in vitro stimulation
by using the RNeasy Mini Kit according to the manufacturer’s instructions.
For real-time PCR (RT-PCR), 300 ng of purified RNA were transcribed into cDNA by using the Quanti
Tect® Reverse Transcription Kit according to the manufacturer’s instructions. RT-PCR was performed
by using the iTaqTM Universal SYBR® Green Supermix according to the manufacturer’s instructions.
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PrimePCRTM SYBR® Green Assay primer for ifnab, ifnb1, stat1, stat2 and stat3 were used. The house-
keeping gene gapdh served as internal control.
For RT2 ProfilerTM PCR array, 500 ng of purified RNA were transcribed into cDNA by using the RT2 First
Strand Kit according to the manufacturer’s instructions. cDNA was mixed with the RT2 Profiler PCR
Array PCR components and dispensed into the array plate for performing real-time PCR according
to the manufacturer’s instructions. Data was analyzed with the web-based PCR Array Data Analysis
Software provided by the manufacturer.
3.7 Flow cytometry analysis of E.coli and myelin phagocytosis
Microglial phagocytosis of bacteria was assessed by using Discosoma red fluorescent protein (DsRed)-
expressing DH5α E.coli. Cultured microglia (200,000/well in 12-well plate) were exposed to the bacterial
solution containing 2 x 106 DsRed DH5α E.coli in culture medium without penicillin / streptomycin, but
with 100 µg/mL ampicillin. After 2 h incubation at 37°C and 5% CO2, the bacterial solution was removed
and remaining bacteria were killed by incubation with 100 µg/mL gentamicin for 1 h at 37°C and 5%
CO2. Subsequently, cells were processed for flow cytometry analysis.
Microglial phagocytosis of myelin was assessed by using myelin, which was labeled with the DyLightTM
550 Labeling Kit according to the manufacturer’s instructions. Cultured microglia (200,000/well in 12-
well plate) were incubated in the presence of DyLight 550 myelin for 2 h at 37°C and 5% CO2, the myelin
solution was removed and cells were processed for flow cytometry analysis.
For that purpose, cells were washed once with culture medium and twice with PBS and detached from
the plate by incubation with 0.05% / 0.02% trypsin / EDTA for 3-5 min at 37°C. The enzymatic reaction
was stopped by adding fresh complete culture medium. Afterwards, cells were scraped carefully and
transferred into 2 mL Eppendorf cups for subsequent centrifugation at 800 x g for 10 min at 4°C. After
washing with FACS buffer, Fc receptors were blocked with an anti-mouse CD16/CD32 antibody for
10 min at 4°C. Finally, cells were stained with an APC anti-mouse CD11b antibody for 25 min at 4°C in
the dark and washed once again. Samples were acquired on BD LSR FortessaTM and 10,000 CD11b+
cells were included for data analysis. Data was evaluated with the software FlowJo.
3.8 Intracerebral E. coli and S. pneumoniae infection
Intracerebral injections of E. coli K1 and S. pneumoniae D39 were used as a model of gram-negative
and gram-positive meningitis, respectively. E. coli K1 is an encapsulated, pathogenic strain that was
originally isolated from the cerebrospinal fluid of a child with neonatal meningitis (Ribes et al. 2013).
It was provided by Dr. G. Zysk, Institute for Medical Microbiology and Virology, Düsseldorf, Germany.
S. pneumoniae D39 is an encapsulated strain that was isolated from a patient in 1916 (Lanie et al.
2007). It was provided by Prof. Dr. S. Hammerschmidt, Department of Genetics of Microorganisms,
Greifswald, Germany. Both strains were passaged through mice, grown overnight on blood agar plates,
harvested with 0.9% saline and stored at -80°C. Frozen aliquots (generously provided by Dr. Sandra
Ribes, Institute for Neuropathology, Göttingen, Germany) were used for the experiments.
In order to induce meningitis, 8-12 week old mice were anesthesized with ketamine (60 mg/kg body-
weight) and xylazine (8 mg/kg bodyweight). Bacteria were diluted in saline and injected into the right
frontal neocortex with a concentration of 2000-5000 CFU / mouse for E. coli and 500-800 CFU / mouse
for S. pneumoniae. As a control, mice were either injected with PBS or not injected. After 24 h, mice
were sacrificed by i.p. injection of 14% chloralhydrate. Blood was taken directly from the heart, plated
on blood agar plates and incubated for 24 h at 37°C in order to quantify the severeness of the infection
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by determining the number of bacteria in the blood. Mice were perfused with PBS via the left ventricle
of the heart, brains were dissected and further processed as described in chapter 3.10.
3.9 Induction of focal NMO-like lesions in mice
Focal NMO-like lesions were induced in 8-12 week old mice by intracortical injection of a human re-
combinant anti-AQP4 antibody (referred to as NMO-Ab) together with human complement. Therefore,
mice were anesthesized as described in chapter 3.8, their skull was shaved and they were placed in a
stereotactic frame. A rostro-caudal cut was performed to expose the skull and a small hole was drilled
0.1 mm caudal and 0.2 mm lateral to the bregma. The last thin layer of the bone was carefully cut with
a microdissecting knife to avoid damaging the brain. 1 µL antibody mixture containing 15 U/mL human
complement, 2.5 mg/mL NMO-Ab and the tracer dye Monastral Blue was slowly injected into the cor-
tex with a fine glass capillary. As a control, mice were either injected with a CNS unspecific human
recombinant antibody directed against measles virus nucleocapsid protein (referred to as CTL-Ab) to-
gether with human complement or injected with PBS. All animals were injected into both hemispheres.
Subsequently, the capillary was slowly withdrawn and the skin was closed by a suture. After 24 h, mice
were sacrificed by i.p. injection of 14% chloralhydrate and perfused with PBS via the left ventricle of the
heart. The brains were dissected and halved. One half was processed as described in chapter 3.10
for flow cytometry analysis and one half was transferred into 4% PFA and processed as described in
chapter 3.11 for histological analysis.
3.10 Preparation of single-cell suspensions from brain tissue for
flow cytometry analysis
Single-cell suspensions for flow cytometry analysis were prepared from perfused brains using the Neu-
ral Tissue Dissociation Kit (T). The brain tissue was dissociated following the manufacturer’s instructions
for automated dissociation using the gentleMACSTM Dissociator. Afterwards, myelin was removed by
a Percoll gradient. Therefore, the cell suspension was resuspended in 5 mL 37% Percoll in complete
culture medium and layered over 4 mL 70% Percoll in complete culture medium in a 15 mL Falcon tube.
After centrifugation at 500 x g for 25 min at 4°C without acceleration and brakes, the myelin debris was
removed and the cells were collected at the interphase. The cells were transferred to FACS tubes
and washed with FACS buffer. Fc receptors were blocked with an anti-mouse CD16/CD32 antibody for
10 min at 4°C and cells were stained for 25 min at 4°C in the dark with the following antibodies: FITC
anti-mouse CD11b, PerCP-Cy5.5 anti-mouse CD45, Pacific Blue anti-mouse Ly6G, APC anti-mouse
Ly6C and PE anti-mouse CD3. After washing, samples were acquired on BD LSR FortessaTM and
10,000 CD11b+ cells were included for data analysis. Data was evaluated with the software FlowJo.
3.11 Histology of focal NMO-like lesions
3.11.1 Preparation for histology
For histological analysis, perfused brains were fixed for at least 2 days at 4°C in Falcon tubes containing
4% PFA solution and afterwards washed with PBS. The tissue was dehydrated via alcohol / xylene and
embedded in paraffin blocks using the Leica TP 1020 Tissue Processor according to the standard
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procedure. The paraffin blocks were cut with a sliding microtome into 2-3 µm thin coronal sections and
transferred to object slides.
Prior to the staining procedure, the tissue was deparaffinized for at least 1 h at 56°C. Subsequent
rehydration was performed using the following xylene / alcohol solutions for the indicated time pe-
riod: xylene (4 x 5 min), isoxylene (1 x 2 min), 100% isopropyl alcohol (2 x 3 min), 90% isopropyl alcohol
(1 x 3 min) 70% isopropyl alcohol (1 x 3 min) and 50% isopropyl alcohol (1 x 3 min). In the end, sections
were washed with aquabidest.
After the staining procedure, sections were dehydrated by performing the above described rehydration
steps in reverse order and mounted in DePeX medium.
3.11.2 Hematoxylin and eosin (HE) staining
Hematoxylin and eosin (HE) staining was used for gaining a general overview of the tissue morphology
and inflammation. Therefore, deparaffinized sections were incubated for 5 min with Mayer’s hemalum
solution, washed with aquabidest and shortly differentiated in 1% HCl-alcohol. After blueing in water
for 10 min, sections were incubated with 1% eosin solution for 5 min and subsequently washed with
aquabidest. Finally, sections were dehydrated and mounted.
3.11.3 Aquaporin 4 (AQP4) staining
Aquaporin 4 (AQP4) staining was performed for analysis of astrocyte pathology and lesion formation.
Therefore, deparaffinized sections were washed with PBS and endogenous peroxidases were blocked
by incubation for 10 min with 3% hydrogen peroxide solution. Sections were washed three times with
PBS and blocked by incubation for 10 min with blocking buffer. The primary antibody directed against
AQP4, diluted in blocking buffer, was added and sections were incubated over night at 4°C. The next day,
sections were washed three times with PBS and incubated for 1 h at RT with the secondary antibody,
diluted in blocking buffer. After three times washing with PBS, 0.1% streptavidin horseradish peroxi-
dase in blocking buffer was added and sections were incubated for 45 min at RT. Following three times
washing with PBS, the staining was developed with a 3,3’ diaminobenzidine (DAB) solution and the
staining intensity was controlled under a microscope. Sections were washed with aquabidest and coun-
terstained in Mayer’s hemalum solution for 0.5 min. Afterwards, sections were washed with aquabidest
and shortly differentiated in 1% HCl-alcohol. Finally, sections were blued in water for 7 min, dehydrated
and mounted.
3.11.4 Chloroacetate esterase (CAE) enzyme histochemistry and acquisition of
neutrophil numbers
Chloroacetate esterase (CAE) staining was used in order to specifically stain neutrophils in the brain
tissue. Therefore, deparaffinized sections were pre-warmed in PBS at 37°C for 1 h, stained with the
naphthol AS-D chloroacetate (specific esterase) kit according to the manufacturer’s instructions and
then mounted using Aquamount.
In order to determine the number of neutrophils, CAE+ cells were counted in the stained sections.
Therefore, a light microscope with an ocular morphometric grid was used and all cells in the area
around the injection site were counted at a 20x magnification.
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3.12 Statistical analysis
Statistical analysis was performed using the GraphPad Prism 6 software. The Mann-Whitney test was
used for non-parametric data to compare two independent groups. For the comparison of more than
two groups, the two-way ANOVA with either Sidak’s correction or Turkey’s correction was used. Sta-
tistical significance was defined as p<0.05 and marked as follows: * p≤0.05, ** p≤0.01, *** p≤0.001,
**** p≤0.0001. All data are mean±SEM.
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4.1 Microglial production of type I interferons
Interferons are important immune mediators that play a crucial role in fighting viral, but also bacterial
infections. They can be produced upon activation of TLRs, which recognize several PAMPs that indicate
the presence of pathogens (Trinchieri 2010). Within the CNS, microglia as the principal immune cells
serve important functions in eradicating invading pathogens. They are equipped with a large variety of
TLRs and potently produce several inflammatory and immunoregulatory factors, such as cytokines and
chemokines, upon activation of these receptors (Kettenmann et al. 2011). Thus, microglia could shape
immune responses within the CNS by producing different interferons in response to various pathogens.
4.1.1 Microglia produce IFNβ, but hardly any IFNα upon TLR stimulation
Type I interferons are the largest subgroup of interferons. This family consists of 8 different interferon
species of which IFNα and IFNβ are the most important ones (Pestka 2007). They can be produced
by many different cell types in response to a variety of stimuli. Therefore, the capability of microglia to
produce IFNα and IFNβ upon activation of different TLRs was assessed.
Cultured, primary microglia were stimulated in vitro with Re-LPS, S-LPS, live E. coli or FN as agonists for
TLR4, Pam3CSK4 as agonist for TLR1/2, MALP-2 as agonist for TLR6/2 or poly I:C as agonist for TLR3.
After 18 h, supernatants containing soluble factors were collected and IFNβ release was determined
by ELISA. While TLR2 agonists completely failed to induce IFNβ production, it was massively released
after poly I:C treatment (Figure 4.1 A). An intermediate production of about 0.1-0.15 ng/mL was triggered
by all different TLR4 agonists. Surprisingly, not only the bacterial ligands, but also the DAMP FN
similarly led to IFNβ production, indicating a role of interferons also in tissue damage. This intermediate
production could be further increased depending on the dose of the stimulus. Re- or S-LPS were slightly
more potent stimulators of IFNβ than FN inducing a maximal release of about 0.3-0.4 ng/mL, while FN
triggered 0.25-0.3 ng/mL (Figure 4.1 C and D). This maximal release was obtained rather quickly. A
time profile of Re-LPS-triggered IFNβ release revealed that a plateau is reached already after 6 h,
which stays stable even over 48 h (Figure 4.1 B). Thus, IFNβ seems to belong to the early cytokines
that are produced after pathogen encounter.
Furthermore, the release of IFNα was analyzed 18 h after stimulation with Re-LPS, Pam3CSK4, MALP-
2 and poly I:C. ELISA measurements showed that only TLR3 activation leads to IFNα production, while
neither TLR4 nor TLR2 agonists had any effect (Figure 4.2 A). To rule out that sensitivity problems of
the ELISA kit caused false negative results, mRNA expression of IFNα was determined. A RT-PCR
array including seven different IFNα subtypes as well as IFNβ, IFNε, IFNκ and IFNζ was performed in
order to get a general overview about regulation of type I interferon expression upon TLR challenges.
Re-LPS and Pam3CSK4 served as respective examples for the TLR challenge. First, the Re-LPS- and
Pam3CSK4-triggered relative gene expression, calculated by 2 -∆cT , of all 89 genes included in the array
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Figure 4.1: Microglia produce IFNβ upon stimulation with several TLR agonists. Cultured microglia from wt mice were stim-
ulated with (A) 10 ng/mL Re-LPS, S-LPS, Pam3CSK4, MALP-2, 2x105 CFU/mL E. coli DsRed DH5α, 100 µg/mL FN or 50 µg/mL
poly I:C for 18h or (B) 10 ng/mL Re-LPS for the indicated time points or increasing doses of (C) Re-LPS, S-LPS or (D) FN as
indicated for 18h. IFNβ release was determined in cell culture supernatants by ELISA. Data are mean±SEM with n=12 from 3
independent experiments. Data from (B) and (C) is already published in Janova et al. (2016).
was correlated (Figure 4.2 B). The middle line indicates perfect correlation and both other lines mark
the confidence interval. Many genes were higher expressed upon TLR4 than TLR1/2 stimulation as
shown by all dots below the lines. Only one gene was slightly more expressed in TLR1/2-stimulated
microglia, namely IFNαB. For a more detailed analysis, the fold regulation of only type I interferons
is shown in Figure 4.2 C. The fold regulation thereby represents the quotient of the relative gene ex-
pression of the Re-LPS- and the Pam3CSK4-stimulated sample. Values greater than 1 indicate an
up-regulation, while values less than -1 indicate a down-regulation. The expression of most of the inter-
ferons was not different between both conditions. IFNαB appeared to be the only gene that was slightly
more expressed in TLR1/2- than TLR4-stimulated microglia as it was already shown by the correlation
analysis. Furthermore, in line with the previously described ELISA data, IFNβ was almost exclusively
expressed in TLR4-stimulated cells. Because the RT-PCR array could be performed only once, the
obtained results should be confirmed by RT-PCR analysis. In this case, cells were stimulated with Re-
LPS, FN, Pam3CSK4, MALP-2 or poly I:C for 3 h and afterwards the relative gene expression of IFNβ
and IFNα was determined. Since there exist 14 IFNα subtypes in mice (van Pesch et al. 2004) and not
all can be covered by using one primer pair, the expression of IFNαB, 6, 12 and 14 was characterized,
which included the one subtype that showed off in the RT-PCR array. According to the ELISA data,
only TLR4 and TLR3 agonists induced IFNβ gene expression (Figure 4.2 D). Interestingly, the mRNA
expression did not correlate with the amount of released protein. FN-induced expression levels were
four times higher than Re-LPS-induced expression levels, even though both ligands led to nearly the
same IFNβ release. Furthermore, poly I:C induced a rather low relative gene expression compared to
the massively triggered protein production. Surprisingly, in neither of the conditions IFNαB, 6, 12 or 14
expression could be observed. Even poly I:C stimulation did not increase mRNA expression, indicating
that probably another IFNα subtype was detected by the ELISA. Furthermore, this points towards a
false positive result regarding IFNαB in the RT-PCR array.
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Figure 4.2: Microglia produce IFNα only in response to TLR3 stimulation. (A) Cultured microglia from wt mice were stim-
ulated with 10 ng/mL Re-LPS, Pam3CSK4, MALP-2 or 50 µg/mL poly I:C for 18 h. IFNα release was determined in cell culture
supernatants by ELISA. Data are mean±SEM with n=4-6 from 2 independent experiments. (B), (C) Cultured microglia from wt
mice were stimulated with 10 ng/mL Re-LPS or Pam3CSK4 for 3 h. RNA was isolated by using the RNeasy Mini Kit and con-
verted into cDNA by using the RT2 First Strand Kit. Real-Time PCR was performed by using a RT2 Profiler PCR Array. Relative
gene expression was calculated by 2 -∆cT . Data are single values from 1 experiment. (B) Correlation analysis of Re-LPS- and
Pam3CSK4-triggered relative gene expression of all 89 genes included in the RT2 Profiler PCR Array. The middle line indicates
exact correlation, while both other lines represent the confidence interval. Dots above the upper line show genes that are more
expressed in response to Pam3CSK4 than Re-LPS, while dots below the lower line indicate genes that are more expressed in re-
sponse to Re-LPS than Pam3CSK4. IFNβ and IFNαB are marked in brown and red, respectively. (C) Comparison of the relative
gene expression of different type I interferons in response to Re-LPS and Pam3CSK4. Fold regulation represents the quotient of
Re-LPS- and Pam3CSK4-triggered relative gene expression. Values greater than 1 indicate an up-regulation, while values less
than -1 indicate a down-regulation. IFNαB and IFNβ are marked in red and brown, respectively. (D) Cultured microglia from wt
mice were stimulated with 10 ng/mL Re-LPS, Pam3CSK4, MALP-2, 100 µg/mL FN or 50 µg/mL poly I:C for 3 h. RNA was isolated
by using the RNeasy Mini Kit and converted into cDNA by using the QuantiTect® Reverse Transcription Kit. Real-Time PCR was
performed by using the iTaqTM Universal SYBR® Green Supermix. Relative gene expression was calculated by 2 -∆cT . Data are
mean±SEM with n=2-4 from 2 independent experiments. IFNαB, 6, 12, 14 expression was partially measured and analyzed by
Dr. Reza Khorooshi at the lab of Prof. Dr. Trevor Owens.
Overall, IFNβ was produced in this cell culture system after TLR challenges. Bacterial and damage-
related TLR4 and viral TLR3 ligands, but not the bacterial TLR2 agonists triggered IFNβ release by
microglia. In contrast to that, the production of IFNα was exclusively linked to viral dsRNA as certain
subtypes were only induced in response to TLR3 stimulation.
4.1.2 IFNβ production is TRIF-dependent
MyD88 and TRIF are the general adaptor proteins that initiate the TLR signaling pathway. The TRIF-
dependent activation of IRF3 is thereby the principal way to induce IFNβ (Fitzgerald et al. 2003). How-
ever, MyD88-dependent activation of IRF7 can under certain circumstances also lead to IFNβ produc-
tion (Dietrich et al. 2010).
Because of this dual use of the two adaptor proteins, the dependence of microglial IFNβ release on
MyD88 and/or TRIF was analyzed. Therefore, myd88 -/- and trif lps2 microglia were stimulated with dif-
ferent TLR agonists, the IFNβ production was measured by ELISA and compared to the production of
wt cells. As described in chapter 4.1.1, substantial amounts of IFNβ were only induced by the TLR4
agonists Re-LPS, S-LPS and FN as well as by the TLR3 agonist poly I:C. This production was not al-
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Figure 4.3: Microglial IFNβ production depends on TRIF, but not MyD88. Cultured microglia from wt and (A) myd88 -/- or
(B) trif lps2 mice were stimulated with 10 ng/mL Re-LPS, S-LPS, Pam3CSK4, MALP-2, 100 µg/mL FN or 50 µg/mL poly I:C for
18 h. IFNβ release was determined in cell culture supernatants by ELISA. Data are mean±SEM with n=12 from 3 independent
experiments. Statistical analysis was performed using the Mann-Whitney test, * represents p≤0.05, **** represents p≤0.0001.
tered by MyD88 deficiency (Figure 4.3 A) as wt and myd88 -/- microglia produced the same amounts of
IFNβ. Surprisingly, basal IFNβ levels in unstimulated cells differed between both genotypes. In contrast
to this, IFNβ levels massively depended on the presence of TRIF (Figure 4.3 B). In the supernatants
of Re- and S-LPS-stimulated trif lps2 microglia, no IFNβ could be detected. Unfortunately, the effect of
TRIF deficiency on FN-triggered IFNβ could not be analyzed as unexpectedly neither the wt nor the
trif lps2 microglia were able to react to this FN preparation. In response to poly I:C, the absence of TRIF
decreased the IFNβ release by about 40%. Thus, microglial IFNβ production in response to TLR4 and
TLR3 agonists depends on the functional presence of TRIF, but not MyD88.
4.1.3 IFNβ production is absent in CD14-deficient microglia
Within the TLR4 signaling cascade, IFNβ production is realized by the TRIF-dependent pathway as
shown in chapter 4.1.2. This pathway is initiated from endosomes after internalization of the recep-
tor complex. The endocytosis of TLR4 is a process that is controlled by CD14 (Zanoni et al. 2011).
Accordingly, CD14 deficiency should affect IFNβ production similar to TRIF deficiency.
Figure 4.4: IFNβ production is completely absent in cd14 -/- microglia. Cultured microglia from wt and cd14 -/- mice were
stimulated with (A) 10 ng/mL Re-LPS, 2x105 CFU/mL E. coli or 100 µg/mL FN for 18 h or (B) 10 ng/mL Re-LPS for the indicated
time points. IFNβ release was determined in cell culture supernatants by ELISA. Data are mean±SEM with n=12 from 3
independent experiments. (A) Statistical analysis was performed using the Mann-Whitney test or (B) compares both genotypes
at each time point individually by using the two-way ANOVA with Sidak’s correction, ** represents p≤0.01, *** represents p≤0.001,
**** represents p≤0.0001. Data from (B) is already published in Janova et al. (2016).
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In order to test this hypothesis, cd14 -/- and wt microglia were stimulated with Re-LPS, E. coli or FN
and the IFNβ release was quantified after 18 h. As expected, IFNβ production was completely absent
in CD14-deficient cells, irrespective of the used TLR4 ligand (Figure 4.4 A). To rule out that cd14 -/-
microglia are in principle able to release IFNβ in response to TLR4 stimulation, but the production is
just delayed, a time course study was performed. In this experiment, IFNβ levels upon stimulation
with Re-LPS were measured in cd14 -/- and wt cells over 48 h with a 2 h analysis interval up to 18 h.
As shown in Figure 4.4 B, no IFNβ was produced in the absence of CD14 throughout the whole time.
Consequently, CD14 deficiency indeed leads to absent IFNβ release independent of the considered
time frame. This indicates a direct link from CD14 to TRIF, which ultimately controls microglial IFNβ
production in response to TLR4 challenges.
4.2 Type I interferon signaling controls TLR4-induced chemokine
production
CD14 is a powerful regulator of microglial responses to TLR4 activation and shapes the outcome of
infectious and non-infectious challenges (Regen et al. 2011; Janova et al. 2016). For reactions to
DAMPs and tissue damage, the presence of CD14 is mandatory. Furthermore, it tightly controls the
LPS-induced production of cytokines and chemokines. In the absence of CD14, microglial sensitivity to
low amounts of LPS is dramatically reduced. Additionally, CD14 deficiency results in overreactions to
massive LPS challenges. These are, amongst others, established in form of excessive CXCL1 produc-
tion. In order to prevent such overreactions, microglia utilize an IFNβ-mediated feedback mechanism.
In this regard, CXCL1 production is negatively regulated by the presence of IFNβ. As all other type I
interferons, IFNβ signals via IFNAR and activates Jak1, Tyk2, STAT1 and STAT2 as the most impor-
tant down-stream mediators. Since IFNβ prevents overshooting microglial reactions to strong infectious
stimuli, the canonical type I interferon signaling pathway could be crucial for mediating regulatory effects
on TLR4-triggered responses.
4.2.1 Regulation of CXCL1 and CCL2 production depends on IFNAR1
IFNAR is the type I interferon receptor and consists of two subunits, IFNAR1 and IFNAR2. Deficiency
in one of the subunits disrupts the whole receptor and impairs ligand binding (Cohen et al. 1995).
Hence, ifnar1 -/- mice served as model for receptor deficiency. In order to evaluate the contribution of
canonical type I interferon signaling to the regulation of TLR4-mediated responses, ifnar1 -/- microglia
were characterized in terms of their chemokine production. The measurements were focused on CXCL1
and CCL2, because CXCL1 is negatively regulated by IFNβ, while CCL2 as a comparison is not (Janova
et al. 2016). Thus, CXCL1 production could depend on IFNAR, whereas CCL2 would be probably
independent.
According to that, wt and ifnar1 -/- microglia were stimulated with Re-LPS, S-LPS or FN to activate TLR4
and the release of CXCL1 and CCL2 was measured by ELISA. For all three agonists the presence
of IFNAR1 was required for a normal CXCL1 production (Figure 4.5 A). In the absence of IFNAR1,
CXCL1 was up to twelvefold overproduced compared to the production by wt cells, indicating a dramatic
dysregulation of this chemokine. In contrast to that, the CCL2 production in ifnar1 -/- microglia was even
slightly reduced compared to wt (Figure 4.5 B).
The observed results could be due to the IFNAR1 deficiency, but a decreased production of IFNβ and
subsequent lack of negative regulation would have a similar effect. To exclude that ifnar1 -/- microglia
have an intrinsically impaired production, their IFNβ release after stimulation with Re-LPS, S-LPS or
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Figure 4.5: IFNAR1 deficiency causes increased CXCL1 and decreased CCL2 production by TLR4-stimulated microglia,
but does not affect IFNβ levels. Cultured microglia from wt and ifnar1 -/- mice were stimulated with 10 ng/mL Re-LPS, S-LPS
or 100 µg/mL FN for 18 h. (A) CXCL1, (B) CCL2 and (C) IFNβ release were determined in cell culture supernatants by ELISA.
Data are mean±SEM with n=12 from 3 independent experiments. Statistical analysis was performed using the Mann-Whitney
test, * represents p≤0.05, **** represents p≤0.0001.
FN was assessed. For all three TLR4 agonists, the IFNβ levels did not differ between ifnar1 -/- and wt
microglia (Figure 4.5 C). Consequently, the massive overproduction of CXCL1 cannot be attributed to
an impairment in IFNβ, but is rather caused by the IFNAR1 deficiency.
4.2.2 IFNAR1 deficiency causes excessive neutrophil infiltration into the brain
of E. coli-infected mice
CXCL1 and CCL2 are important chemokines for shaping inflammatory reactions. Their release by
tissue-resident immune cells upon recognition of pathogens leads to the recruitment of neutrophils and
monocytes to the site of inflammation, where these cells contribute to the elimination of the infectious
agents (Wengner et al. 2008; Tsou et al. 2007). Infections with gram-negative bacteria, such as E. coli,
are mainly sensed via TLR4 as it is activated by their cell wall component LPS (Hoshino et al. 1999).
Within the brain, microglia serve as the tissue-resident cells that recognize bacterial infections and sub-
sequently mount an appropriate immune response, including recruitment of peripheral immune cells.
Because the neutrophil chemoattractant CXCL1 was excessively produced and the monocyte chemoat-
tractant CCL2 was slightly less produced upon TLR4 stimulation in IFNAR1-deficient microglia in vitro,
this could also have implications for the in vivo recruitment of these cells in response to pathogens.
As a model for gram-negative bacterial CNS infection, wt and ifnar1 -/- mice were intracerebrally inocu-
lated with E. coli K1, a serotype that is associated with neonatal meningitis (Robbins et al. 1974). 24 h
after the infection, the infiltration of monocytes and neutrophils into the brain of infected mice was an-
alyzed by flow cytometry, because these cells represent the first line of defense that is recruited very
rapidly. In order to distinguish the different cell populations, single-cell suspensions of whole brains
were stained for CD11b, CD45, Ly6G and Ly6C. Based on the expression of CD11b and CD45, in-
filtrating immune cells were identified. Because microglia and infiltrating cells are both CD11b+, they
were separated by CD45 expression. Microglia express low levels and infiltrating cells high levels of
CD45. For distinguishing monocytes and neutrophils within the population of infiltrating cells, the mark-
ers Ly6G and Ly6C were used. Inflammatory monocytes were considered Ly6Chigh Ly6G-, patrolling
monocytes Ly6Clow Ly6G- and neutrophils Ly6C+ Ly6G+ (Figure 4.6 A). In infected wt and ifnar1 -/- ani-
mals, recruitment of substantial amounts of inflammatory monocytes and neutrophils into the brain was
observed (Figure 4.6 C and D). However, numbers of patrolling monocytes were not significantly altered
by the infection in comparison to not injected animals independent of the genotype (Figure 4.6 B). Only
PBS-injected mice overall showed a slight reduction in patrolling monocytes. Regarding the inflam-
matory monocytes, no difference between infected wt and ifnar1 -/- mice was observed (Figure 4.6 C).
In contrast to that, IFNAR1 deficiency caused a significantly higher amount of infiltrating neutrophils
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Figure 4.6: Neutrophil infiltration into the brain of E. coli-infected ifnar1 -/- mice is higher than in wt mice. Wt and ifnar1 -/-
mice were intracerebrally injected with 2000-5000 CFU E. coli K1 per mouse. As a control, mice were either injected with PBS or
not injected. After 24 h, mice were perfused with PBS. Single-cell suspensions were prepared from whole brains using the MACS
Neural Tissue Dissociation Kit (T) and stained for flow cytometry as indicated. For analysis, 10,000 CD11b+ cells were collected.
(A) Representative flow cytometry plots showing the sequence of gating for identification of inflammatory monocytes, neutrophils
and patrolling monocytes based on the expression of CD11b, CD45, Ly6G and Ly6C. (B), (C) and (D) Quantification of the cell
types as described in (A). Data are individual values from 4 independent experiments. Statistical analysis was performed using
the two-way ANOVA with Turkey’s correction, * represents p≤0.05, *** represents p≤0.001, **** represents p≤0.0001.
(Figure 4.6 D). This can be linked to the in vitro data, showing that in the absence of IFNAR1, mi-
croglia excessively produce the neutrophil chemoattractant CXCL1. So indeed, these results have also
relevance in an in vivo infection model.
4.2.3 IFNAR1 deficiency does not impair microglial phagocytosis
In response to pathogens and tissue damage, microglia execute a variety of different functions. For
eradication of bacteria, their ability to phagocytose infectious agents was suggested to be an important
feature to prevent spread of the infection (Ribes et al. 2009). If the infection is not cleared, peripheral
immune cells are recruited to the CNS. This means that an impaired phagocytic capacity could lead
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to increased numbers of infiltrating cells. Because IFNAR1-deficient mice, which were intracerebrally
infected with E. coli, showed an increased recruitment of especially neutrophils into the brain, it had to
be ruled out that this is caused by impaired microglial phagocytosis.
Therefore, cultured microglia were incubated with DsRed-labeled E. coli for 2 h. After removal of re-
maining, not engulfed bacteria by antibiotics, microglia were processed for flow cytometry analysis.
They were stained for CD11b as pan-populational marker and the percentage of DsRed+ cells was an-
alyzed. As shown in Figure 4.7 A, about 80% of the cells phagocytosed E. coli within the 2 h. This was
the case for wt as well as ifnar1 -/- microglia. Thus, impaired phagocytosis could not be causative for
increased neutrophil recruitment in E. coli-infected ifnar1 -/- mice.
Figure 4.7: The phagocytic capacity does not differ between wt and ifnar1 -/- microglia. Cultured microglia from wt and
ifnar1 -/- mice were were challenged with (A) 2x106 CFU/mL DsRed-labeled E. coli or (B) 10 µg/mL DyLight 550-labeled myelin
for 2 h. Subsequently, cells were stained for flow cytometry with an APC-anti-CD11b antibody. For data analysis, 10,000 CD11b+
events were included. The graphs show the phagocytosis rate as percentage of CD11b+ cells. Data are mean±SEM with n=6
from 3 independent experiments. Statistical analysis was performed using the Mann-Whitney test.
In addition to infectious agents, microglia are also able to phagocytose endogenous material. This
includes myelin under homeostatic, but also pathological conditions, such as demyelinating diseases.
As the phagocytosis of bacteria was not altered by IFNAR1 deficiency, myelin phagocytosis would most
probably also not be affected. To test this, microglia were incubated with DyLight 550-labeled myelin
for 2 h and the phagocytosis rate was determined by flow cytometry. Comparable to E. coli, myelin
was phagocytosed by about 70% of all CD11b+ microglia and this was not changed in the absence of
IFNAR1 (Figure 4.7 B). This shows that in both genotypes, microglia have the same capacity for the
phagocytosis of pathogens and endogenous material.
4.2.4 Neutrophil infiltration in a model of focal NMO is independent of IFNAR1
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS, characterized by op-
tic neuritis and transverse myelitis (Kimbrough et al. 2012). The pathogenesis of this disease is closely
linked to the presence of specific NMO-antibodies (NMO-Ab) (Lennon et al. 2004) that target aquaporin
4, a water channel located in astrocytic endfeet (Lennon et al. 2005). Pathologically, NMO presents
with lesions in the CNS that show extensive demyelination and astrocyte loss. Inflammatory infiltrates
in these lesions consist of monocytes, macrophages, lymphocytes and polymorphonuclear cells, such
as neutrophils, basophils and eosinophils (Lucchinetti et al. 2002). The infiltration of polymorphonu-
clear granulocytes into NMO lesions in different animal models was shown to occur within 24 h. In a
rat model of focal NMO, in which circumscribed astrocyte-depleted lesions were achieved by stereo-
tactic injection of human NMO-Ab together with human complement, granulocytes were not detected
1 h or 3 h, but 24 h after lesion induction (Wrzos et al. 2014). Similar results were also obtained in a
mouse model (Winkler, unpublished). Hence, this model of focal NMO shares some features with the
previously described E. coli infection model. Both are inflammatory conditions that lead to the infiltration
of neutrophils into the CNS. This recruitment is achieved in response to the respective causing agent
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within 24 h. Because the number of infiltrating neutrophils in the E. coli infection model was IFNAR1
dependent (see chapter 4.2.2), this could be also the case in the focal NMO model.
Figure 4.8: Intracortical injection of NMO-Ab together with human complement leads to the formation of astrocyte-
depleted lesions and infiltration of neutrophils. Wt and ifnar1 -/- mice were intracortically injected with 1 µL antibody mixture,
containing 15 U/mL human complement and 2.5 mg/mL recombinant anti-AQP4 antibody (NMO-Ab), or 1 µL PBS as a control into
both hemispheres. After 24h, mice were perfused with PBS and one hemisphere was used for histological analysis. Represen-
tative light microscopy images of HE-, AQP4- and CAE-stained sections are shown. AQP4 is stained in brown and CAE in pink.
Monastral blue marks the injection site. Solid lines indicate the area of astrocyte loss. Scale bar 1 mm
Accordingly, the neutrophil recruitment in the focal NMO model was analyzed in detail. For induction
of focal NMO-like lesions, wt and ifnar1 -/- mice received a stereotactic injection of human NMO-Ab
together with human complement into the cortex. PBS-injected mice served as control. 24 h after lesion
induction, a histological analysis was performed. This included HE staining for a general overview
of the tissue morphology and the inflammation, AQP4 staining in order to detect astrocyte-depleted
lesions and CAE staining for specific identification of neutrophils in the tissue. As shown in Figure 4.8,
lesions were only present in animals injected with NMO-Ab and human complement and this lesion
formation was accompanied by infiltration of neutrophils. In order to compare neutrophil numbers in wt
and ifnar1 -/- mice, all CAE positive cells in the area around the injection site were counted using a light
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microscope with an ocular morphometric grid. This revealed no difference between both genotypes
(Figure 4.9 B).
Figure 4.9: Neutrophil infiltration into focal NMO-like lesions is not affected by IFNAR1 deficiency. Wt and ifnar1 -/- mice
were intracortically injected with 1 µL antibody mixture, containing 15 U/mL human complement and 2.5 mg/mL recombinant
anti-AQP4 antibody (NMO-Ab), or 1 µL PBS as a control into both hemispheres. After 24h, mice were perfused with PBS. Single-
cell suspensions were prepared from one hemisphere using the MACS Neural Tissue Dissociation Kit (T) and stained for flow
cytometry as indicated. For analysis, 10,000 CD11b+ cells were collected. (A) Representative flow cytometry plots showing the
sequence of gating for identification of inflammatory monocytes, neutrophils and patrolling monocytes based on the expression
of CD11b, CD45, Ly6G and Ly6C. (B) Quantification of neutrophil numbers based on the CAE staining. All CAE+ cells in the area
around the injections site were counted at a 20x magnification in the stained sections. (C), (D) and (E) Quantification of the cell
types as described in (A). Data are individual values from 3 independent experiments. Statistical analysis was performed using
the two-way ANOVA with Turkey’s correction.
To confirm this result, a flow cytometry analysis similar to that described in chapter 4.2.2 for the E. coli
infection model was performed. In this case, not only the infiltrating neutrophils (referred to as CD11b+
CD45high Ly6C+ Ly6G+), but also numbers of inflammatory monocytes (referred to as CD11b+ CD45high
Ly6Chigh Ly6G-) and patrolling monocytes (referred to as CD11b+ CD45high Ly6Clow Ly6G-) were quan-
tified (Figure 4.9 A). Even though more neutrophils were detected in mice injected with NMO-Ab and
human complement than in PBS controls, no difference between wt and ifnar1 -/- mice was observed
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(Figure 4.9 C). The same also applied to the inflammatory monocytes (Figure 4.9 D). Numbers of pa-
trolling monocytes were neither changed by injection of NMO-Ab and human complement nor showed
differences between both genotypes (Figure 4.9 E). Overall, this data indicates that the infiltration of
neutrophils into focal NMO-like lesions is completely independent of IFNAR1.
Figure 4.10: Intracerebral CXCL1 production is similarly induced in wt and ifnar1 -/- mice with focal NMO-like lesions. Wt
and ifnar1 -/- mice were intracortically injected with 1 µL antibody mixture, containing 15 U/mL human complement and 2.5 mg/mL
of either recombinant anti-AQP4 antibody (NMO-Ab) or recombinant 2B4 antibody (CTL-Ab), into both hemispheres. After 24h,
mice were perfused with PBS. Brain lysates were prepared from one hemisphere and CXCL1 release was determined by ELISA.
Data are mean±SEM with n=2-4 from 1 experiment. N/A means data not available. Statistical analysis was performed using the
Mann-Whitney test.
Because the excessive neutrophil infiltration in E. coli-infected ifnar1 -/- mice correlated with the exces-
sive production of the neutrophil chemoattractant CXCL1 by ifnar1 -/- microglia, intracerebral CXCL1
levels of mice with focal NMO-like lesions could also mirror neutrophil numbers. For that reason, wt
and ifnar1 -/- mice were either injected with human NMO-Ab or with a CNS non-specific human antibody
directed against measles virus nucleocapsid protein (CTL-Ab) together with human complement. 24 h
after the injection, brain lysates were prepared and CXCL1 was measured by ELISA. Figure 4.10 shows
that indeed CXCL1 levels are elevated in NMO-Ab-injected compared to CTL-Ab-injected animals. Un-
fortunately, only CTL-Ab-injected wt mice were available. Nevertheless, this increase in CXCL1 produc-
tion matches the increase in neutrophil infiltration upon injection of NMO-Ab, which was observed in the
histological and flow cytometry analysis (Figure 4.9 B and C). In line with the data on neutrophil num-
bers, there was no difference in CXCL1 levels of NMO-Ab-injected wt and ifnar1 -/- mice. This shows
that also in this model, the production of CXCL1 and recruitment of neutrophils into the brain follow a
similar pattern.
4.2.5 IFNAR1-deficient mice display lower T cell numbers in the brain
When analyzing infiltrating cells in the brains of ifnar1 -/- and wt mice by flow cytometry, it became
obvious that also a population of T cells can be observed. This population was characterized as
CD11b- CD45high CD3+ (Figure 4.11 A). To get an overall impression, T cell counts in wt and ifnar1 -/-
mice were compared in the context of several treatments. This included animals, which received either
no injection or an injection of PBS, E. coli or NMO-Ab together with human complement.
A comparison of T cell counts in both genotypes 24 h after the treatment revealed significantly lower
numbers in IFNAR1-deficient mice under all conditions (Figure 4.11 B). Only untreated animals did not




Figure 4.11: IFNAR1-deficient mice display lower T cell numbers in the brain following different treatments. Wt and if-
nar1 -/- mice were intracerebrally injected with 10 µL PBS or 2000-5000 CFU E. coli K1 or intracortically injected with 1 µL antibody
mixture, containing 15 U/mL human complement and 2.5 mg/mL of recombinant anti-AQP4 antibody (NMO-Ab), per mouse. After
24 h, mice were perfused with PBS. Single-cell suspensions were prepared from whole brains using the MACS Neural Tissue
Dissociation Kit (T) and stained for flow cytometry as indicated. For analysis, 10,000 CD11b+ cells were collected. (A) Represen-
tative flow cytometry plots showing the sequence of gating for identification of T cells based on the expression of CD11b, CD45
and CD3. (B) Quantification of T cells counts. Data are individual values from 3-4 independent experiments. Statistical analysis
was performed using the Mann-Whitney test, ** represents p≤0.01, *** represents p≤0.001.
4.2.6 Altered chemokine production in IFNAR1-deficient microglia is not res-
cued by time
As described in chapter 4.2.1, IFNAR1 deficiency led to a dramatic dysregulation of microglial CXCL1
release in response to TLR4 agonists. Furthermore, it caused excessive neutrophil recruitment into the
brain of E. coli-infected mice (see chapter 4.2.2). This indicates that proper regulation of CXCL1 might
be crucial for mounting appropriate immune responses. In order to understand the IFNAR1-dependent
control of the production of chemokines, ifnar1 -/- microglia were further characterized concerning their
CXCL1 and CCL2 release. As previously described, CXCL1 was massively overproduced, while CCL2
was slightly less produced in IFNAR1-deficient microglia 18 h after stimulation with different TLR4 ag-
onists (see Figure 4.5). However, for a complete dependence of these factors on the presence of
IFNAR1, this effect needs to be permanent and not restricted to only one time point.
To prove this, wt and ifnar1 -/- microglia were stimulated with Re-LPS for 48 h and the CXCL1 and CCL2
release was quantified over time. While a significant increase of CXCL1 levels was observed at the
16 h time point (Figure 4.12 A), CCL2 levels were significantly decreased in IFNAR1-deficient microglia
already after 8 h of stimulation (Figure 4.12 B). This effect was maintained during the following time
and the difference between both genotypes further increased continuously. This argues for a complete
dependence of the regulation of microglial CXCL1 and CCL2 production on IFNAR1.
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Figure 4.12: Altered CXCL1 and CCL2 production by ifnar1 -/- microglia in response to TLR4 stimulation is stable over
time. Cultured microglia from wt and ifnar1 -/- mice were stimulated with 10 ng/mL Re-LPS for the indicated time points. (A)
CXCL1 and (B) CCL2 release were determined in cell culture supernatants by ELISA. Absolute values were normalized to
amounts produced by wt cells stimulated for 48 h (endpoint). Data are mean±SEM with n=12 from 3 independent experiments.
Statistical analysis compares both genotypes at each time point individually and was performed using the two-way ANOVA with
Sidak’s correction, * represents p≤0.05, **** represents p≤0.0001.
4.2.7 IFNAR1 deficiency leads to similar changes in the chemokine production
of microglia and macrophages
Because it was shown that the regulation of CXCL1 and CCL2 production by microglia depends on
the presence of IFNAR1 (see chapter 4.2.1), it was investigated whether this is a cell type-specific
phenomenon or similar also in other macrophages. Bone marrow-derived macrophages (BMDM) and
peritoneal macrophages (pMΦ) were chosen as comparative examples, because they are also tissue-
resident macrophages, but differ in their origin and location from microglia.
Figure 4.13: IFNAR1 deficiency similarly affects TLR4-induced CXCL1 and CCL2 production by microglia, BMDM and
pMΦ. Cultured microglia, BMDM and pMΦ from wt and ifnar1 -/- mice were stimulated with 10 ng/mL Re-LPS, S-LPS or 100 µg/mL
FN for 18 h. CXCL1 and CCL2 release were determined in cell culture supernatants by ELISA. Data are mean±SEM with n=8-
12 from 3-4 independent experiments. Statistical analysis was performed using the Mann-Whitney test, * represents p≤0.05,
** represents p≤0.01, *** represents p≤0.001, **** represents p≤0.0001.
For a comparison of these three different cell types, microglia, BMDM and pMΦ from wt and ifnar1 -/-
mice were stimulated with Re-LPS, S-LPS or FN. After 18 h, the production of CXCL1 and CCL2 was
measured by ELISA. As shown in Figure 4.13, the release pattern of all cell types was very similar. In
microglia as well as BMDM and pMΦ, CXCL1 was massively overproduced in response to the TLR4
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agonists in the absence of IFNAR1. Furthermore, IFNAR1-deficiency led to a slightly decreased CCL2
production under all conditions, which was partially significant in microglia and pMΦ, but completely
significant in BMDM. In summary, this comparison revealed no major differences between the three
different cell types. Similar to microglia, the CXCL1 and CCL2 production was dramatically altered in
ifnar1 -/- BMDM and pMΦ. This points towards a general control of IFNAR1 over CXCL1 and CCL2
production, which is not cell type-specific.
4.2.8 IFNAR1 deficiency can be phenocopied by functional block
The IFNAR1-deficient cells that were used for the analysis of CXCL1 and CCL2 production have been
generated from mice with a global knock-out of IFNAR1. This knock-out affects the whole body already
during development and could therefore cause intrinsic problems of these cells that would ultimately
lead to alterations in chemokine production.
Figure 4.14: Functional block of IFNAR1 increases microglial CXCL1 and decreases CCL2 levels, but does not affect
IFNβ production in response to TLR4 stimulation. Cultured microglia from wt mice were either pre-incubated (+ α-IFNAR1)
or not pre-incubated (w/o α-IFNAR1) with 10 µg/mL α-IFNAR1 antibody for 1 h and afterwards stimulated with 10 ng/mL Re-LPS
or 100 µg/mL FN for 18 h in the presence or absence of 10 µg/mL α-IFNAR1 antibody. (A) CXCL1, (B) CCL2 and (C) IFNβ
release were determined in cell culture supernatants by ELISA. Absolute values were normalized to amounts produced by cells
stimulated in the absence of α-IFNAR1 antibody. Data are mean±SEM with n=12 from 3 independent experiments. Statistical
analysis was performed using the Mann-Whitney test, * represents p≤0.05, **** represents p≤0.0001.
To rule out such a phenomenon, fully functional wt microglia were stimulated with Re-LPS or FN, while
IFNAR1 was blocked by an anti (α)-IFNAR1 antibody. The blocking antibody was applied to the cells
1 h before the stimulation, so that the receptor was already not functional at the time point of stimu-
lation and was then continuously present. In the presence of α-IFNAR1 antibody, CXCL1 production
was significantly increased by 50-100% compared to the amount produced by cells stimulated in the
absence of α-IFNAR1 antibody (Figure 4.14 A). This effect was similar, but not as striking as in ifnar1 -/-
microglia, where an up to twelvefold overproduction was observed (Figure 4.5). Regarding the CCL2
production, a significant reduction by 30% was achieved by IFNAR1 blockade in Re-LPS-stimulated
microglia, while the slight reduction in FN-stimulated cells was not significant (Figure 4.14 B). Similar to
ifnar1 -/- microglia, the release of IFNβ was not significantly changed by the IFNAR1-blocking antibody
(Figure 4.14 C). Overall, functional blockade of IFNAR1 could phenocopy the effects on chemokine pro-
duction that were present in ifnar1 -/- microglia. This means that changes in CXCL1 and CCL2 levels
were indeed only due to IFNAR1 deficiency and not caused by other, cell intrinsic alterations.
4.2.9 Regulation of CXCL1 and CCL2 production depends on IFNAR2
As described previously, IFNAR consists of the two subunits IFNAR1 and IFNAR2, which are both
required for effective ligand binding (Cohen et al. 1995). Nevertheless, it was shown that under certain
circumstances IFNβ can specifically ligate to IFNAR1 in an IFNAR2-independent manner (de Weerd et
al. 2013). Because all experiments described so far have only considered IFNAR1, effects of IFNAR2
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should also be investigated. In particular, the regulation of CXCL1 and CCL2 production by IFNAR2
was subject of this analysis.
Figure 4.15: Functional block of IFNAR2 increases microglial CXCL1 and decreases CCL2 levels, but does not affect
IFNβ production in response to TLR4 stimulation. Cultured microglia from wt mice were either pre-incubated (+ α-IFNAR2)
or not pre-incubated (w/o α-IFNAR2) with 10 µg/mL α-IFNAR2 antibody for 1 h and afterwards stimulated with 10 ng/mL Re-LPS
or 100 µg/mL FN for 18 h in the presence or absence of 10 µg/mL α-IFNAR2 antibody. (A) CXCL1, (B) CCL2 and (C) IFNβ
release were determined in cell culture supernatants by ELISA. Absolute values were normalized to amounts produced by cells
stimulated in the absence of α-IFNAR2 antibody. Data are mean±SEM with n=12 from 3 independent experiments. Statistical
analysis was performed using the Mann-Whitney test, ** represents p≤0.01, *** represents p≤0.001.
Microglia were treated with an α-IFNAR2 antibody as described in chapter 4.2.8 and stimulated with
Re-LPS or FN for 18 h. The release of CXCL1, CCL2 and IFNβ after the stimulation is summarized in
Figure 4.15. Similar to what was obtained with the α-IFNAR1 antibody (Figure 4.14), IFNAR2 blockade
resulted in a 60-70% increase of CXCL1 production compared to the amount produced in the absence
of α-IFNAR2 antibody (Figure 4.15 A). However, this effect could be only shown to be significant in
Re-LPS-stimulated microglia. In contrast to that, CCL2 levels were only affected in FN-stimulated cells,
where the α-IFNAR2 antibody decreased the release by 30% (Figure 4.15 B). The production of IFNβ
was again not significantly altered (Figure 4.15 C). So overall, the release pattern was rather similar
between IFNAR1- and IFNAR2-blocked microglia. Both antibodies led to an increase of CXCL1, a
decrease of CCL2 and no change in IFNβ production. However, none of the blocking antibodies resulted
in alterations that were as dramatic as in the ifnar1 -/- microglia, indicating a reduced potency of receptor
blockade by antibody compared to complete knock-out. Nevertheless, a contribution of IFNAR2 to the
regulation of microglial CXCL1 and CCL2 production could be shown. This points towards a cooperative
ligand binding by IFNAR1 and IFNAR2, which further controls chemokine production.
4.2.10 Functional absence of IFNAR1 and IFNAR2 exceeds effects of either de-
ficiency
Because the previously described results showed that IFNAR1 and IFNAR2 independently affect TLR4-
triggered CXCL1 and CCL2 production, both subunits of IFNAR could cooperate in controlling these
chemokines. This would mean that the observed effects could be even enhanced in the absence of
IFNAR1 and IFNAR2 simultaneously.
To test this hypothesis, ifnar1 -/- microglia were treated with the IFNAR2-blocking antibody in order to
mimic an IFNAR1 / IFNAR2 double knock-out. The cells were treated with the blocking antibody as
previously described and for a comparison, the α-IFNAR2 antibody was also used in wt microglia. So
overall, four different conditions were compared: fully functional IFNAR (wt), IFNAR1 not functional
(ifnar1 -/-), IFNAR2 not functional (wt with α-IFNAR2 antibody) and IFNAR1 / IFNAR2 not functional (if-
nar1 -/- with α-IFNAR2 antibody). Within all groups, cells were triggered to produce CXCL1 and CCL2
by stimulation with Re-LPS or FN. The chemokine release is summarized in Figure 4.16. For a better
comparison, absolute values were normalized to amounts produced by wt cells with fully functional IF-
NAR. Similar to what was described in chapter 4.2.9, IFNAR2-blockade increased the CXCL1 release
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Figure 4.16: Functional absence of IFNAR1 and IFNAR2 cooperatively affects microglial CXCL1, but not CCL2 production
in response to TLR4 stimulation. Cultured microglia from wt and ifnar1 -/- mice were either pre-incubated (+ α-IFNAR2) or not
pre-incubated (w/o α-IFNAR2) with 10 µg/mL α-IFNAR2 antibody for 1 h and afterwards stimulated with 10 ng/mL Re-LPS or
100 µg/mL FN for 18 h in the presence or absence of 10 µg/mL α-IFNAR2 antibody. (A) CXCL1 and (B) CCL2 release were
determined in cell culture supernatants by ELISA. Absolute values were normalized to amounts produced by wt cells stimulated
in the absence of α-IFNAR2 antibody. Data are mean±SEM with n=12 from 3 independent experiments.
in wt cells by about 45-85% (Figure 4.16 A). The effect of IFNAR1 knock-out was again much more
striking as the CXCL1 level increased by 200-350%. However, this could be even further enhanced by
IFNAR2-blockade in ifnar1 -/- cells. IFNAR2-blockade had an additional effect of 15% on CXCL1 pro-
duction in Re-LPS-stimulated ifnar1 -/- cells, while it even doubled the CXCL1 release by FN-stimulated
ifnar1 -/- cells. So indeed, functional absence of IFNAR1 and IFNAR2 simultaneously had a cooperative
effect on increasing CXCL1 levels and exceeded the individual effect of either IFNAR1 or IFNAR2 de-
ficiency. Regarding the regulation of CCL2 production, the results were not as clear. When analyzing
Re-LPS-stimulated cells, the CCL2 release of wt microglia was decreased by 30% in the presence of
α-IFNAR2 antibody (Figure 4.16 B). In contrast to that, CCL2 production by wt microglia was increased
by 30%, when applying the α-IFNAR2 antibody to FN-stimulated cells. However, CCL2 levels triggered
by both TLR4 agonists were substantially reduced in ifnar1 -/- microglia, resulting in less than half of the
response observed in wt cells. This already low CCL2 release could not be further changed by IFNAR2-
blockade. Overall, this could mean that effects of the simultaneous, functional absence of IFNAR1 and
IFNAR2 were not detectable, because the CCL2 levels were already as low as achievable.
4.2.11 Regulation of CXCL1 and CCL2 production depends on janus kinases
Tyk2 and Jak1 are tyrosine kinases that are constitutively associated with IFNAR1 and IFNAR2, re-
spectively. Upon ligand binding to the receptor, they initiate a tyrosine phosphorylation cascade, which
ultimately activates the canonical type I interferon signaling pathway (Stark et al. 1998). Because both
IFNAR subunits were involved in the regulation of microglial CXCL1 and CCL2 production, it was inves-
tigated whether this effect is mediated by the two associated kinases.
In order to test the involvement of Jak1 and Tyk2 in general, microglia were treated with increasing
concentrations of Jak inhibitor I, which is a reversible, ATP-competitive janus kinase inhibitor. With this
compound, the activity of both kinases was blocked for 1 h, before cells were stimulated with Re-LPS
for 18 h. During the whole stimulation period, the inhibitor was present for continuous kinase inhibition.
After 18 h, CXCL1 and CCL2 production was measured by ELISA. The release of both chemokines in
dependency of the inhibitor concentration is summarized in Figure 4.17 A. To allow a comparison of the
effect on both chemokines, absolute values were normalized to amounts produced by cells that were
stimulated with Re-LPS in the absence of Jak inhibitor I. With increasing concentrations of the inhibitor,
CXCL1 levels continuously rose in a dose-dependent manner, while an opposing trend was observed
for CCL2. CCL2 levels were significantly decreased compared to the Re-LPS-stimulated control at
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an inhibitor concentration of 100 nM. At the same concentration, the CXCL1 release was significantly
above control level. With the maximum inhibitor concentration of 500 nM, CXCL1 was increased by
nearly 100%, while CCL2 was decreased by 75%. Thus, the opposing effect of Jak inhibitor I on both
chemokines was achieved dose-dependently with a similar potency and a high maximal effect.
Figure 4.17: Janus kinase inhibition increases CXCL1 and decreases CCL2 production in response to TLR4 stimulation
in a dose-dependent manner. Cultured microglia from wt mice were pre-incubated with the indicated doses of (A) Jak inhibitor I,
(B) GLPG0634 or (C) Solcitinib for 1 h and afterwards stimulated with 10 ng/mL Re-LPS for 18 h in the presence of the respective
dose of the inhibitor. CXCL1 and CCL2 release were determined in cell culture supernatants by ELISA. Absolute values were
normalized to amounts produced by cells stimulated in the absence of the inhibitor. Data are mean±SEM with (A), (B) n=12
from 3 independent experiments or (C) n=20 from 5 independent experiments. Statistical analysis compares the release in
the presence of the respective inhibitor at the indicated concentration with the release in the absence of the inhibitor and was
performed using the Mann-Whitney test, * represents p≤0.05, ** represents p≤0.01, *** represents p≤0.001, **** represents
p≤0.0001.
For dissecting the role of Jak1 and Tyk2 individually, an inhibitor that is more selective for Jak1, namely
GLPG0634, was used. In a similar experimental setup, increasing concentrations of GLPG0634 were
applied to Re-LPS-stimulated microglia. As shown in Figure 4.17 B, this inhibitor revealed a lower
potency for increasing the CXCL1 release. Only at a concentration of 500 nM, a significant increase
compared to control levels was obtained. Because this was the highest used concentration, no dose-
dependency could be proven. Regarding the CCL2 production, GLPG0634 was slightly more potent. A
significant reduction of the CCL2 release was observed at a concentration of 50 nM and it was slightly
further decreased by the presence of higher concentrations of GLPG0634. However, a maximal reduc-
tion of only 40% was achieved. Similar to that, the production of CXCL1 could be only increased by 45%.
In summary, GLPG0634 had a markedly lower maximal effect on CXCL1 and CCL2 production com-
pared to Jak inhibitor I. The release of CXCL1 was less potently increased and no dose-dependency
could be shown. Therefore, GLPG0634 did not serve as a good tool for investigating the role of Jak1
for the regulation of microglial chemokine production in comparison to Tyk2.
Thus, the inhibitor Solcitinib, which is selective for Jak1, was used. In contrast to GLPG0634, this com-
pound showed to be highly potent and effective in regulating both, CXCL1 and CCL2 release. Already
at a concentration of 10 nM, the CXCL1 production was significantly increased by 20% (Figure 4.17 C).
This effect was further enhanced in a dose-dependent manner and reached a maximum of 225% com-
pared to the baseline, representing Re-LPS-stimulated cells without any inhibitor. The regulation of
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CCL2 levels was similarly striking. Solcitinib reduced the CCL2 release by 25% at a concentration of
50 nM and dose-dependently reached a 75% decrease at the maximum concentration of 500 nM.
Overall, inhibition of Jak1 and Tyk2 resulted in a similar outcome as IFNAR1 or IFNAR2 deficiency,
an increased CXCL1 and a decreased CCL2 production by microglia in response to TLR4 stimulation.
This indicates that IFNAR operates via Jak1 and Tyk2 to regulate these two chemokines. Furthermore,
the use of the selective Jak1 inhibitor allowed to prove the dependence of this regulation on Jak1
specifically.
4.2.12 Tyk2 E775K microglia show properties that deviate from the previous re-
sults
By using different kinase inhibitors, it could be shown that the regulation of microglial CXCL1 and CCL2
production depends on the activity of janus kinases. In particular, the involvement of Jak1 was verified.
However, not only Jak1, but also Tyk2 is activated downstream of IFNAR within the canonical type I
interferon signaling pathway. Therefore, it was of interest whether Tyk2 is also important for mediating
the regulatory effect of IFNβ on CXCL1 and CCL2 release. Because no specific Tyk2 inhibitor was
available, a mouse strain with a naturally occurring missense mutation in the tyk2 gene (tyk2 E775K) was
used in order to analyze the effect of Tyk2 deficiency.
Figure 4.18: Tyk2 E775K microglia produce less CXCL1, more CCL2 and slightly less IFNβ than wt cells in response to
TLR4 stimulation. Cultured microglia from wt and tyk2 E775K mice were stimulated with 10 ng/mL Re-LPS, S-LPS or 100 µg/mL
FN for 18 h. (A) CXCL1, (B) CCL2 and (C) IFNβ release were determined in cell culture supernatants by ELISA. Data are
mean±SEM with n=16 from 4 independent experiments. Statistical analysis was performed using the Mann-Whitney test, ** rep-
resents p≤0.01, *** represents p≤0.001, **** represents p≤0.0001.
Thus, microglia were isolated from these mice and their chemokine production was assessed. Following
stimulation with Re-LPS, S-LPS or FN, the release of CXCL1 and CCL2 was measured by ELISA and
then compared to wt cells. Because blockade of janus kinase activity resulted in a dose-dependent
increase of CXCL1 levels (see Figure 4.17 A), a similar outcome was expected by using tyk2 E775K
microglia. However, the complete opposite was the case. Regardless of the used TLR4 agonist, the
CXCL1 production was significantly decreased in tyk2 E775K cells (Figure 4.18 A). They produced about
half the amount that was obtained in wt cells. Regarding the CCL2 release, it was expected to be
reduced in tyk2 E775K microglia according to the results of janus kinase blockade that caused a dose-
dependent decrease of CCL2 (see Figure 4.17 A). But also in this case, the results were opposing to
the expectations. In response to Re-LPS, S-LPS and FN, tyk2 E775K microglia produced nearly double
the amount of CCL2 that was released by wt cells (Figure 4.18 B).
A possible explanation for these unexpected findings could lie in altered IFNβ levels. Therefore, IFNβ
production upon TLR4 stimulation was measured in wt and tyk2 E775K cells. As shown Figure 4.18 C, the
production was slightly reduced in tyk2 E775K microglia. To rule out that this reduction is causative for the
unexpected regulation of CXCL1 and CCL2, IFNβ levels of tyk2 E775K and wt microglia were evened out
by adding high amounts of external IFNβ. These amounts exceeded the intrinsic microglial production
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Figure 4.19: Tyk2 E775K microglia are responsive to IFNβ-mediated regulation of TLR4-induced CXCL1 production. Cul-
tured microglia from wt and tyk2 E775K mice were stimulated with 10 ng/mL Re-LPS or 100 µg/mL FN for 18 h in the presence
(+ IFNβ) or absence (w/o IFNβ) of 10 ng/mL recombinant IFNβ. CXCL1 release was determined in cell culture supernatants
by ELISA. Absolute values were normalized to amounts produced by wt cells stimulated in the absence of IFNβ. Data are
mean±SEM with n=12 from 3 independent experiments.
so much that the differences in the release of both genotypes were neglectable. Subsequently, wt
and tyk2 E775K microglia were stimulated with Re-LPS or FN to induce chemokine production. However,
only measurements of CXCL1 could be included into the evaluation, because IFNβ itself triggered CCL2
production (data not shown) and therefore, no conclusions on TLR4-induced responses could be drawn.
The results of this experiment are shown in Figure 4.19. 100% represents the production by wt microglia
in the absence of additional IFNβ. If IFNβ was added to these cells, this led to a 75-80% reduction of
CXCL1 upon either Re-LPS or FN stimulation. Tyk2 E775K microglia produced per se only 50-60% of the
CXCL1 that was obtained by wt cells. These already reduced levels could be even further decreased
by adding IFNβ, reaching an equal amount as compared to wt cells. Thus, tyk2 E775K microglia were
similarly responsive to IFNβ treatment. This argues for a still functional IFNβ regulatory feedback in
these cells, even though they carry a missense mutation in tyk2.
For finally disrupting this regulatory feedback, two of the in chapter 4.2.11 described inhibitors were
used. First of all, Jak inhibitor I was applied to wt and tyk2 E775K microglia stimulated with Re-LPS.
This inhibitor blocks Jak1 and Tyk2 meaning that, if Tyk2 was still functional in the tyk2 E775K cells, its
activity should be blocked by the inhibitor. Consequently, an effect on CXCL1 and CCL2 levels would
be expected. But while CXCL1 was increased in a dose-dependent manner in wt cells, the tyk2 E775K
microglia did not react to the inhibitor (Figure 4.20 A). At all used concentrations, the CXCL1 production
was only 30% of the control level, represented by Re-LPS-stimulated wt cells in the absence of the
inhibitor, and could not be further increased. In contrast to that, CCL2 levels were similarly affected by
Jak inhibitor I in wt and tyk2 E775K microglia. Both genotypes showed a dose-dependent decrease of the
CCL2 production, which was even more potent in tyk2 E775K microglia, where already the lowest inhibitor
concentration significantly reduced the CCL2 release (Figure 4.20 B). This indicates that the regulation
of CCL2 can be regained in tyk2 E775K microglia by janus kinase blockade, while CXCL1 seems to be
generally dysregulated.
As a comparison to the general janus kinase blockade, Solcitinib was used in the same experimental
setting, because it specifically inhibits Jak1 and does not affect Tyk2. Interestingly, the pattern of CXCL1
and CCL2 release was completely the same as observed for Jak inhibitor I. Solcitinib increased the
CXCL1 production only in wt, but not in tyk2 E775K microglia (Figure 4.20 C). The release of CXCL1
in tyk2 E775K cells stayed at 30% of the wt control, independent of the applied inhibitor concentration.
However, the CCL2 production was dose-dependently decreased in both genotypes with a similar curve
progression, but slightly higher potency in tyk2 E775K microglia (Figure 4.20 D). So also in this case, the
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inhibitor led to a regulation of CCL2, while it failed to affect CXCL1. This argues for a generally impaired
CXCL1 production in tyk2 E775K microglia rather than a dysregulation of this chemokine.
Figure 4.20: Janus kinase inhibition decreases TLR4-induced CCL2 production by tyk2 E775K microglia in a dose-
dependent manner, but does not affect CXCL1 release by these cells. Cultured microglia from wt and tyk2 E775K mice
were pre-incubated with the indicated doses of (A), (B) Jak inhibitor I or (B), (C) Solcitinib for 1 h and afterwards stimulated with
10 ng/mL Re-LPS for 18 h in the presence of the respective dose of the inhibitor. (A), (C) CXCL1 and (B), (D) CCL2 release were
determined in cell culture supernatants by ELISA. Absolute values were normalized to amounts produced by wt cells stimulated
in the absence of the inhibitor. Data are mean±SEM with n=16 from 4 independent experiments. Statistical analysis compares
the release of both genotypes stimulated in the presence of the inhibitor to the release of wt cells stimulated in the absence of the
inhibitor and was performed using the Mann-Whitney test, * represents p≤0.05, ** represents p≤0.01, *** represents p≤0.001,
**** represents p≤0.0001.
4.2.13 Regulation of CXCL1 and CCL2 production depends on STAT1 and STAT2
STAT proteins are intracellular transcription factors that become primarily activated by janus kinases.
Within the canonical type I interferon signaling pathway, activation of Jak1 and Tyk2 results in the recruit-
ment and phosphorylation of several STATs. The most important ones are STAT1 and STAT2, which
associate with IRF9 to form the ISGF3 complex and subsequently regulate the transcription of ISGs
(Platanias 2005). Because STAT1 and STAT2 are the most important mediators of type I interferon
responses downstream of IFNAR and Jak1/Tyk2, they might be involved in the regulation of microglial
CXCL1 and CCL2 production in response to TLR4 challenges.
A prerequisite for such an involvement would be the activation of STAT1 and STAT2 in response to
TLR4 agonists. The up-regulation of both genes upon stimulation of TLR4 would already argue for that.
Therefore, the expression of STAT1 and STAT2 as well as STAT3 was analyzed. Wt microglia were
stimulated with Re-LPS or FN for 3 h and afterwards, mRNA expression was assessed by RT-PCR.
The house-keeping gene gapdh served as internal control and accordingly, ∆cT values were calculated
by cT (gene of interest) - cT (gapdh). Furthermore, unstimulated cells were regarded as baseline gene
expression control and so -∆∆cT values were calculated by ∆cT (unstimulated cells) - ∆cT (stimulated
cells). Hence, values greater than 1 represent an up-regulation, while values less than -1 represent a
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Figure 4.21: Expression of STAT1 and STAT2, but not STAT3 is up-regulated in response to TLR4 stimulation. Cultured
microglia from wt mice were stimulated with 10 ng/mL Re-LPS or 100 µg/mL FN for 3 h. RNA was isolated by using the RNeasy
Mini Kit and converted into cDNA by using the QuantiTect® Reverse Transcription Kit. Real-Time PCR was performed by using the
iTaqTM Universal SYBR® Green Supermix. Gapdh served as internal control and unstimulated cells were regarded as baseline
gene expression control. The interval between the dotted lines indicates no change in gene expression. Data are mean±SEM
with n=3 from 3 independent experiments.
down-regulation. As shown in Figure 4.21, STAT1 and STAT2 expression was up-regulated in response
to Re-LPS or FN, while the expression of STAT3 was not changed. This already points towards a
participation of STAT1 and STAT2 in TLR4-mediated responses.
Nevertheless, this did not necessarily refer to the regulation of TLR4-induced chemokine production.
For proving such a direct relation, STAT1-deficient microglia were used. After stimulation with Re-LPS,
S-LPS or FN, the release of CXCL1 and CCL2 was measured and compared to wt cells. In the absence
of STAT1, the CXCL1 production was up to four times higher than in wt microglia (Figure 4.22 A). But
even though a similar trend was observed for all three TLR4 ligands, a significant difference between wt
and stat1 -/- cells was only observed upon Re-LPS stimulation. The CCL2 release of stat1 -/- microglia
was significantly decreased under all different conditions (Figure 4.22 B).
Figure 4.22: STAT1 deficiency causes increased CXCL1 and decreased CCL2 as well as IFNβ production by TLR4-
stimulated microglia. Cultured microglia from wt and stat1 -/- mice were stimulated with 10 ng/mL Re-LPS, S-LPS or 100 µg/mL
FN for 18 h. (A) CXCL1, (B) CCL2 and (C) IFNβ release were determined in cell culture supernatants by ELISA. Data are
mean±SEM with n=16 from 4 independent experiments. Statistical analysis was performed using the Mann-Whitney test, * rep-
resents p≤0.05, ** represents p≤0.01, **** represents p≤0.0001.
To rule out that the changes in CXCL1 and CCL2 levels were caused by deficient IFNβ production
in the absence of STAT1, this cytokine was also measured. However, IFNβ levels were indeed re-
duced in stat1 -/- compared to wt microglia (Figure 4.22 C). This reduction was significant for Re-LPS-
stimulated cells. Thus, it needed to be dissected whether this decrease in IFNβ is causative for the
altered chemokine production or just an independent observation. In order to determine that, wt and
stat1 -/- microglia were supplemented with high amounts of IFNβ that finally led to a nearly equal level
in both genotypes. Afterwards, cells were stimulated with Re-LPS or FN and the CXCL1 release was
measured. This release was normalized to the amounts obtained by wt microglia in the absence of addi-
tional IFNβ. In Re-LPS-stimulated wt cells, CXCL1 levels were decreased by 80% through the presence
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Figure 4.23: Stat1 -/- microglia are less responsive to IFNβ-mediated regulation of TLR4-induced CXCL1 production
than wt cells. Cultured microglia from wt and stat1 -/- mice were stimulated with 10 ng/mL Re-LPS or 100 µg/mL FN for 18 h in
the presence (+ IFNβ) or absence (w/o IFNβ) of 10 ng/mL recombinant IFNβ. CXCL1 release was determined in cell culture
supernatants by ELISA. Absolute values were normalized to amounts produced by wt cells stimulated in the absence of IFNβ.
Data are mean±SEM with n=16 from 4 independent experiments.
of external IFNβ (Figure 4.23). Stat1 -/- microglia showed per se a 500% increase of CXCL1 compared
to wt. This overproduction could be reduced by addition of IFNβ, but it still exceeded the normal pro-
duction by 150%. When analyzing the FN stimulation, wt microglia behaved completely similar, but the
effect in STAT1-deficient cells was even more striking. Stat1 -/- microglia showed a 600% increase of
CXCL1 compared to wt and IFNβ treatment reduced this by less than 15%. So even though stat1 -/-
microglia were partially affected by high amounts of additional IFNβ, they were much less sensitive than
wt cells. This indicates that the observed changes in CXCL1 and CCL2 production are attributed to the
absence of STAT1 rather than the minor IFNβ deficiency.
Figure 4.24: STAT2 deficiency causes increased CXCL1 and decreased CCL2 production by TLR4-stimulated microglia,
but does not affect IFNβ levels. Cultured microglia from wt and stat2 -/- mice were stimulated with 10 ng/mL Re-LPS, S-LPS or
100 µg/mL FN for 18 h. (A) CXCL1, (B) CCL2 and (C) IFNβ release were determined in cell culture supernatants by ELISA. Data
are mean±SEM with n=24 from 6 independent experiments. Statistical analysis was performed using the Mann-Whitney test,
* represents p≤0.05, ** represents p≤0.01, **** represents p≤0.0001.
Because STAT1 was shown to regulate CXCL1 and CCL2, it was likely that STAT2 is also involved.
STAT2-deficient microglia were used in order to test this hypothesis. In a similar experiment as de-
scribed above, the CXCL1 and CCL2 release by stat2 -/- and wt cells upon TLR4 stimulation was com-
pared. Figure 4.24 A shows that stat2 -/- microglia produced significantly more CXCL1 in response to
LPS than wt cells. The LPS-triggered CCL2 release was significantly reduced in the absence of STAT2
(Figure 4.24 B). Unfortunately, the data on FN stimulation could not be evaluated, because neither of
the genotypes reacted to this FN preparation. So with regard to the CXCL1 and CCL2 levels, STAT1
and STAT2 deficiency resulted in a similar outcome.
Concerning IFNβ production, stat1 -/- and stat2 -/- microglia showed differences. While IFNβ was de-
creased in the absence of STAT1 (Figure 4.22 C), STAT2-deficiency did not alter its release (Figure
4.24 C). Nevertheless, the responsiveness of stat2 -/- cells to high amounts of additional IFNβ was in-
vestigated. As already demonstrated, IFNβ reduced CXCL1 levels in wt cells by more than 80% (Fig-
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Figure 4.25: Stat2 -/- microglia are less responsive to IFNβ-mediated regulation of TLR4-induced CXCL1 production than
wt cells. Cultured microglia from wt and stat2 -/- mice were stimulated with 10 ng/mL Re-LPS for 18 h in the presence (+ IFNβ)
or absence (w/o IFNβ) of 10 ng/mL recombinant IFNβ. CXCL1 release was determined in cell culture supernatants by ELISA.
Absolute values were normalized to amounts produced by wt cells stimulated in the absence of IFNβ. Data are mean±SEM with
n=18-28 from 7 independent experiments. N/A means data not available.
ure 4.25). However, the excessive CXCL1 production in the absence of STAT2 was decreased by only
40% through addition of IFNβ and still remained higher than the normal wt level. So similar to stat1 -/-,
stat2 -/- microglia were only moderately responsive to IFNβ treatment.
Under normal conditions, STAT1 and STAT2 form heterodimers and jointly regulate transcription. How-
ever, the absence of either of these proteins could probably force the respective other to carry out
this task autonomously. Such a phenomenon would interfere with the results obtained in stat1 -/- and
stat2 -/- microglia, because transcriptional regulation would be partially functional. Thus, a compen-
satory mechanism had to be ruled out in both knock-out strains. For that reason, microglia from STAT1-
and STAT2-deficient mice were stimulated with Re-LPS or FN to activate TLR4. As already described,
such a stimulation led to the up-regulation of STAT1 and STAT2, but not STAT3 expression in wt cells
(Figure 4.21). If a compensatory mechanism would apply, STAT2 should be up-regulated in stat1 -/- mi-
croglia and vice versa. However, this was not the case. In the absence of STAT1, STAT2 expression was
not up-regulated as shown by -∆∆cT values around 1 (Figure 4.26 A). The same was true for stat2 -/-
microglia, were no change in STAT1 expression after the stimulation was observed (Figure 4.26 B).
This shows that both transcription factors are cooperatively activated upon TLR4 stimulation and corre-
sponds with the fact that stat1 -/- and stat2 -/- microglia had rather similar properties.
Figure 4.26: Expression of STAT1, STAT2 and STAT3 is not changed by TLR4 stimulation in stat1 -/- and stat2 -/- microglia.
Cultured microglia from (A) stat1 -/- and (B) stat2 -/- mice were stimulated with 10 ng/mL Re-LPS or 100 µg/mL FN for 3 h. RNA was
isolated by using the RNeasy Mini Kit and converted into cDNA by using the QuantiTect® Reverse Transcription Kit. Real-Time
PCR was performed by using the iTaqTM Universal SYBR® Green Supermix. Gapdh served as internal control and unstimulated
cells were regarded as baseline gene expression control. The interval between the dotted lines indicates no change in gene
expression. Data are mean±SEM with n=3 from 3 independent experiments.
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4.3 IFNAR controls TLR2-induced chemokine production
Within the TLR4 system, type I interferon signaling was shown to play a crucial role in controlling
microglial chemokine production. The regulation of CXCL1 and CCL2 essentially depended on an
IFNβ-mediated feedback that used the canonical type I interferon signaling pathway for exerting its
effect. Regarding this, it was of interest whether the same regulatory mechanism applies also to other
TLR systems. Because especially TLR4 responses to bacterial ligands and gram-negative infections
were analyzed, another TLR that is important for fighting bacterial infections was chosen. TLR2 is
essential for mounting reactions to gram-positive bacteria (Akira et al. 2006) and also able to induce
the production of type I interferons under certain circumstances (Barbalat et al. 2009; Dietrich et al.
2010). Thus, regulatory effects of canonical type I interferon signaling could potentially also apply to
TLR2-induced microglial responses.
4.3.1 Regulation of CXCL1 production depends on IFNAR1
The signaling of all type I interferons is initiated by ligand binding to IFNAR. Therefore, this receptor
would be the first important mediator of an IFN-dependent regulation of microglial chemokine produc-
tion in response to TLR2 activation. However, the analysis of chemokine production was in this case
limited to CXCL1. In contrast to the TLR4 system, where CXCL1 and CCL2 are released upon stimu-
lation, activation of the TLR2 receptor complex only triggers CXCL1. Microglia that were treated with
Pam3CSK4 as agonist for TLR1/2 or MALP-2 as agonist for TLR6/2 did not produce any CCL2 as
shown in Figure 4.27 A.
Figure 4.27: While CCL2 is in general not released in response to TLR2 stimulation, IFNAR1 deficiency causes increased
CXCL1 production by TLR2-stimulated microglia. Cultured microglia from (A), (B) wt and (B) ifnar1 -/- mice were stimulated
with 10 ng/mL Pam3CSK4 or MALP-2 for 18 h. (A) CCL2 and (B) CXCL1 release were determined in cell culture supernatants
by ELISA. Data are mean±SEM with n=12 from 3 independent experiments. Statistical analysis was performed using the
Mann-Whitney test, **** represents p≤0.0001.
For evaluating the role of IFNAR1 in regulating CXCL1 production, reactions of wt and ifnar1 -/- microglia
to Pam3CSK4 and MALP-2 were assessed. The comparison of both genotypes revealed differences
after stimulation with both TLR2 ligands. In the absence of IFNAR1, Pam3CSK4- or MALP-2-induced
CXCL1 was more than threefold increased compared to wt levels (Figure 4.27 B). This indicates that
IFNAR1 is indeed important for regulating TLR2-mediated CXCL1 release.
4.3.2 IFNAR1 deficiency does not affect neutrophil infiltration into the brain of
S. pneumoniae-infected mice
S. pneumoniae is a leading cause of bacterial pneumonia, meningitis and sepsis in children worldwide.
Around 11% of all deaths in children aged 1–59 months are attributed to this pathogen (O’Brien et
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al. 2009). Within the CNS, bacterial infections are recognized by the tissue-resident microglia. As a
gram-positive bacterium, S. pneumoniae leads to the activation of TLR2 on these cells (Mogensen et al.
2006). In response to this activation, microglia produce chemokines and recruit peripheral immune cells,
such as monocytes and neutrophils, to the site of inflammation. Because microglial production of the
neutrophil chemoattractant CXCL1 upon TLR2 stimulation in vitro was increased by IFNAR1 deficiency,
the attraction of neutrophils in a gram-positive bacterial infection could be enhanced accordingly.
Figure 4.28: Neutrophil infiltration into the brain of S. pneumoniae-infected mice is not affected by IFNAR1 deficiency.
Wt and ifnar1 -/- mice were intracerebrally injected with 500-800 CFU S. pneumoniae D39 per mouse. As a control, mice were
either injected with PBS or not injected. After 24 h, mice were perfused with PBS. Single-cell suspensions were prepared from
whole brains using the MACS Neural Tissue Dissociation Kit (T) and stained for flow cytometry as indicated. For analysis,
10,000 CD11b+ cells were collected. (A) Representative flow cytometry plots showing the sequence of gating for identification
of inflammatory monocytes, neutrophils and patrolling monocytes based on the expression of CD11b, CD45, Ly6G and Ly6C.
(B), (C) and (D) Quantification of the cell types as described in (A). Data are individual values from 4 independent experiments.
Statistical analysis was performed using the two-way ANOVA with Turkey’s correction, ** represents p≤0.01.
To test this hypothesis, wt and ifnar1 -/- mice were intracerebrally infected with S. pneumoniae D39 and
the subsequent infiltration of monocytes and neutrophils into the brain was assessed by flow cytometry
after 36 h. Monocytes and neutrophils were identified according to their differential expression of the
markers CD11b, CD45, Ly6C and Ly6G. Inflammatory monocytes were considered CD11b+ CD45high
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Ly6Chigh Ly6G-, patrolling monocytes CD11b+ CD45high Ly6Clow Ly6G- and neutrophils CD11b+ CD45high
Ly6C+ Ly6G+ (Figure 4.28 A). Regarding the amount of patrolling monocytes, no obvious systematic
changes were observed in infected compared to PBS-injected or untreated animals independent of
the genotype (Figure 4.28 B). Only numbers of PBS-injected and S. pneumoniae-infected ifnar1 -/- mice
were significantly different. The amount of recruited inflammatory monocytes was slightly increased by
the infection, but the values of single animals varied a lot, so that this increase was not significant (Fig-
ure 4.28 C). Nevertheless, no differences between wt and ifnar1 -/- mice were observed. The same was
true for the neutrophils, where the infection similarly increased the amounts in wt and ifnar1 -/- animals
(Figure 4.28 D). Thus, IFNAR1 deficiency had no effect on the recruitment of peripheral immune cells
in a model of gram-positive bacterial CNS infection.
4.3.3 Altered chemokine production in IFNAR1-deficient microglia is not res-
cued by time
As described in chapter 4.3.1, the absence of IFNAR1 enhanced the microglial production of CXCL1
in response to TLR2 activation. The release upon stimulation with different TLR2 agonists for 18 h
was significantly increased (Figure 4.27 B). However, this does not necessarily mean that the CXCL1
production is generally dysregulated in ifnar1 -/- microglia. Instead, the absence of IFNAR1 could also
cause a delay in the regulation, meaning that the differences in CXCL1 levels between wt and ifnar1 -/-
would even out over time.
Figure 4.29: Altered CXCL1 and CCL2 production by ifnar1 -/- microglia in response to TLR2 stimulation is stable over
time. Cultured microglia from wt and ifnar1 -/- mice were stimulated with 10 ng/mL (A) Pam3CSK4 or (B) MALP-2 for the indicated
time points. CXCL1 release was determined in cell culture supernatants by ELISA. Absolute values were normalized to amounts
produced by wt cells stimulated for 48 h (endpoint). Data are mean±SEM with n=8 from 2 independent experiments. Statistical
analysis compares both genotypes at each time point individually and was performed using the two-way ANOVA with Sidak’s
correction, * represents p≤0.05, ** represents p≤0.01, **** represents p≤0.0001.
In order to rule out such a case, wt and ifnar1 -/- microglia were stimulated with Pam3CSK4 or MALP-
2 for 48 h and the release of CXCL1 was measured over time. A significant difference between both
genotypes was observed after 16 h of stimulation with Pam3CSK4 (Figure 4.29 A) and already after 8 h
of stimulation with MALP-2 (Figure 4.29 B). From this time point on, ifnar1 -/- microglia continuously pro-
duced more CXCL1 than wt cells. With an increasing stimulation interval, CXCL1 levels always further
increased in Pam3CSK4-stimulated cells of both genotypes. In contrast to that, MALP-2 stimulation
induced a slightly different release pattern that in ifnar1 -/- microglia reached a peak after 24 h and after-
wards already decreased again. Still, the IFNAR1-dependent increase in CXCL1 production remained
constantly present in both conditions, indicating no rescue effect by time.
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4.3.4 IFNAR1 deficiency leads to similar changes in the chemokine production
of microglia and bone marrow-derived, but not peritoneal macrophages
Microglia were shown to overproduce CXCL1 in response to Pam3CSK4 and MALP-2 in the absence
of IFNAR1 (see Figure 4.27 B). Since they are the tissue-resident macrophages within the CNS, it was
of interest whether a similar effect could also be observed in other tissue macrophages.
Figure 4.30: IFNAR1 deficiency similarly affects TLR2-induced CXCL1 production by microglia and BMDM, but not by
pMΦ. Cultured microglia, BMDM and pMΦ from wt and ifnar1 -/- mice were stimulated with 10 ng/mL Pam3CSK4 or MALP-2
for 18 h. CXCL1 release was determined in cell culture supernatants by ELISA. Data are mean±SEM with n=8-12 from 3-4
independent experiments. Statistical analysis was performed using the Mann-Whitney test, ** represents p≤0.01, **** represents
p≤0.0001.
Therefore, microglia, BMDM and pMΦ from wt and ifnar1 -/- mice were stimulated with the two TLR2 ag-
onists and the CXCL1 release was quantified. In microglia and BMDM, CXCL1 levels were significantly
enhanced in the absence of IFNAR1 (Figure 4.30). Ifnar1 -/- microglia showed a threefold increase and
ifnar1 -/- BMDM a doubling compared to wt. In contrast to that, the CXCL1 production of pMΦ was not
altered by IFNAR1 deficiency. So overall, CXCL1 production seems not to be generally controlled by
IFNAR1, but is rather differentially affected in certain cell types.
4.3.5 IFNAR1 deficiency can be partially phenocopied by functional block
Because so far all experiments that analyzed effects of IFNAR1 deficiency were performed using cells
isolated from mice with a global IFNAR1 knock-out, the possibility of knock-out-specific impairments
had to be ruled out. A good option for doing this was the comparison of ifnar1 -/- cells with a functional
block of IFNAR1 in wt cells.
Figure 4.31: Functional block of IFNAR1 increases microglial CXCL1 production in response to MALP-2, but not
Pam3CSK4 stimulation. Cultured microglia from wt mice were either pre-incubated (+ α-IFNAR1) or not pre-incubated (w/o
α-IFNAR1) with 10 µg/mL α-IFNAR1 antibody for 1 h and afterwards stimulated with 10 ng/mL Pam3CSK4 or MALP-2 for 18 h
in the presence or absence of 10 µg/mL α-IFNAR1 antibody. CXCL1 release was determined in cell culture supernatants by
ELISA. Absolute values were normalized to amounts produced by cells stimulated in the absence of α-IFNAR1 antibody. Data




For functionally blocking IFNAR1, wt microglia were treated with an α-IFNAR1 antibody for 1 h. Af-
terwards, cells were stimulated with Pam3CSK4 or MALP-2 for 18 h in the presence of the blocking
antibody. The subsequent release of CXCL1 is summarized in Figure 4.31. Absolute values were
normalized to the amount produced by wt cells that were stimulated in the absence of α-IFNAR1 anti-
body. Microglial CXCL1 production in response to Pam3CSK4 was not altered by functional blockade
of IFNAR1. However, CXCL1 levels following MALP-2 stimulation were more than doubled in the pres-
ence of α-IFNAR1 antibody. This mimics the effect that was observed in ifnar1 -/- microglia, but only for
MALP-2-stimulated cells.
4.3.6 Regulation of CXCL1 production depends on IFNAR2
The type I interferon receptor comprises not only IFNAR1, but also IFNAR2. Because thus far only the
involvement of IFNAR1 in the control of TLR2-induced microglial chemokine production was demon-
strated, a potential role for the other receptor subunit should be investigated.
Figure 4.32: Functional block of IFNAR2 increases microglial CXCL1 production in response to TLR2 stimulation. Cul-
tured microglia from wt mice were either pre-incubated (+ α-IFNAR2) or not pre-incubated (w/o α-IFNAR2) with 10 µg/mL α-
IFNAR2 antibody for 1 h and afterwards stimulated with 10 ng/mL Pam3CSK4 or MALP-2 for 18 h in the presence or absence
of 10 µg/mL α-IFNAR2 antibody. CXCL1 release was determined in cell culture supernatants by ELISA. Absolute values were
normalized to amounts produced by cells stimulated in the absence of α-IFNAR2 antibody. Data are mean±SEM with n=12 from
3 independent experiments. Statistical analysis was performed using the Mann-Whitney test, *** represents p≤0.001.
In this regard, an α-IFNAR2 antibody served as tool to functionally block IFNAR2 and analyze effects
of IFNAR2 absence. Microglia were treated with this antibody as described in the previous chapter
and the release of CXCL1 upon stimulation with Pam3CSK4 or MALP-2 was measured by ELISA. The
production in the presence of α-IFNAR2 antibody was normalized to the production in the absence of
the antibody upon treatment with the respective TLR2 agonist. As shown in Figure 4.32, functional
blockade of IFNAR2 significantly enhanced CXCL1 levels in response to Pam3CSK4 or MALP-2. The
release was twice as high as in the absence of α-IFNAR2 antibody. This is rather comparable to effects
that were observed in ifnar1 -/- microglia, which produced three times more CXCL1 than wt cells (see
Figure 4.27 B). Consequently, both IFNAR subunits seem to cooperate in mediating the regulation of
TLR2-triggered CXCL1.
4.3.7 Functional absence of IFNAR1 and IFNAR2 exceeds effects of either de-
ficiency
As previously described, the functional absence of either IFNAR1 or IFNAR2 had an effect on the
CXCL1 production. Because this suggests a cooperation of both IFNAR subunits in regulating this
chemokine, a direct proof of such a fact was requested.
For simultaneous disruption of IFNAR1 and IFNAR2, ifnar1 -/- microglia were treated with the α-IFNAR2
antibody. In this case, both receptor subunits should not be functional. In comparison to that, microglia
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Figure 4.33: Functional absence of IFNAR1 and IFNAR2 cooperatively affects microglial CXCL1 production in response
to TLR2 stimulation. Cultured microglia from wt and ifnar1 -/- mice were either pre-incubated (+ α-IFNAR2) or not pre-incubated
(w/o α-IFNAR2) with 10 µg/mL α-IFNAR2 antibody for 1 h and afterwards stimulated with 10 ng/mL Pam3CSK4 or MALP-2 for
18 h in the presence or absence of 10 µg/mL α-IFNAR2 antibody. CXCL1 release was determined in cell culture supernatants by
ELISA. Absolute values were normalized to amounts produced by wt cells stimulated in the absence of α-IFNAR2 antibody. Data
are mean±SEM with n=12 from 3 independent experiments.
with only IFNAR1 deficiency and solely IFNAR2-blocked microglia were used. All cells were stimulated
with Pam3CSK4 or MALP-2 and the CXCL1 production was quantified after 18 h. The α-IFNAR2 anti-
body was applied to the cells 1 h prior to the stimulation and remained present the whole time. In order
to compare the CXCL1 levels, absolute values were normalized to amounts produced by wt cells. As
already described in chapter 4.3.1, IFNAR1 deficiency caused a more than 130% increase in CXCL1
production compared to wt levels (Figure 4.33). Furthermore, similar to the results shown in chap-
ter 4.3.6, IFNAR2 blockade increased the CXCL1 release in Pam3CSK4- and MALP-2-stimulated wt
microglia, in this case by 35-40%. In the absence of IFNAR1 and IFNAR2 simultaneously as achieved
by IFNAR2 blockade in ifnar1 -/- microglia, CXCL1 levels were even further increased compared to ei-
ther IFNAR1 knock-out or IFNAR2 blockade. IFNAR2-blocked ifnar1 -/- cells produced more than double
the amount of CXCL1 than IFNAR2-blocked wt cells. Apart from that, IFNAR2 blockade had an addi-
tional effect on the already increased CXCL1 release by ifnar1 -/- cells of about 25%. Overall, ifnar1 -/-
microglia treated with the α-IFNAR2 antibody produced nearly 350% of the normal CXCL1 release in
wt cells. So in summary, functional absence of IFNAR1 and IFNAR2 resulted in an enhanced CXCL1
production that exceeded the effect of deficiency in either receptor subunit.
4.3.8 Regulation of CXCL1 production is independent of janus kinases
The canonical type I interferon signaling pathway, which is initiated by ligand binding to IFNAR, further
uses the two tyrosine kinases Jak1 and Tyk2 for signal transduction (Stark et al. 1998). As IFNAR1
and IFNAR2 were shown to cooperatively affect microglial CXCL1 production, the involvement of both
downstream kinases in this regulation was investigated.
A first overview about the general contribution of Jak1 and Tyk2 was obtained by blocking their ki-
nase activity with increasing concentrations of Jak inhibitor I. Therefore, microglia were treated with
the inhibitor 1 h prior to and then continuously during the stimulation with Pam3CSK4 or MALP-2 for
18 h. The release of CXCL1 in response to both TLR2 agonists is shown in Figure 4.34 A. Regarding
Pam3CSK4-stimulated cells, only a minor effect of Jak inhibitor I was observed. At a concentration of
10 nM and 100 nM, CXCL1 levels were significantly increased compared to the amounts produced by
cells that were stimulated with Pam3CSK4 in the absence of Jak inhibitor I. However, none of the other
tested concentrations had any effect on the release, meaning that no dose-dependent influence could
be demonstrated. In contrast to that, a slight decrease of CXCL1 by high concentrations of Jak inhibitor
I was observed in MALP-2-stimulated microglia. The two highest concentrations of 100 nM and 500 nM
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reduced the CXCL1 production by 20% and 35%, respectively. This points towards a dose-dependent,
but rather low effect of the inhibitor on MALP-2-triggered CXCL1 release.
Figure 4.34: Janus kinase inhibition does not affect CXCL1 and CCL2 production in response to TLR2 stimulation in a
dose-dependent manner. Cultured microglia from wt mice were pre-incubated with the indicated doses of (A) Jak inhibitor I,
(B) GLPG0634 or (C) Solcitinib for 1 h and afterwards stimulated with 10 ng/mL Pam3CSK4 or MALP-2 for 18 h in the presence
of the respective dose of the inhibitor. CXCL1 release was determined in cell culture supernatants by ELISA. Absolute values
were normalized to amounts produced by cells stimulated in the absence of the inhibitor. Data are mean±SEM with n=12 from
3 independent experiments. Statistical analysis compares the release in the presence of the respective inhibitor at the indicated
concentration with the release in the absence of the inhibitor and was performed using the Mann-Whitney test, * represents
p≤0.05, ** represents p≤0.01, *** represents p≤0.001, **** represents p≤0.0001.
Because no direct link between overall janus kinase inhibition and CXCL1 production in response to
Pam3CSK4 or MALP-2 could be established, the individual role of Jak1 and Tyk2 should be determined.
For a more selective Jak1 inhibition, GLPG0634 was used, which has a markedly lower IC50 value
for Jak1 than Tyk2. Increasing concentrations of this inhibitor were applied to Pam3CSK4- or MALP-
2-stimulated microglia in the same way as described above. Similar to Jak inhibitor I, GLPG0634
had an unexpected influence on Pam3CSK4-triggered CXCL1 levels. Concentrations of 5 nM, 10 nM
and 100 nM, but no other concentration, significantly increased the CXCL1 production (Figure 4.34 B).
However, there was no general trend observable, meaning that in principle the CXCL1 release remained
more or less stable around the control level. This was even more obvious in response to MALP-2
stimulation, where no difference between inhibitor presence or absence was observed.
For verifying this low impact of Jak1 inhibition on the CXCL1 release, a selective Jak1 inhibitor, namely
Solcitinib, was used. As shown in Figure 4.34 C, neither Pam3CSK4- nor MALP-2-stimulated microglia
changed their CXCL1 production by the presence of this inhibitor. Irrespective of the used concentration,
CXCL1 levels were always completely the same as in the absence of the inhibitor. So indeed, blocking
the kinase activity of Jak1 did not result in alterations of CXCL1.
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4.3.9 Tyk2 E775K microglia show properties that deviate from the previous re-
sults
With the help of different kinase inhibitors and especially the Jak1-specific inhibitor Solcitinib, it was
shown that Jak1 is not involved in the regulation of CXCL1 release. Furthermore, it was already par-
tially indicated by overall janus kinase inhibition with Jak inhibitor I that Tyk2 does also not play a role in
this scenario. For proving this, responses of tyk2 E775K microglia to Pam3CSK4 and MALP-2 stimulation
were evaluated in comparison to wt cells. The CXCL1 release is summarized in Figure 4.35 A. Sur-
prisingly, the tyk2 missense mutation resulted in a substantial decrease of CXCL1 production by about
80%, irrespective of the used TLR2 ligand.
Figure 4.35: Tyk2 E775K microglia produce less CXCL1 than wt cells in response to TLR2 stimulation and this production
can be even lowered by IFNβ treatment. (A) Cultured microglia from wt and tyk2 E775K mice were stimulated with 10 ng/mL
Pam3CSK4 or MALP-2 for 18 h. (B) Cells were stimulated as in (A) in the presence (+ IFNβ) or absence (w/o IFNβ) of 10 ng/mL
recombinant IFNβ. CXCL1 release was determined in cell culture supernatants by ELISA. Data are mean±SEM with n=16 from
4 independent experiments. (A) Statistical analysis was performed using the Mann-Whitney test, **** represents p≤0.0001. (B)
Absolute values were normalized to amounts produced by wt cells stimulated in the absence of IFNβ.
In order to find an explanation for this unexpected result, it was investigated whether maybe type I
interferon signaling is still functional in the tyk2 E775K microglia. As explained in chapter 4.2, IFNβ is
able to negatively regulate CXCL1 production in response to TLR4 agonists. If tyk2 E775K cells would be
able to signal upon type I interferon treatment, IFNβ could possibly also decrease CXCL1 upon TLR2
stimulation. Therefore, high amounts of IFNβ were applied to wt and tyk2 E775K microglia together with
Pam3CSK4 or MALP-2 for induction of TLR2-dependent CXCL1 release. As expected, addition of IFNβ
decreased the CXCL1 level in wt microglia by nearly 90% (Figure 4.35 B). This is similar to what was
observed for IFNβ treatment of TLR4-stimulated wt cells (see Figure 4.19, 4.23 and 4.25). Interestingly,
tyk2 E775K microglia did also respond to IFNβ, meaning that the already really low CXCL1 production in
these cells could be further decreased by about 30%. This indicates that the tyk2 missense mutation
does not disrupt the type I interferon signaling completely.
A possibility to entirely block type I interferon signaling in the tyk2 E775K microglia would be the inhibition
of all janus kinases. This was achieved by using Jak inhibitor I in these cells. Because this inhibitor
targets Jak1 and Tyk2, it should also block remaining kinase activity of Tyk2 in tyk2 E775K microglia. A
comparison of wt and tyk2 E775K cells treated with increasing concentrations of Jak inhibitor I is shown in
Figure 4.36 A and B. Similar to what was described in chapter 4.3.8, the inhibitor had no dose-dependent
effect on the production of CXCL1 by wt microglia in response to Pam3CSK4 or MALP-2. Only some
concentrations affected the CXCL1 level, but mostly, the release stayed around the control level. When
analyzing the tyk2 E775K microglia, also no effect of treatment with Jak inhibitor I was observed. The
CXCL1 production constantly stayed below 15% of the release that was obtained by wt cells, which
were stimulated in the absence of the inhibitor. Even the highest concentration of 500 nM could not
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increase this really low CXCL1 level in tyk2 E775K microglia. This indicates that these cells are in general
impaired in their CXCL1 production.
In case of such a general impairment, also specific Jak1 inhibition should not change the CXCL1 release
by tyk2 E775K microglia. Thus, these cells were treated with Solcitinib, which only blocks Jak1, but not
Tyk2 activity. Treatment with this inhibitor revealed a similar pattern as described for Jak inhibitor I.
Solcitinib also had no dose-dependent effect on the production of CXCL1 by wt microglia in response to
Pam3CSK4 or MALP-2 (Figure 4.36 C and D). Even though some concentrations affected the CXCL1
levels, no overall trend was observable. In tyk2 E775K microglia, the CXCL1 production was not affected
at all by increasing concentrations of Solcitinib. The release stayed below 15% of the wt control and
could not be changed by any inhibitor concentration. This supports the assumption that tyk2 E775K
microglia are generally impaired in producing CXCL1.
Figure 4.36: Janus kinase inhibition does not affect TLR2-induced CXCL1 production by tyk2 E775K microglia. Cultured
microglia from wt and tyk2 E775K mice were pre-incubated with the indicated doses of (A), (B) Jak inhibitor I or (B), (C) Solcitinib
for 1 h and afterwards stimulated with 10 ng/mL (A), (C) Pam3CSK4 or (B), (D) MALP-2 for 18 h in the presence of the respective
dose of the inhibitor. CXCL1 release was determined in cell culture supernatants by ELISA. Absolute values were normalized to
amounts produced by wt cells stimulated in the absence of the inhibitor. Data are mean±SEM with n=16 from 4 independent
experiments. Statistical analysis compares the release of both genotypes stimulated in the presence of the inhibitor to the release
of wt cells stimulated in the absence of the inhibitor and was performed using the Mann-Whitney test, * represents p≤0.05,
** represents p≤0.01, *** represents p≤0.001, **** represents p≤0.0001.
4.3.10 Regulation of CXCL1 production is independent of STAT1 and STAT2
STAT1 and STAT2 are the most important downstream effectors of the canonical type I interferon sig-
naling pathway. They shape type I interferon responses by regulating the expression of ISGs upon
activation of IFNAR (Platanias 2005). Because IFNAR1 and IFNAR2 were shown to cooperatively
affect the production of CXCL1, the two STAT proteins could be important for mediating this effect.
This would require that STAT1 and STAT2 are activated in response to TLR2 challenges. Such an acti-
vation would be accompanied by elevated expression of both transcription factors. Thus, microglia were
stimulated with Pam3CSK4 or MALP-2 for 3 h and the STAT1 and STAT2 expression was determined by
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Figure 4.37: Expression of STAT1, STAT2 and STAT3 is not changed by TLR2 stimulation in wt, stat1 -/- and stat2 -/-
microglia. Cultured microglia from (A) wt, (B) stat1 -/- and (C) stat2 -/- mice were stimulated with 10 ng/mL Pam3CSK4 or MALP-
2 for 3 h. RNA was isolated by using the RNeasy Mini Kit and converted into cDNA by using the QuantiTect® Reverse Transcription
Kit. Real-Time PCR was performed by using the iTaqTM Universal SYBR® Green Supermix. Gapdh served as internal control
and unstimulated cells were regarded as baseline gene expression control. The interval between the dotted lines indicates no
change in gene expression. Data are mean±SEM with n=3 from 3 independent experiments.
RT-PCR. As a comparison, STAT3 was also analyzed. According to the explanation in chapter 4.2.13,
-∆∆cT values were calculated and served as relative measurement for up- or down-regulation of the
respective genes. Values greater than 1 represent an up-regulation and values less than -1 a down-
regulation. As shown in Figure 4.37 A, all -∆∆cT values were within the 1 to -1 interval. Hence, the
expression of none of the three STAT proteins was changed by activation of TLR2.
However, the expression of STAT genes could be different in the absence of either of these transcription
factors. Lack of one STAT protein could result in an increase of another STAT. In order to test this hypoth-
esis, stat1 -/- and stat2 -/- microglia were analyzed. Both genotypes were stimulated with Pam3CSK4 or
MALP-2 and the STAT1, STAT2 and STAT3 expression was measured. Similar to what was observed in
wt cells, no change in gene expression upon TLR2 stimulation could be demonstrated. STAT1-deficient
microglia did not up-regulate STAT2 or STAT3 (Figure 4.37 B) and STAT2-deficient microglia showed no
increase in STAT1 or STAT3 levels (Figure 4.37 C). This is in line with the above described phenomenon
that STAT1, STAT2 or STAT3 are not activated by TLR2 agonists in wt microglia.
Figure 4.38: STAT1 and STAT2 deficiency do not affect CXCL1 production by TLR2-stimulated microglia. Cultured mi-
croglia from wt and (A) stat1 -/- or (B) stat2 -/- mice were stimulated with 10 ng/mL Pam3CSK4 or MALP-2 for 18 h. CXCL1 release
was determined in cell culture supernatants by ELISA. Data are mean±SEM with (A) n=16 from 4 independent experiments and
(B) n=24 from 6 independent experiments. Statistical analysis was performed using the Mann-Whitney test.
However, this does not necessarily mean that STAT1 and STAT2 could not be involved in IFNAR-
mediated regulation of CXCL1 production. For directly demonstrating a contribution of the two tran-
scription factors to the effect of IFNAR, stat1 -/- and stat2 -/- microglia were used. Both genotypes were
stimulated with Pam3CSK4 or MALP-2 and the release of CXCL1 was quantified. If STAT1 and STAT2
would mediate the regulation of this chemokine, an overproduction as observed in the absence of IF-
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NAR1 (see Figure 4.27 B) or IFNAR2 (see Figure 4.32) would be expected. However, no difference in
the production of CXCL1 was observed in the absence of either STAT1 or STAT2 in comparison to wt
levels irrespective of the used TLR2 ligand (Figure 4.38 A and B). So indeed, both transcription factors
did not participate in the regulation of CXCL1 as it was indicated by the expression analysis.
4.4 Type I interferon signaling controls TLR3-induced chemokine
production
The regulation of chemokine production in response to TLR4 activation was shown to be controlled by
the canonical type I interferon signaling pathway. In contrast to this, only IFNAR was demonstrated
to be involved in regulating TLR2-induced chemokines. So finally, a third TLR system was analyzed
regarding the requirement of type I interferon signaling for control of chemokine production. With TLR4
and TLR2, two TLRs with differences in their signaling were chosen. While TLR4 uses the MyD88- and
the TRIF-dependent signaling pathway, TLR2 recruits only MyD88 (Akira et al. 2006). To complete the
picture, a TLR that requires only TRIF for its signaling was missing and thus, TLR3 was selected.
Figure 4.39: While CXCL1 is in general not released in response to TLR3 stimulation, IFNAR1 deficiency causes de-
creased CCL2 production by TLR3-stimulated microglia. Cultured microglia from (A), (B) wt and (B) ifnar1 -/- mice were
stimulated with 50 µg/mL poly I:C for 18 h. (A) CXCL1 and (B) CCL2 release were determined in cell culture supernatants by
ELISA. Data are mean±SEM with n=12 from 3 independent experiments. Statistical analysis was performed using the Mann-
Whitney test, *** represents p≤0.001.
However, in this system just a reduced set of experiments was performed, which focused on the most
important parts of the canonical type I interferon signaling pathway. Because CXCL1 was not produced
in response to TLR3 stimulation (Figure 4.39 A), the analysis of chemokines was limited to CCL2.
First of all, the involvement of IFNAR in the regulation of CCL2 release in response to poly I:C as
representative TLR3 agonist was assessed. In order to model receptor deficiency, IFNAR1-deficient
microglia were used. These cells were stimulated with poly I:C and the production of CCL2 was mea-
sured in comparison to wt levels. In the absence of IFNAR1, CCL2 release was significantly decreased
as ifnar1 -/- microglia produced 80% less CCL2 than wt cells (Figure 4.39 A). This shows that the regu-
lation of TLR3-triggered CCL2 production depends on IFNAR1.
A similar phenomenon was also observed in other tissue macrophages. In the absence of IFNAR1,
BMDM failed to produce any CCL2 in response to poly I:C (Figure 4.40). Thus, the effect of IFNAR1
deficiency on CCL2 release was even more striking than in microglia. In contrast to this, pMΦ showed
the same production of CCL2 in the presence or absence of IFNAR1. However, this production was in
general very low compared to the CCL2 levels that were obtained by microglia or BMDM.
Downstream of IFNAR, the two transcriptions factors STAT1 and STAT2 were analyzed in terms of their
contribution to the IFNAR1-mediated regulation of CCL2. By using stat1 -/- and stat2 -/- microglia, it
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Figure 4.40: IFNAR1 deficiency similarly affects TLR3-induced CCL2 production by microglia and BMDM, but not by pMΦ.
Cultured microglia, BMDM and pMΦ from wt and ifnar1 -/- mice were stimulated with 50 µg/mL poly I:C for 18 h. CCL2 release
was determined in cell culture supernatants by ELISA. Data are mean±SEM with n=8-12 from 3-4 independent experiments.
Statistical analysis was performed using the Mann-Whitney test, *** represents p≤0.001, **** represents p≤0.0001.
Figure 4.41: STAT1 and STAT2 deficiency cause decreased CCL2 production by TLR3-stimulated microglia. Cultured mi-
croglia from wt and (A) stat1 -/- or (B) stat2 -/- mice were stimulated with 50 µg/mL poly I:C for 18 h. CCL2 release was determined
in cell culture supernatants by ELISA. Data are mean±SEM with (A) n=16 from 4 independent experiments and (B) n=24 from 6
independent experiments. Statistical analysis was performed using the Mann-Whitney test, ** represents p≤0.01, **** represents
p≤0.0001.
could be demonstrated that adequate CCL2 production depends on the presence of both transcriptions
factors. In the absence of STAT1, CCL2 levels were reduced by 50%, while in STAT2-deficient cells
the reduction was even more than 75% (Figure 4.41 A and B). Thus, STAT1 and STAT2 seem to be
mediators of the IFNAR1-dependent control of TLR3-induced CCL2 production.
Figure 4.42: Deficient type I interferon signaling impairs IFNβ production by TLR3-stimulated microglia. Cultured microglia
from wt and (A) ifnar1 -/-, (B) stat1 -/- or (C) stat2 -/- mice were stimulated with 50 µg/mL poly I:C for 18 h. IFNβ release was
determined in cell culture supernatants by ELISA. Data are mean±SEM with (A) n=12 from 3 independent experiments, (B)
n=16 from 4 independent experiments and (C) n=24 from 6 independent experiments. Statistical analysis was performed using
the Mann-Whitney test, * represents p≤0.05, **** represents p≤0.0001.
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However, deficient type I interferon signaling did not only affect the release of CCL2, but also impaired
IFNβ production. In ifnar1 -/-, stat1 -/- and stat2 -/- microglia, IFNβ levels were significantly reduced com-
pared to wt. This reduction ranged from 65% in ifnar1 -/- and stat1 -/- microglia to 90% in stat2 -/- cells
(Figure 4.42 A, B and C). These results indicate that functional type I interferon signaling is required for
ensuring the high levels of IFNβ that are produced in response to TLR3 activation.
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The CNS is an essential organ for survival and thus, definitely needs to be defended from harmful
threats. As first line of defense, the innate immune system is crucial for protection against pathogens or
tissue damage. Within the CNS, microglia serve as principle innate immune cells that can initiate a vari-
ety of responses and execute different protective functions depending on the respective context. In this
regard, they are able to secrete various soluble factors that further shape the immune reaction. Among
these, interferons are of great importance for fighting viral and also bacterial infections. Apart from that,
they have been implicated in several autoimmune diseases and even homeostatic processes (Owens
et al. 2014). During the last years, increasing evidence for additional immunomodulatory functions of
interferons accumulated. It has been shown that they regulate innate and adaptive immune responses
under physiological and pathological conditions. On the one hand, they restrain the development of sev-
eral immunopathologies and are even approved as treatment and on the other hand, they can increase
the severity of some diseases (González-Navajas et al. 2012). Interestingly, the molecular mechanisms
by which interferons exert these opposing regulatory functions are still largely unknown. Nevertheless,
especially negative control of immune responses could be clearly protective for the host, considering
that excessive inflammatory reactions can lead to tissue impairment and even death. Since the CNS
has a restricted cell renewal and regenerative capacity, it is extremely vulnerable to uncontrolled auto-
destructive immune and inflammatory responses, which makes a tight control of these processes even
more important (Gao and Hong 2008). Therefore, we investigated how microglial responses to CNS
infection and damage are regulated by IFNβ as representative interferon and propose a mechanism
how it exerts its effects.
5.1 Microglia mainly produce IFNβ in response to activation of
different TLRs
Interferons are signaling molecules within the immune system that can be released upon encounter
with several pathogens, such as bacteria, viruses and parasites. They regulate immune responses and
serve important functions in fighting infections. Their production is induced by a large variety of PRRs,
including TLRs (Trinchieri 2010). TLRs are expressed on cells of the innate immunity in order to detect
pathogens and tissue damage by recognition of PAMPs and DAMPs, respectively. Within the CNS,
most of the different TLRs are expressed on microglia as the tissue-resident macrophage population
(Kettenmann et al. 2011). Thus, these cells are in principle capable of producing interferons. About
12 interferon species have been identified that are classified in three different types (Pestka 2007).
The subgroup of type I interferons includes several interferon proteins with IFNα and IFNβ being the
immunologically most relevant. Therefore, the production of these two molecules by microglia was as-
sessed in response to activation of different TLRs.
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Interferons have important antiviral functions, meaning that they are produced during viral infections
(Sen 2001). A molecular pattern associated with such infections is double-stranded RNA, which can be
recognized by TLR3 (Akira et al. 2006). As a synthetic analog of double-stranded RNA, poly I:C also
activates TLR3 (Takeuchi and Akira 2010). In line with previous studies in human embryonic kidney cells
(Alexopoulou et al. 2001), we showed that IFNβ expression was induced by poly I:C in microglia. Even
though only moderate expression levels were detected, these resulted in massive amounts of protein
production. While no expression of four different IFNα subtypes (IFNαB, 6, 12, 14) was detected,
substantial IFNα release in response to poly I:C could be measured. Thus, microglia seem to fight viral
infections by producing both type I interferons. Indeed, they were shown to be, together with astrocytes,
the major source of IFNβ in La Crosse virus-infected mice (Kallfass et al. 2012) and also produce IFNα
in response to Theiler’s murine encephalomyelitis virus (Olson and Miller 2004).
Apart from their involvement in viral infections, interferons also participate in immune responses to bac-
terial pathogens (Decker et al. 2005). Bacteria can be sensed by different TLRs, including TLR2 and
TLR4. While the TLR2 complex mainly detects gram-positive bacteria, TLR4 is responsible for recogni-
tion of gram-negative bacteria (Kawai and Akira 2010). TLR2 is activated by different ligands that vary
depending on the respective receptor heterodimer. For example, TLR1/2 recognizes the triacylated
lipopeptide Pam3CSK4 (Jin et al. 2007) and TLR6/2 the diacylated lipopeptide MALP-2 (Takeuchi et al.
2001). In general, it is assumed that type I interferons are not produced in response to these bacterial
TLR2 agonists (Toshchakov et al. 2002; Barbalat et al. 2009). Even though Dietrich et al. (2010) could
show a low IFNβ production following stimulation with Pam3CSK4 or MALP-2, this seems to be highly
dependent on the cell type and respective context. In our experiments, neither IFNα nor IFNβ was
produced in response to Pam3CSK4 or MALP-2 as verified by mRNA expression analysis via RT-PCR
and protein measurements by ELISA. Similarly, activation of TLR4 by Re-LPS failed to induce IFNα
on mRNA and protein level, probably due to the lack of IRF7 induction (Noppert et al. 2007), which is
required for IFNα production (Kawai et al. 2004). In contrast to this, several TLR4 agonists were able to
induce IFNβ in microglia as it was already demonstrated by others (Jung et al. 2005; Regen et al. 2011;
Menzfeld et al. 2015). According to these studies, a comparison of Re-LPS- and Pam3CSK4-induced
type I interferon expression confirmed that only the TLR4 and not the TLR2 agonist triggers IFNβ. Apart
from Re-LPS, also S-LPS and live E. coli led to IFNβ release by microglia at an intermediate level. In
line with previous studies, the production stayed markedly lower than the amount obtained by poly I:C
stimulation (Jack et al. 2005). Nevertheless, it could be increased dependent on the dose of stimulus.
The same holds true for FN, which dose-dependently induced IFNβ release similar to LPS and E. coli.
FN represents a major component of the extracellular matrix, but is also an abundant soluble constituent
of plasma (Pankov and Yamada 2002). Thus, it can serve as a DAMP indicating tissue damage or vas-
cular leakage. Because IFNβ release was triggered by FN, this points towards a role of IFNβ also in
tissue impairment. Interestingly, FN-stimulated microglia had a much higher IFNβ mRNA expression
than Re-LPS-stimulated cells, but a similar protein production. Accordingly, IFNβ release cannot be
only transcriptionally controlled. Rather translational regulation needs to also occur as it was already
demonstrated by others (Grafi et al. 1993).
The differences in induction of type I interferons between the examined TLR systems correlated with
differences in their respective signaling pathways. In general, TLR signaling is initiated by TIR domain-
containing adaptor proteins (O’Neill and Bowie 2007). There exist two major signaling routes. One
pathway utilizes MyD88, while the other recruits TRIF. Upon recruitment of TRIF, the activation of IRF3
leads to type I interferon production (Fitzgerald et al. 2003). In contrast to that, MyD88-dependent type
I interferon production by endosomal TLRs and TLR2 requires IRF7 (Takeuchi and Akira 2010; Dietrich
et al. 2010). Considering the TLR systems that we investigated, they differentially use the described
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signaling pathways. TLR3 exclusively signals via TRIF, TLR2 uses only MyD88 and TLR4 activates
both signaling cascades (Akira et al. 2006). As only TLR3 and TLR4, but not TLR2 stimulation led to
type I interferon production by microglia, we hypothesized that this might be due to the use of TRIF.
Because IFNα was only released upon poly I:C treatment, we hereinafter focused on IFNβ. Analysis
of MyD88- and TRIF-deficient microglia revealed that indeed only TRIF is required for IFNβ production
by microglia. While IFNβ levels were completely the same in wt and myd88 -/- cells, TRIF deficiency
dramatically impaired IFNβ release. In response to TLR4 agonists, no IFNβ could be detected in trif lps2
microglia. Additionally, the production was decreased by one third in poly I:C-stimulated trif lps2 cells. So
similar to other studies (Yamamoto et al. 2003), we could show a TRIF dependence of microglial IFNβ
production.
The TRIF-dependent signaling pathway is not initiated from the cell surfaces, but from endosomal com-
partments. TLR3 is located at endosomes and can therefore directly recruit the adaptor protein TRIF.
However, TLR4 is a cell surface receptor and thus, the receptor complex needs to be internalized by
endocytosis in order to get access to the TRIF signaling route (Kagan et al. 2008). This process is
controlled by the TLR4 co-receptor CD14 (Zanoni et al. 2011). Because TRIF was shown to enable mi-
croglial IFNβ production, this link from CD14 to the TRIF-dependent signaling suggests a crucial role for
CD14. Therefore, TLR4-stimulated microglia from wt and cd14 -/- mice were compared concerning their
IFNβ release. In CD14-deficient microglia, IFNβ production in response to Re-LPS was completely
absent. This is in line with previous studies, showing that cd14 -/- peritoneal macrophages, BMDM
and dendritic cells do not produce IFNβ upon LPS stimulation (Jiang et al. 2005; Zanoni et al. 2011).
Furthermore, also live E. coli and FN did not trigger IFNβ release by cd14 -/- microglia. This indicates
a global dependence of different TLR4 agonists on the presence of CD14 for mounting IFNβ responses.
Overall, we demonstrated that microglia produce IFNα and IFNβ during viral infections as mimicked by
poly I:C stimulation. Furthermore, TLR4 agonists related to gram-negative bacteria and tissue damage
induced IFNβ release. This production depended on the TRIF signaling pathway, which is controlled
by CD14 in TLR4-triggered responses. In contrast to that, bacterial ligands activating TLR2 failed to
induce IFNα and IFNβ release by microglia.
5.2 IFNAR controls chemokine production in response to TLR4,
TLR2 and TLR3
Apart from their important functions in fighting viral and bacterial infections, interferons exert a variety
of immunomodulatory functions. They regulate innate as well as adaptive immune responses under
physiological and pathological conditions. This includes modulation of generation, trafficking and effec-
tor activity of several immune cells. In this regard, interferons can control cell trafficking by regulating
the expression of different chemokines in response to various stimuli or diseases (Rauch et al. 2013).
The activation of TLRs by stimulation with PAMPs and DAMPs leads to the production of chemokines
as well as type I interferons. This means that interferons could regulate TLR-induced chemokines within
the same response. As shown by Regen et al. (2011), IFNβ differently regulates several chemokines
that were released by microglia in response to different variants of the TLR4 agonist LPS. Among these
chemokines, CXCL1 was clearly less produced in the presence of IFNβ. A similar effect was observed
for TLR2-induced responses, where CXCL1 levels were also decreased by IFNβ treatment (Regen, un-
published). The regulation of TLR4-induced CXCL1 was further proven to be CD14-dependent (Janova
et al. 2016). In the absence of CD14, microglia overreacted to strong infectious stimuli and this also
manifested in a massive overproduction of CXCL1. However, normal CXCL1 levels could be restored by
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an IFNβ-mediated feedback mechanism. In contrast to that, other chemokines showed opposing fea-
tures. As an example, LPS-induced CCL2 production was not increased, but even slightly decreased
in cd14 -/- microglia. However, normal CCL2 levels could be regained by addition of IFNβ. Because
IFNβ was shown to opposingly regulate CXCL1 and CCL2, the mechanism underlying this effect was
investigated. In response to all type I interferons, the canonical type I interferon signaling pathway is
initiated. Thus, this pathway could be essential for controlling TLR-induced chemokine production.
The cell surface receptor that recognizes all type I interferons is called IFNAR. It consist of the two
subunits IFNAR1 and IFNAR2 that are both required for effective ligand binding (Cohen et al. 1995).
Consequently, this receptor would be the first critical step of an IFNβ-mediated regulatory mechanism.
In order to dissect the role of IFNAR in this setting, receptor deficiency was modeled by IFNAR1 knock-
out (Müller et al. 1994). Microglia from ifnar1 -/- mice were isolated and their chemokine production in
response to the stimulation of different TLRs was analyzed. Similar to the investigation of type I in-
terferon production, experiments focused on TLR4, TLR2 and TLR3 as representative TLR systems.
According to their potential to be regulated by IFNβ, chemokine measurements included CXCL1 and
CCL2. However, only TLR4 agonists were able to induce both chemokines. In contrast to this, we
could not detect any CCL2 18 h after Pam3CSK4 or MALP-2 stimulation. This can be explained by the
fact that CCL2 production in response to TLR2 agonists needs more than 18 h to be established as
indicated by previous work (Regen, unpublished) showing that no plateau in microglial CCL2 levels is
present even 72 h after Pam3CSK4 or MALP-2 stimulation. Apart from that, no CXCL1 was released
by poly I:C-stimulated microglia.
When comparing ifnar1 -/- with wt microglia, dramatic changes in their CXCL1 and CCL2 release were
observed. CXCL1 production was increased in response to all tested TLR4 and TLR2 agonists, but
the overproduction was markedly higher in TLR4- than TLR2-stimulated cells. Nevertheless, this effect
was shown to be present over a time period of 48 h in both TLR systems, indicating a stable effect
that cannot be rescued by time. So similar to CD14 deficiency (Janova et al. 2016), IFNAR1 knock-out
resulted in a loss of negative regulation of microglial CXCL1 production in response to TLR4 stimu-
lation. This directly links the CD14-dependent IFNβ-mediated feedback to type I interferon signaling.
However, this mechanism cannot account for the TLR2 system. Even though CD14 was demonstrated
to enhance TLR2 activity (Yoshimura et al. 1999), no increase of CXCL1 production in the absence
of CD14 could be shown (Janova, unpublished). Furthermore, as described in chapter 4.1, no IFNβ
was released upon Pam3CSK4 or MALP-2 stimulation. Thus, overproduction of CXCL1 in response to
TLR2 stimulation can neither be attributed to CD14 nor to an IFNβ-mediated regulatory feedback. Inter-
estingly, the regulation of CXCL1 by IFNAR1 seems to be highly dependent on the respective context.
CXCL1 production was shown to be higher in influenza-infected ifnar1 -/- mice following secondary in-
fection with S. pneumoniae as compared to wt controls (Shahangian et al. 2009). Since S. pneumoniae
activate TLR2 (Yoshimura et al. 1999; Mogensen et al. 2006), this is in line with our data concerning
overproduction of CXCL1 in TLR2-challenged ifnar1 -/- microglia. In contrast to that, early CXCL1 ex-
pression was diminished in kidneys of Candida albicans-infected ifnar1 -/- compared to wt mice (Majer
et al. 2012). A possible explanation could be that sensing of Candida albicans requires cooperative
recognition by CLRs and TLRs (Netea et al. 2006), while we only investigated responses to TLRs. This
would argue for a differential regulatory impact of IFNAR on chemokine production depending on the
type of the triggering receptor. Additionally, this could also indicate a cell type-specificity, since we
observed an effect of IFNAR1-deficiency on microglial CXLC1 production and not on kidney cells.
Regarding CCL2 production, TLR4- and TLR3-stimulated microglia were similarly affected by IFNAR1
deficiency. Under both conditions, ifnar1 -/- microglia released less CCL2 than wt cells. Similar to what
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was described for CXCL1, these results indicate that IFNβ regulates microglial chemokine production
via its receptor IFNAR. This is supported by the fact that CCL2 production was shown to be controlled by
IFNAR during the late phase of Listeria monocytogenes infection (Jia et al. 2009) and septic peritonitis
(Weighardt et al. 2006). Since IFNβ was released in response to LPS and poly I:C, its regulatory effect
applies to the TLR4 as well as the TLR3 system. In both cases, IFNβ-mediated regulation could be
attributed to CD14, as this is not only used as TLR4 co-receptor (Wright et al. 1990), but also enhances
TLR3 activation in response to poly I:C (Lee et al. 2006).
However, these results do not necessarily refer to the absence of IFNAR1. If ifnar1 -/- microglia would
have an impairment in IFNβ production, this would cause a similar outcome. As shown for cd14 -/- mi-
croglia, the lack of IFNβ leads to a dysregulation of several chemokines, including CXCL1 and partially
CCL2 (Janova et al. 2016). Thus, alterations of IFNβ levels in ifnar1 -/- microglia had to be ruled out. In
response to several TLR4 agonists, no difference between IFNβ release by wt and ifnar1 -/- cells was
observed. So indeed, the IFNAR1 deficiency rather than an impairment in IFNβ seems to be causative
for the observed alterations in the production of CXCL1 and CCL2. However, this was different for poly
I:C-triggered responses. In this case, IFNβ levels were dramatically reduced in the absence of IFNAR1.
Most likely, this is due to lack of the positive feedback that normally amplifies IFNβ production during
viral infections. This amplification is initiated by small amounts of IFNβ that bind to IFNAR and thereby
lead to the release of IFNα and more IFNβ (Sato et al. 1998). As a consequence, IFNβ production can-
not be enhanced in ifnar1 -/- cells. Accordingly, we could not conclude whether IFNAR1 deficiency or
this lowered IFNβ level causes the decreased CCL2 production in poly I:C-stimulated ifnar1 -/- microglia.
Microglia are tissue-resident macrophages of the CNS, but within different other tissues there exists a
variety of these tissue-resident cells. This includes, for example, peritoneal macrophages in serosal
tissue or bone marrow macrophages within the bone (Davies et al. 2013). These cells differ from mi-
croglia not only in their location, but also in their origin (Epelman et al. 2014). Nevertheless, they share
many functions in terms of tissue surveillance and responses to infection. For this reason, the regu-
lation of their chemokine production could be similarly organized. In order to test this, microglia, pMΦ
and BMDM from wt and ifnar1 -/- mice were compared regarding their CXCL1 and CCL2 release in re-
sponse to TLR stimulation. When stimulated with agonists for TLR4, TLR2 and TLR3, microglia and
BMDM showed overall a similar release pattern. CXCL1 was increased and CCL2 decreased in the
absence of IFNAR1. In contrast to that, pMΦ reacted partially different. While they showed the same
picture as microglia and BMDM in response to TLR4 activation, IFNAR1 deficiency did not change their
TLR2-induced CXCL1 and TLR3-induced CCL2 levels. A possible explanation could lie in the different
location of these cells. Microglia reside in tissue of an immune-privileged organ (Galea et al. 2007)
and the bone marrow is also mainly separated from the rest of the body providing immune-privileged
sites for haematopoietic stem cells (Mercier et al. 2012). In contrast to that, pMΦ are located within the
peritoneal cavity, which is in close proximity to the gastro-intestinal tract. Thus, pMΦ come into contact
with bacterial and viral products from either invading pathogens or the microbiota more frequently than
microglia or BMDM. This could require additional regulatory mechanisms that prevent excessive activa-
tion of pMΦ, so that IFNAR1 only partially controls the chemokine production of these cells.
However, using a complete knock-out system bears some risks as it affects all cells within the body also
already during development. So far, all described results concerning effects of IFNAR1 deficiency were
obtained by using ifnar1 -/- cells isolated from mice with a global knock-out of IFNAR1. Because IFNAR1
is expressed in all tissues and organs, this could have far-reaching functional consequences (de Weerd
et al. 2007). Ifnar1-/- mice are more susceptible to viral infections (Müller et al. 1994), have impaired
responses to parasites (Xin et al. 2010) and show enhanced osteoclastogenesis with decreased bone
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density (Teitelbaum and Ross 2003). These systemic alterations suggest that also ifnar1 -/- microglia
could have impairments in their immune functions. In order to rule out knock-out specific, intrinsic
problems, IFNAR1 was functionally blocked in wt cells. This system has the advantage of properly
developed, fully functional cells that only cannot activate IFNAR1. Thus, differences in their chemokine
production can be completely attributed to the presence or absence of the IFNAR1-blocking antibody.
Indeed, IFNAR1 blockade revealed very similar results to IFNAR1 knock-out. In response to TLR4 and
partially TLR2 stimulation, an increase in CXCL1 and decrease in CCL2 levels was observed. Only
CXCL1 production by Pam3CSK4-stimulated microglia was not enhanced by the IFNAR1-blocking an-
tibody, which might be due to incomplete receptor blockade. So overall, IFNAR1 blockade could mimic
the properties of the knock-out. However, effects in IFNAR1-blocked microglia were not as striking as
in ifnar1 -/- cells. Most probably, this is due to a reduced efficiency of the blocking antibody compared
to a 100% effective knock-out. Nevertheless, this proves that the chemokine production by ifnar1 -/-
microglia is not altered per se, but rather IFNAR1 directly regulates CXCL1 and CCL2 production.
Even though IFNAR1 and IFNAR2 were shown to cooperate for effective ligand binding (Cohen et al.
1995), several type I interferons have different affinities for either of the receptor subunits (Jaks et al.
2007). In this regards, it was shown that IFNβ can bind to IFNAR1 in an IFNAR2-independent manner
(de Weerd et al. 2013). Therefore, it was investigated whether IFNAR2 participates in the IFNAR1-
mediated regulation of microglial chemokine production. Because no IFNAR2 knock-out mice were
available, an antibody was used to functionally block IFNAR2 in wt cells. Similar to the IFNAR1 block-
ade, application of an α-IFNAR2 antibody increased the CXCL1 and decreased the CCL2 production
by microglia. With this approach, we could demonstrate that IFNAR2 is also involved in regulating the
TLR4- and TLR2-induced chemokine release.
So finally, we wanted to investigate whether both receptor subunits cooperate for the regulation of
microglial chemokine production. In order to create an IFNAR1 / IFNAR2-deficient system, ifnar1 -/-
microglia were treated with the IFNAR2-blocking antibody. The CXCL1 and CCL2 release of these
double-deficient cells was compared to IFNAR1-deficient, IFNAR2-blocked and wt microglia. In the
absence of IFNAR1 and IFNAR2 simultaneously, effects on TLR4- and TLR2-triggered CXCL1 levels
were even stronger than in individual deficiency. The already increased production in ifnar1 -/- compared
to wt cells could be further enhanced by IFNAR2-blockade. In contrast to that, no additional effect of
IFNAR2-blockade on CCL2 release by ifnar1 -/- microglia could be observed. While CCL2 levels were
lower in ifnar1 -/- compared to wt cells, this could be not further decreased with the α-IFNAR2 antibody.
Possibly, the CCL2 production by ifnar1 -/- microglia was already as low as achievable. Nevertheless,
the results concerning CXCL1 demonstrated a cooperative regulation by IFNAR1 and IFNAR2.
All in all, we could show that IFNAR with its both subunits IFNAR1 and IFNAR2 is critical for the regula-
tion of chemokine production. This is the case for microglia, but also other tissue-resident macrophages.
In particular, CXCL1 and CCL2 release in response to TLR stimulation were controlled by this receptor.
Thus, the canonical type I interferon signaling pathway could be essential for this regulatory mechanism.
5.3 IFNAR1 regulates the infiltration of neutrophils in a model of
gram-negative, but not gram-positive meningitis
Meningitis is an acute inflammation of the meninges that can be life-threatening, especially in neonates.
In 2013, 16 million people worldwide suffered from meningitis (Global Burden of Disease Study 2013
Collaborators 2015) of which 303,000 died (GBD 2013 Mortality and Causes of Death Collaborators
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2015). The disease is typically caused by infectious agents, including several bacteria. In neonates,
the most common meningeal pathogens are group B streptococci and E. coli K1. Infants and small
children are mostly affected by S. pneumoniae, Neisseria meningitidis and Haemophilus influenzae
type B, while in children older than 5 years and adults bacterial meningitis is almost exclusively caused
by S. pneumoniae and Neisseria meningitidis (Sáez-Llorens and McCracken 2003).
The meninges are in direct contact with the brain and therefore, bacterial constituents can reach the
brain tissue leading to a large-scale inflammation. Such inflammatory reactions involve microglia as the
tissue-resident immune cells, which can sense the presence of bacterial components by recognition
of PAMPs, for example through TLRs (Barichello et al. 2016). Activation of these receptors triggers
the production of several cytokines and chemokines with subsequent recruitment of peripheral immune
cells into the CNS (Gerber and Nau 2010). As a first line of defense, monocytes and neutrophils are
rapidly recruited to the site of inflammation. Thereby, monocytes follow chemotactic gradients of CCL2
and CCL7 (Tsou et al. 2007), while neutrophils migrate along CXCL1 and CXCL2 gradients (Wengner
et al. 2008).
As a model of gram-negative meningitis, infection was induced by intracerebral injection of E. coli K1.
Similarly, gram-positive meningitis was evoked by S. pneumoniae D39 injection. While E. coli contain
LPS within their cell wall, which is sensed by TLR4 (Hoshino et al. 1999), peptidoglycan and lipotei-
choic acid as cell wall components of S. pneumoniae are recognized by TLR2 (Yoshimura et al. 1999;
Mogensen et al. 2006). Because we could show that following stimulation of TLR4 or TLR2, microglial
production of the neutrophil chemoattractant CXCL1 and the monocyte chemoattractant CCL2 in vitro
is regulated by IFNAR, we hypothesized that this receptor also controls the in vivo recruitment of these
cells accordingly. Therefore, we compared wt and ifnar1 -/- mice concerning their infiltration of mono-
cytes and neutrophils into the brain after intracerebral injection of E. coli or S. pneumoniae. Because
both infections have a different latency period until the onset of disease symptoms, E. coli-injected mice
were analyzed 24 h and S. pneumoniae-injected animals 36 h after the infection.
In E. coli-infected wt and ifnar1 -/- mice, substantial amounts of inflammatory monocytes and neutrophils
infiltrated the brain after 24 h. While no difference between both genotypes regarding monocyte num-
bers was observed, significantly more neutrophils were detected in the brains of ifnar1 -/- mice. Similar
results were obtained in response to sterile axotomy, where IFNAR1 deficiency increased the infiltration
of leukocytes into the brain (Khorooshi and Owens 2010) and in a model of septic peritonitis, in which
peritoneal neutrophil recruitment and activation was augmented in ifnar1 -/- mice (Weighardt et al. 2006).
In our E. coli meningitis model, the elevated neutrophil numbers mirror our in vitro data that revealed a
massive overproduction of the neutrophil chemoattractant CXCL1 by TLR4-stimulated microglia in the
absence of IFNAR1. In contrast to that, the slightly decreased CCL2 production by ifnar1 -/- microglia
was not reflected in reduced monocyte numbers. This could be attributed to the fact that monocytes do
not only follow CCL2, but also CCL7 gradients (Tsou et al. 2007).
Importantly, this difference in the recruitment of neutrophils could not be caused by an exacerbated
disease progression due to impaired microglial phagocytosis in ifnar1 -/- mice. Microglia are capable of
phagocytosing different nonencapsulated and encapsulated bacteria, including E. coli (Kaur et al. 2004;
Ribes et al. 2009) and S. pneumoniae (Ribes et al. 2010). This ability is a powerful mechanism to fight
against brain infections, such as meningitis (Sierra et al. 2013). If microglia are not able to properly
phagocytose the invading E. coli, this could lead to multiplication of the bacteria and thus, to a spread of
the infection (Ribes et al. 2009). Accordingly, this would result in an increased recruitment of peripheral
immune cells in order to cope with the infection. However, we demonstrated that ifnar1 -/- microglia
have the same capacity as wt cells to phagocytose pathogens, represented by E. coli and endogenous
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material, represented by myelin. This is in line with previous reports showing that the phagocytosis
of bacteria by macrophages is not altered by IFNAR deficiency (Kelly-Scumpia et al. 2010; Rathinam
et al. 2012). Thus, it appears to be really the IFNAR-dependent regulation of TLR4-induced CXCL1 that
makes the difference in neutrophil recruitment during E. coli meningitis.
As the production of CXCL1 in response to TLR2 stimulation was also increased by IFNAR1 defi-
ciency, we hypothesized that the recruitment of neutrophils during S. pneumoniae meningitis would
be enhanced similar to the E. coli model. However, already the amount of recruited monocytes and
neutrophils was markedly lower in S. pneumoniae- than E. coli-infected mice. Even though more cells
compared to untreated animals or PBS controls were observed, these numbers did not reach statistical
significance. One reason for that is the high variation between individual animals. While E. coli-infected
mice showed a relatively homogeneous disease severity as determined by bacteremia, S. pneumoniae
infection was much more variable with a markedly higher mortality rate (data not shown). Within the
first 36 h, this mortality rate did not differ between wt and ifnar1 -/- mice (data not shown), indicating
no difference in disease susceptibility in our short-term model. Considering long-term survival studies,
results concerning the influence of IFNAR1 on resistance against S. pneumoniae are, however, contro-
versial (Mancuso et al. 2007; Mitchell et al. 2012). Apart from the high variation of the disease outcome,
another reason for the low amount of infiltrating immune cells might lie in the time point. In this regard,
36 h could prove to be suboptimal. As shown by Janova et al. (2016), monocyte and neutrophil numbers
in the brain peak 24 h after intracerebral E. coli injection and subsequently decrease again. Additionally,
the leukocyte density in the CSF of S. pneumoniae-infected mice is also highest 24 h after the injection
and already lower at the 36 h time point, even though disease symptoms are worst after 36 h (Gerber
et al. 2001). However, it was necessary to wait 36 h instead of 24 h for the animals to show disease
symptoms, because the S. pneumoniae infection has a higher latency. Nevertheless, also the overall
lower amounts of infiltrating cells allowed a comparison of wt and ifnar1 -/- mice. This revealed no dif-
ference in monocyte and neutrophil numbers between both genotypes. Hence, the overproduction of
CXCL1 by TLR2-stimulated ifnar1 -/- microglia did not correlate with the neutrophil recruitment in the
S. pneumoniae meningitis model. A possible explanation for this could be that S. pneumoniae do not
only activate TLR2, but also TLR4 and TLR9 (Mogensen et al. 2006; Lee et al. 2007). Furthermore,
NOD2 contributes to sensing of S. pneumoniae by intracellular recognition (Opitz et al. 2004). Thus, the
recruitment of neutrophils could be organized more complex than simply depending on TLR2-induced
chemokine production. In this context, also the release of CXCL2 as neutrophil chemoattractant could
play a crucial role. IFNAR1-deficient microglia that were stimulated with Pam3CSK4 or MALP-2 for ac-
tivating the TLR2 complex did not produce more CXCL2 than wt cells (data not shown). This indicates
that CXCL2 in contrast to CXCL1 release is not controlled by IFNAR1. Therefore, neutrophils could
also follow an IFNAR1-independent gradient of CXCL2 during S. pneumoniae meningitis.
In summary, we identified IFNAR1 as important regulator of gram-negative CNS infection. In a model
of E. coli meningitis, controlled infiltration of neutrophils was dependent on the presence of IFNAR1. In
contrast to that, gram-positive S. pneumoniae meningitis seems to be organized independent of type I
interferon signaling.
5.4 The infiltration of neutrophils into focal NMO-like lesions is
independent of IFNAR1
NMO is a chronic inflammatory demyelinating disease of the CNS. In contrast to bacterial infections,
such as meningitis, the inflammation is in this case not caused by invading pathogens, but linked to
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autoantibodies directed against AQP4 (Lennon et al. 2005). These serum autoantibodies have been
found in about 60-80% of the NMO patients (Jarius et al. 2011). Because in the CNS AQP4 is mainly
expressed on astrocytes (Nagelhus et al. 2004), these cells are the primary target of the autoantibod-
ies. Thus, NMO lesions are characterized by extensive loss of astrocytes (Roemer et al. 2007; Misu
et al. 2007) with subsequent reduction of oligodendrocyte numbers and demyelination (Lucchinetti et al.
2002; Wrzos et al. 2014).
In our model, focal NMO-like lesions were induced by stereotactic injection of a human recombinant
anti-AQP4 antibody (NMO-Ab) together with human complement into the cortex of mice. In accordance
with other studies in mice (Saadoun et al. 2010) and rats (Wrzos et al. 2014), the injection resulted in
astrocyte depletion and lesion formation. This process was accompanied by infiltration of immune cells.
As described by Lucchinetti et al. (2002), inflammatory infiltrates within human NMO lesions consist of
monocytes, macrophages, lymphocytes and polymorphonuclear cells, such as neutrophils, basophils
and eosinophils. Similar observations were made in animal models of focal NMO (Asavapanumas et al.
2014; Wrzos et al. 2014). According to that, we were able to detect substantial amounts of neutrophils
within the lesions 24 h after the injection.
Because we could show that the infiltration of neutrophils in a model of gram-negative meningitis is
controlled by IFNAR1, we hypothesized that a similar regulation could also apply to other inflamma-
tory conditions. In this regard, NMO is a very interesting model as it is no bacterial infection, but an
autoimmune disorder. For dissecting the role of IFNAR1 in this context, we compared the infiltration
of neutrophils into focal NMO-like lesions of wt and ifnar1 -/- mice by using two different approaches.
On the one hand, neutrophils were counted in CAE-stained sections and on the other hand, they were
detected in whole brain single-cell suspensions by flow cytometry. Even though neutrophil numbers
were in general rather low compared to the meningitis model, more infiltrating cells were observed in
NMO-Ab-injected animals than in PBS-injected controls. However, there was no difference between wt
and ifnar1 -/- mice. Analysis of inflammatory monocytes and patrolling monocytes revealed also similar
numbers in both genotypes. Thus, immune cell infiltration into focal NMO-like lesions was not altered
by IFNAR1 deficiency in our model. At first glance, this seems to be in contrast to a study by Khorooshi
et al. (2013), which showed a dependence of NMO-like pathology on type I interferon responses. They
observed a reduced NMO histopathology in IFNAR1-deficient mice that also manifested in reduced
numbers of infiltrating granulocytes 4 days after lesion induction. However, the different timing is most
probably the point that makes the difference. At 2 days after lesion induction, no significant changes
in granulocyte numbers of ifnar1 -/- compared to wt mice were observed in this study. Considering that
we already analyzed neutrophil numbers after 24 h, this early infiltration proves to be independent of
IFNAR1.
An important mechanism to guide immune cells into damaged tissue is the establishment of chemotactic
gradients (Hesselgesser and Horuk 1999). The migration of neutrophils is thereby mainly determined
by CXCL1 and CXCL2 (Wengner et al. 2008). These chemokines are rapidly upregulated under several
neuropathologic conditions (Omari et al. 2006; Semple et al. 2010; Johnson et al. 2011), including NMO
(Herges et al. 2012). According to that, we observed elevated intracerebral CXCL1 levels in mice with
focal NMO-like lesions. A comparison of wt and ifnar1 -/- animals 24 h after lesion induction revealed a
similarly increased production, indicating no influence of type I interferon signaling on CXCL1 levels in
the lesions. This correlated with the fact that early neutrophil infiltration was independent of IFNAR1.
However, it contrasts our findings concerning CXCL1 production in response to TLR4 and TLR2, where
we demonstrated an IFNAR-dependent control. Accordingly, involvement of type I interferon signaling
71
5. DISCUSSION
in the regulation of CXCL1 levels might be highly dependent on the pathway that triggers the chemokine
production.
Apart from CXCL1 and CXCL2, the anaphylatoxin C5a acts as potent neutrophil chemoattractant (Ward
and Newman 1969; Fernandez et al. 1978). C5a is a protein fragment that is released upon activation of
the complement cascade (Nesargikar et al. 2012). During NMO, the complement cascade is initiated by
binding of the autoantibodies to AQP4 on astrocytes leading to complement-mediated astrocyte dam-
age, followed by granulocyte infiltration and oligodendrocyte death (Papadopoulos and Verkman 2012).
It was shown in human NMO lesions that the complement cascade is extensively activated (Lucchinetti
et al. 2002) and thus, the presence of C5a could lead to the recruitment of neutrophils. This is sup-
ported by the fact that C5a levels were found to be significantly elevated in the CSF of NMO patients
(Kuroda et al. 2013). Hence, attraction of neutrophils to NMO lesions might depend on activation of the
complement cascade rather than CXCL1 production.
Overall, our results indicate mechanistic differences in immune cell attraction during different diseases
of the CNS. While IFNAR1 was demonstrated to be an important regulator of neutrophil recruitment in
a model of gram-negative meningitis, it had no influence on this process in a model of focal NMO. In
this regard, especially the involvement of TLRs and subsequent CXCL1 production seems to be the key
issue concerning the influence of IFNAR1.
5.5 Janus kinases control chemokine production in response to
TLR4, but not TLR2
Janus kinases are a family of intracellular, non-receptor tyrosine kinases. This family comprises four
members, namely Jak1, Jak2, Jak3 and Tyk2. They are involved in signaling cascades of receptors that
use the so-called Jak-STAT pathway for their signal transduction (Ghoreschi et al. 2009). One of these
receptors is IFNAR and accordingly, Jak1 and Tyk2 are the central kinases within the canonical type I
interferon signaling pathway. Upon binding of type I interferons to IFNAR, they initiate a tyrosine phos-
phorylation cascade that ultimately leads to the activation of STAT transcription factors and expression
of ISGs (Platanias 2005).
We demonstrated that IFNAR is an important regulator of TLR-induced chemokine production. In partic-
ular, CXCL1 and CCL2 levels were shown to be opposingly affected by IFNAR deficiency. Considering
that IFNAR mainly exerts its effects via the canonical type I interferon signaling, Jak1 and Tyk2 could
be important mediators of the IFNAR-dependent control of these chemokines.
In order to get an overview about a possible influence of janus kinases in general, the kinase activity
of all family members was blocked. Therefore, microglia were stimulated with agonists for TLR4 and
TLR2 to induce CXCL1 and CCL2 production in the presence of Jak inhibitor I. This compound is a re-
versible, ATP-competitive janus kinase inhibitor, which potently blocks kinase activity with an IC50 value
of 15 nM for Jak1 and 1 nM for Tyk2 (Thompson et al. 2002). In response to Re-LPS as TLR4 agonist,
Jak inhibitor I dose-dependently decreased CCL2 and increased CXCL1 production. Interestingly, so far
mostly negative regulatory effects of janus kinase inhibitors on different cytokines and chemokines were
observed. Similar to our results regarding Re-LPS-induced CCL2, Jak inhibitor I was shown to decrease
dsRNA-induced production of CXCL10 and CCL5 in microglia (Nakamichi et al. 2005). Furthermore,
the Jak1 / Jak2 inhibitor Ruxolitinib reduced the production of IL-12 by dendritic cells (Heine et al. 2013)
and the Jak1 / Jak3 inhibitor Tofacitinib suppressed synovial expression of CCL2, CXCL10 and CXCL13
in patients with rheumatoid arthritis (Boyle et al. 2015). Consequently, the marked increase that we
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observed in CXCL1 production upon treatment with Jak inhibitor I seems to be rather unique. Neverthe-
less, this reflects our observations in an IFNAR-deficient system, indicating that indeed janus kinases
mediate the regulatory effect of IFNAR. However, even though Jak inhibitor I was claimed to be highly
potent (Williams et al. 2009), a concentration of 100 nM, which by far exceeds the above mentioned
IC50 values, was necessary to obtain significant differences in CXCL1 and CCL2 levels. Nevertheless,
a high maximal effect on both chemokines could be achieved. In response to MALP-2 as TLR2 ago-
nist, a dose-dependent decrease of CXCL1 production with a similar potency, but much lower maximal
effect than in the TLR4 system was observed. This trend is in contrast to our results regarding IFNAR,
whose deficiency consistently increased TLR2-triggered CXCL1 levels. Interestingly, Jak inhibitor I had
no dose-dependent effect on Pam3CSK4-induced CXCL1, but increased its production at seemingly
random concentrations. Thus, the regulation of TLR2-induced chemokine production is most probably
independent of janus kinases and the observed findings are attributed to off-target effects.
All janus kinases share the same structure. They consist of seven Jak homology (JH) regions that
contain a kinase domain (JH1), a pseudokinase domain (JH2), a SH2 domain (JH3, JH4), and a four-
point-one, ezrin, radixin, moesin (FERM) domain (JH6, JH7) (Ghoreschi et al. 2009). The enzymatic
activity resides within the kinase domain, while the catalytically inactive pseudokinase domain has only
regulatory functions (Chen et al. 2000; Saharinen and Silvennoinen 2002). The janus kinase SH2
domain is structurally important, but does not have its classical phospho-tyrosine-binding capability
(Radtke et al. 2005) and the FERM domain mediates protein-protein interactions, linking janus kinases
with their cognate transmembrane cytokine receptor proteins (Tanner et al. 1995; Girault et al. 1998).
This overall high structural similarity is also reflected in the kinase domain that shares about 50%
sequence identity (Williams et al. 2009). According to that, it is very difficult to design kinase inhibitors
that specifically target only one member of the janus kinase family. In order to dissect the individual
role of Jak1 and Tyk2 in the regulation of TLR-induced chemokine production, we used GLPG0634.
This inhibitor is more selective for Jak1 than Tyk2 as indicated by the IC50 values of 10 nM for Jak1 and
116 nM for Tyk2 (Van Rompaey et al. 2013). In comparison to Jak inhibitor I, GLPG0634 had a reduced
potency and lower maximal effect on the production of CXCL1 and CCL2 in response to Re-LPS. Only
the highest concentration significantly increased CXCL1, so that no dose-dependency could be shown.
Concerning the reduction of CCL2 levels, which was already described previously (Van Rompaey et
al. 2013), the potency was higher, but overall, the dose-response curves did not show a continuous
curve progression. On the one hand, this markedly lower effect of GLPG0634 could be attributed to
the fact that it more selectively targets Jak1, while Jak inhibitor I blocks Jak1 and Tyk2 relatively equal.
This would point towards a cooperative effect of both kinases in the regulation of CXCL1 and CCL2
production. On the other hand, biochemical properties of the compound and correspondingly lower
biological activity could be an explanation. Thus, we could not conclude on a selective impact of Jak1
on TLR4-induced chemokine production. Regarding TLR2-triggered CXCL1 levels, GLPG0634 had no
systematic effect. While it increased CXCL1 production in response to Pam3CSK4 at some random
concentrations, it had no effect on MALP-2 -induced release. So similar to Jak inhibitor I, we could
not show an involvement of janus kinases in IFNAR-dependent control of CXCL1 levels in response to
TLR2.
For finally investigating the role of Jak1 in regulating TLR4- versus TLR2-induced chemokines, we took
advantage of a new compound that is a Jak1-specific inhibitor, namely Solcitinib (Kahl et al. 2016).
Because of its novelty, so far no IC50 value was published. When applying this inhibitor to Re-LPS-
stimulated microglia, it proved to be highly potent and effective in increasing CXCL1 and decreasing
CCL2 levels in a dose-dependent manner. In contrast to this, no effect on TLR2-induced CXCL1 pro-
duction was observed. So by using this compound, we could demonstrate that Jak1 specifically partici-
pates in the control of TLR4-, but not TLR2-induced chemokine production. Unfortunately, these results
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could not be verified in a Jak1 knock-out system, because jak1 -/- mice fail to nurse and die perinatally
(Rodig et al. 1998).
By using different inhibitors, we could show that janus kinases and in particular Jak1 are important regu-
lators of CXCL1 and CCL2 production in response to TLR4 stimulation. This links the IFNAR-dependent
control of these chemokines with the key kinases of the canonical type I interferon signaling pathway.
Nevertheless, a direct proof for an involvement of Tyk2 in this scenario was missing. Because no Tyk2-
specific inhibitor was available, a Tyk2-deficient mouse strain should be used in order to investigate the
individual role of this kinase. As we did not have access to tyk2 -/- mice (Shimoda et al. 2000), we used
a mouse strain with a naturally occurring missense mutation in the tyk2 gene (tyk2 E775K). This mutation
is located in an invariant motif of the pseudokinase domain within the JH2 region (Shaw et al. 2003),
which is required for Tyk2 activation by phosphorylation and also for its kinase activity (Velazquez et al.
1995). Accordingly, no active Tyk2 can be detected in tyk2 E775K mice (Shaw et al. 2003). Therefore,
tyk2 E775K mice served as a model of Tyk2 deficiency.
Interestingly, tyk2 E775K microglia showed totally unexpected properties. Because overall blockade of
janus kinases by Jak inhibitor I resulted in increased CXCL1 and decreased CCL2 levels in TLR4-
stimulated cells, we hypothesized a similar pattern in tyk2 E775K microglia. However, we observed com-
pletely opposite results as the Tyk2 missense mutation resulted in increased CCL2 and decreased
CXCL1 production. This was not only true for TLR4-, but also for TLR2-induced responses. Consid-
ering that none of the tested janus kinase inhbitors dose-dependently altered TLR2-triggered CXCL1
release, this was even more surprising. A possible explanation for these unexpected findings could
lie in altered IFNβ production. The presence of high IFNβ levels decreases Re-LPS- or FN-induced
CXCL1 release dramatically (Janova et al. 2016). Furthermore, IFNβ triggers CCL2 production even
in the absence of any TLR agonist (McManus et al. 2000; Fantuzzi et al. 2001), which we also ob-
served in tyk2 E775K microglia (data not shown). So overall, higher IFNβ levels in tyk2 E775K microglia
could cause the observed decrease in CXCL1 and increase in CCL2. However, the IFNβ production
was even slightly reduced in tyk2 E775K microglia, indicating that another mechanism accounts for this
phenomenon. Surprisingly, we could even show that tyk2 E775K microglia react to high amounts of exoge-
nous IFNβ by decreasing CXCL1 levels similar to wt cells, which argues for a functional IFNβ-mediated
regulatory feedback. Thus, type I interferon signaling is not completely disrupted by the Tyk2 missense
mutation. In line with that, it was shown that type I interferon responses are only partially impaired in
Tyk2-deficient mice (Karaghiosoff et al. 2000; Shimoda et al. 2000). A possible explanation could lie
in still functional Jak1. It was shown that tyk2 E775K cells express normal levels of Jak2 protein and
exhibit a Jak2 phosphorylation response (Shaw et al. 2003), so most probably the same also applies to
Jak1. Accordingly, Jak1 could mediate an IFNβ-induced regulation of CXCL1 production independent
of Tyk2. This would indicate that either both kinases do not need to cooperate for signal transduction
or that Jak1 functionally dominates over Tyk2. In order to prove such a possibility, janus kinases were
completely blocked by using Jak inhibitor I. With this inhibitor, Jak1 as well as possibly remaining Tyk2
kinase activity should be disrupted. However, even the highest concentration did not affect the really
low CXCL1 production in both, TLR4- and TLR2-stimulated tyk2 E775K microglia. Similar results were
obtained by using Solcitinib as selective Jak1 inhibitor. Taken together, this data argues for a gen-
eral impairment of CXCL1 production in tyk2 E775K microglia. In line with that, CXCL1 expression in an
anti-type II collagen antibody-induced arthritis model (Ishizaki et al. 2011) as well as an IL-23-induced
psoriasis-like skin inflammation model (Ishizaki et al. 2014) was significantly lower in tyk2 -/- than wt
mice. Furthermore, selectivity of the CXCL1 impairment is supported by the fact that CCL2 production
by tyk2 E775K microglia could be dose-dependently decreased by Jak inhibitor I and Solcitinib similar to
wt cells. However, inconsistent with the previously described results, wt and tyk2 E775K cells showed a
74
5. DISCUSSION
comparable CCL2 production in these experiments. When comparing this to the literature, Tyk2 knock-
out, in contrast to the Tyk2 missense mutation, even results in decreased expression of CCL2 under
inflammatory conditions (Ishizaki et al. 2011; Ishizaki et al. 2014). Nevertheless, this demonstrates that
tyk2 E775K microglia are in principle sensitive to janus kinase inhibition and wt levels of CCL2 can be
restored.
Overall, it could not be clarified whether Tyk2 participates in mediating the IFNAR-dependent control of
TLR-induced chemokine production by using tyk2 E775K microglia. On the one hand, the obtained re-
sults would indicate that Tyk2 is not crucial, because the Tyk2 impairment was not sufficient to decrease
CCL2 levels, but rather complete janus kinase blockade or Jak1 inhibition were required. However, no
conclusions on CXCL1 production could be drawn. On the other hand, the necessity of janus kinase
blockade for obtaining a regulatory effect could also indicate that Tyk2 is still functional in tyk2 E775K
microglia. Even though it was reported that no active Tyk2 can be detected in these cells, the mu-
tation only affects the pseudokinase domain (Shaw et al. 2003). This could result in residual kinase
activity that interferes with our results. Accordingly, blockade of Tyk2 kinase activity would cause the
decreased CCL2 production and consequently, Tyk2 could be important for mediating effects of IFNAR
on chemokine production. Furthermore, it has to be considered that probably also protein-protein in-
teractions of Tyk2 are still present in tyk2 E775K cell, which have a completely functional FERM domain.
This is underlined by the fact that only the FERM domain, stabilized by JH3-5, is required for Tyk2 bind-
ing to IFNAR1 (Richter et al. 1998). Hence, Tyk2 could exert regulatory effects, apart from acting as
kinase, by interacting with other proteins. Thus, microglia carrying a missense mutation in the tyk2 gene
did not serve as a good tool for investigating the role of Tyk2 in an IFNβ-mediated IFNAR-dependent
regulatory feedback.
In summary, we demonstrated by using different kinase inhibitors that CXCL1 and CCL2 levels in re-
sponse to TLR4 stimulation are regulated by janus kinases and in particular Jak1. This is in line with our
observations regarding IFNAR as regulator of these chemokines. In contrast to that, the TLR2 system
was shown to be mainly independent of these kinases, even though CXCL1 levels were controlled by
IFNAR. Thus, janus kinases selectively mediate IFNAR-dependent effects on different TLR systems.
5.6 STAT1 and STAT2 control chemokine production in response
to TLR4 and TLR3, but not TLR2
STAT proteins are a group of transcription factors that transmit extracellular signals into the nucleus.
They are mainly activated by membrane receptor-associated janus kinases and thus, serve as essential
mediators within Jak-STAT signaling (Darnell et al. 1994). So far, seven different mammalian STAT
proteins have been identified: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 (Shuai and
Liu 2003). They were first described for their involvement in the interferon system (Fu et al. 1992; Shuai
et al. 1993), but also participate in signal transduction of other cytokine receptors and growth factors
(Sadowski et al. 1993).
Downstream of IFNAR, several STATs become activated. STAT1 and STAT2 are the essential mediators
of the canonical type I interferon signaling, but STAT3 and STAT5 can be also involved in type I interferon
responses (Yang et al. 1996; Meinke et al. 1996). Upon activation, STAT1 and STAT2 heterodimerize
and recruit IRF9 in order to form the ISGF3 complex (Martinez-Moczygemba et al. 1997). This complex
binds to ISREs in the promoter of ISGs and thereby regulates gene transcription (Schindler et al. 1992).
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Following activation of different TLRs, several interferons are released leading to activation of type I
interferon signaling. The striking cross-talk of both pathways is illustrated by the fact that several TLR-
mediated functions are not generated in the absence of IFNAR (Hwang et al. 1995; Hamilton et al.
1996). Apart from that, involvement of type I interferon signaling in TLR-induced responses can be
demonstrated by activation of STAT proteins as crucial transcription factors within this pathway (Ohmori
and Hamilton 2001). Upon stimulation of TLR4 by LPS, STAT1 becomes activated as shown by tyrosine
phosphorylation (Toshchakov et al. 2002). This holds also true for TLR3 activation by poly I:C, but not
for the TLR2 agonist Pam3CSK4 (Rhee et al. 2003; Luu et al. 2014). In line with these findings, we
observed up-regulation of STAT1 gene expression in microglia stimulated with Re-LPS or FN, but not
Pam3CSK4 or MALP-2. However, since STAT1 also participates in responses to IFNγ, the activation of
this protein is not necessarily specific to type I interferon signaling (Platanias 2005). Therefore, we also
measured the expression of STAT2, which rather specifically regulates transcription in response to type
I, but not type II interferons (Shuai et al. 1992). This analysis revealed a similar up-regulation of STAT1
and STAT2 expression in TLR4-, but not TLR2-stimulated microglia. Accordingly, STAT1/2 heterodimers
as essential transcriptional regulators of type I interferon signaling could participate in TLR4-mediated
responses.
For this reason, STAT1 and STAT2 would be promising candidates for meditating the IFNAR-dependent
and janus kinase-mediated regulation of microglial CXCL1 and CCL2 production in response to TLR4,
but not TLR2. In order to test this hypothesis, stat1 -/- and stat2 -/- microglia were analyzed concerning
their chemokine release triggered by TLR4, TLR2 and additionally also TLR3 stimulation.
Within the TLR2 system, deficiency in STAT1 or STAT2 did not affect microglial CXCL1 production,
which is in line with the previously shown absence of STAT1 involvement in TLR2-mediated responses
(Toshchakov et al. 2002; Rhee et al. 2003) and our observations concerning gene expression. Fur-
thermore, this reflects our results regarding janus kinases. Since they most probably do not participate
in responses to TLR2 as indicated by chemokine production independent of these kinases, they could
also not activate the downstream transcription factors STAT1 and STAT2.
In contrast to that, TLR3-triggered responses were altered by STAT1 and STAT2 deficiency. CCL2
production was decreased in stat1 -/- and stat2 -/- compared to wt microglia. However, also IFNβ levels
in response to poly I:C were significantly lower in the absence of STAT1 or STAT2. As already described
in chapter 5.2, this could be causative for alterations in CCL2 release. IFNβ is a potent inducer of this
chemokine (McManus et al. 2000; Fantuzzi et al. 2001), which we also observed in stat1 -/- and stat2 -/-
microglia (data not shown). Furthermore, impaired IFNβ production correlates with dysregulation of
CCL2 (Janova et al. 2016). So similar to what was described for IFNAR1 deficiency, it could not be
concluded whether altered CCL2 release by poly I:C-stimulated stat1 -/- and stat2 -/- microglia is due to
deficiency in the respective transcription factor or caused by the low IFNβ levels.
Concerning responses to TLR4, it was already indicated that STAT1 and STAT2 play an important role
as stated above. Indeed, this could be proven in both knock-out systems. In line with our observations
regarding IFNAR and janus kinases, STAT1 and STAT2 deficiency resulted in increased CXCL1 and de-
creased CCL2 production. However, a partially impaired IFNβ release was present, but only in stat1 -/-
microglia. Thus, we had to rule out that alterations in IFNβ levels affect the chemokine release by these
cells. Therefore, we evened out these differences by addition of high amounts of exogenous IFNβ,
which by far exceeded the intrinsic microglial production. This demonstrated that only wt, but neither
stat1 -/- nor stat2 -/- microglia were highly sensitive to this treatment. While addition of IFNβ dramatically
decreased CXCL1 levels in wt cells, the production by stat1 -/- and stat2 -/- stayed markedly higher than
normal wt levels even in the presence of IFNβ. Since the effect of STAT deficiency on CXCL1 was really
stable, this proves that the minor impairment of IFNβ in stat1 -/- cells cannot account for the observed
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changes in CXCL1 and CCL2 production. This argues for a STAT1- and STAT2-dependent control of
these chemokines.
Nevertheless, we had to consider that no STAT1 / STAT2 double knock-out was available and analyz-
ing deficiency in only one of the transcription factors bears the risk of compensation effects. Such a
phenomenon could lead to still, at least partially, functional transcriptional regulation and would thus in-
terfere with our results obtained in stat1 -/- and stat2 -/- microglia. Besides its ability to form heterodimers
with STAT1, STAT2 is also able to heterodimerize with STAT3 (Hervas-Stubbs et al. 2011). Because
it was shown that STAT3 can be also involved in type I interferon signaling (Yang et al. 1996), we had
to rule out involvement of this transcription factor in regulation of TLR-induced microglial responses.
Thus, STAT3 expression upon either TLR4 or TLR2 stimulation was measured. In contrast to STAT1
and STAT2, its expression was not up-regulated in response to TLR stimulation, indicating that STAT3 is
not activated in this scenario. Apart from that, we had to take into account that STAT1 can also form ho-
modimers (Hervas-Stubbs et al. 2011). This provides the potential for autonomous actions of STAT1 in
the absence of STAT2. Such a compensation would be accompanied by up-regulation of the stat1 gene
in STAT2-deficient cells. However, the expression STAT1 could not be up-regulated in stat2 -/- microglia
by either TLR4 or TLR2 stimulation. The same holds true for STAT2, whose expression remained also
unchanged in stat1 -/- cells. This strongly suggests that STAT1 and STAT2 need to cooperate in order to
exert effects in TLR-stimulated microglia.
Finally, these results clearly show an involvement of STAT1 and STAT2 in responses to TLR4 and ac-
cordingly, both transcription factors are important mediators of the IFNAR-dependent and janus kinase-
mediated regulation of TLR4-triggered chemokine production. In contrast to that, they do not participate
in responses to TLR2 and their contribution to TLR3-induced CCL2 release remains still questionable.
5.7 Type I interferon signaling controls TLR4-induced chemokine
production, while responses to TLR2 are regulated by IFNAR
Altogether, we showed that microglial responses to gram-positive and gram-negative bacteria are indi-
vidually organized. The TLR2 and TLR4 system as exemplary examples for cell surface receptors that
sense bacterial ligands differently utilize parts of the canonical type I interferon signaling pathway for
regulating the production of chemokines. Thus, we want to propose two different mechanisms how type
I interferon signaling controls TLR-induced responses.
TLR2 can be activated by bacterial ligands, such as Pam3CSK4 or MALP-2 (Jin et al. 2007; Takeuchi
et al. 2001). Subsequently, the MyD88-dependent signaling pathway is initiated, which leads to the
production of several cytokines and chemokines (Kawai and Akira 2010). 18 h after stimulation of the
receptor, this includes CXCL1, but not CCL2. In order to control the amount of released CXCL1, another
signaling pathway gets involved. We demonstrated that both subunits of the type I interferon receptor
cooperatively regulate TLR2-induced CXCL1 production. However, we could not identify the respective
ligand, since neither IFNα nor IFNβ was produced upon TLR2 stimulation. One possible explanation
could be low sensitivity of our methods. More likely, the release of another type I interferon apart from
IFNα or IFNβ is triggered by TLR2. Even though we could not identify the respective ligand, IFNAR be-
comes activated in this scenario. Downstream of IFNAR, several signaling pathways could be triggered.
The most prominent is the canonical type I interferon signaling pathway, which involves the kinases Jak1
and Tyk2 as well as the transcription factors STAT1 and STAT2 (Platanias 2005). However, we did not
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find any of these mediators to control TLR2-induced chemokine production. Thus, the canonical type
I interferon signaling pathway seems not to play a role in responses to TLR2. Alternatively, the CRKL,
MAPK or PI3K pathway could be activated by IFNAR (Hervas-Stubbs et al. 2011). However, since they
all require Jak1 and/or Tyk2 for signal transduction (Platanias 2005) and we could not observe involve-
ment of janus kinases in general, it is unlikely that one of these pathways is triggered. However, no
janus kinase-independent pathway downstream of IFNAR could be identified. Thus, it remains enig-
matic how IFNAR regulates responses to TLR2.
In contrast to that, the mechanism for controlling TLR4-induced chemokine levels can be explained con-
siderably better. TLR4 gets activated by the bacterial ligand LPS and also by the DAMP FN (Poltorak
et al. 1998; Hoshino et al. 1999; Okamura et al. 2001). Upon activation, TLR4 triggers the MyD88- and
the TRIF-dependent signaling pathway (Kawai and Akira 2010). In order to initiate the TRIF-dependent
signaling, the TLR4 complex is internalized by CD14-induced endocytosis (Kagan et al. 2008; Zanoni
et al. 2011). The activation of both signaling pathways results in the production of CXCL1 and CCL2
as well as IFNβ. Thereby, as shown by us and also others, the production of IFNβ completely de-
pends on CD14 and TRIF (Yamamoto et al. 2003; Janova et al. 2016). The released IFNβ can bind
to its receptor IFNAR, which initiates the canonical type I interferon signaling pathway. This involves
activation of Jak1 and Tyk2 with subsequent recruitment of STAT1 and STAT2. The two transcription
factors can then either form the ISGF3 complex together with IRF9 and bind to ISREs or bind to GAS,
if they are not associated with IRF9 (Platanias 2005; Li et al. 1996). We could show that the canoni-
cal type I interferon signaling pathway, which is triggered in response to TLR4 activation, controls the
production of TLR4-induced chemokines. While CXCL1 levels are negatively regulated, the release of
CCL2 is positively regulated by this pathway. This provides evidence for a crosstalk between TLR and
IFN signaling. The most important parts of the canonical type I interferon signaling pathway, namely
IFNAR1 and IFNAR2, janus kinases, STAT1 and STAT2, were demonstrated to participate in an IFNβ-
mediated feedback regulation of CXCL1 and CCL2. In this regard, CCL2 expression could be either
controlled by ISGF3 binding to its ISRE or STAT1/STAT2 heterodimer binding to its GAS (Valente et al.
1998; Graves et al. 1999). Within the CXCL1 promoter so far only a GAS was identified, which points
towards a STAT1/STAT2-mediated regulation independent of IRF9 (Burke et al. 2014). Apart from these
direct transcriptional effects, CCL2 and CXCL1 expression could be also indirectly regulated by another
STAT1/STAT2-dependent gene, which controls chemokine expression. As a summary, the proposed
mechanism is shown in Figure 5.1.
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Figure 5.1: Proposed mechanism for the regulation of TLR4-induced chemokine production by the canonical type I
interferon signaling pathway TLR4 gets activated by its ligand, here represented by LPS, and subsequently, the MyD88- and
the TRIF-dependent signaling pathway are triggered. The TRIF-dependent signaling is enabled by CD14-induced endocytosis
of the TLR4 complex. The activation of both signaling pathways induces the production of CXCL1 and CCL2 as well as IFNβ.
Thereby, the production of IFNβ completely depends on CD14 and TRIF. IFNβ can then bind to its receptor IFNAR, which initiates
the canonical type I interferon signaling pathway. This involves activation of Jak1 and Tyk2 with subsequent recruitment of STAT1
and STAT2. Consequently, this pathway negatively regulates CXCL1 and positively regulates CCL2 production. Partially adapted
from O’Neill et al. (2013) and Ivashkiv and Donlin (2014).
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Microglia are the tissue-resident macrophages of the brain parenchyma that serve as first and most
important active immune defense within the CNS. They are equipped with a broad range of different
receptor types in order to sense pathogens and homeostatic disturbances. Among these, TLRs that
recognize highly conserved structures on foreign as well as host molecules play an important role.
Depending on the type of challenge, activation of these receptors triggers different microglial functions
and initiates an appropriate immune response.
Interferons are crucial cytokines for fighting viral, but also bacterial infections and are thus produced in
response to several pathogens. Under different circumstances, microglia were already demonstrated
to produce these immune mediators. We here investigated, which type I interferons can be produced
upon activation of different TLRs. In response to viral infection as mimicked by the TLR3 ligand poly
I:C, we showed that microglia are able to produce high amounts of IFNβ and IFNα. In contrast to
that, only IFNβ was released in response to bacterial ligands and damage-related molecules that are
sensed by TLR4. Surprisingly, bacterial ligands of TLR2 completely failed to induce any type I inter-
feron. However, these differences in interferon production correlated with the differential involvement of
the major TLR signaling routes. While TLR3 signals via the TRIF-dependent pathway and TLR2 uses
the MyD88-dependent pathway, TLR4 activates both signaling cascades. We showed that production of
IFNβ exclusively depends on the presence of TRIF and accordingly, only TLR3 and TLR4 that activate
this signaling adaptor protein triggered IFNβ. Within the TLR4 system, IFNβ release further depended
on the TLR4 co-receptor CD14, which enables access of the receptor complex to TRIF-dependent sig-
naling and therefore allows IFNβ production.
In addition to their important functions in host defense against viral and bacterial infections, various
immunomodulatory effects of type I interferons have been identified. It was previously shown that
microglial chemokine production upon activation of different TLRs can be regulated by IFNβ. Here, we
propose a mechanism how this regulation is achieved. We demonstrated that microglial CXCL1 and
CCL2 release in response to TLR4, TLR2 and TLR3 are controlled by the type I interferon receptor.
While CCL2 was positively regulated by IFNAR, the production of CXCL1 was under negative control of
this receptor. An effect similar to that in microglia was observed in BMDM, while pMΦ reacted partially
different. Accordingly, IFNAR-dependent regulation of chemokine production is not restricted to the
CNS, but still limited to specific immunological niches.
Within the TLR4 system, the regulatory effect of IFNβ involved all important parts of the canonical type
I interferon signaling pathway. We proved that both type I interferon receptor subunits, IFNAR1 and
IFNAR2, cooperatively regulate CXCL1 and CCL2 production. This regulation was mediated by janus
kinases and further utilized the transcription factors STAT1 and STAT2. Within the TLR2 system, only
IFNAR1 and IFNAR2 participated in the regulation of CXCL1 production by a signaling cascade that
could not be further identified. This reveals an individual organization of responses to different TLRs
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under the control of distinct type I interferon signaling pathways.
Apart from identification of these regulatory mechanisms, we also demonstrated their relevance during
CNS infection. In a model of gram-negative bacterial meningitis, type I interferon signaling controlled
immune cell infiltration and thus, could shape disease outcome. In the absence of IFNAR1, excessive
amounts of neutrophils were present in the brain of infected animals, which could lead to further dam-
age of the tissue. In contrast to that, neutrophil infiltration in models of gram-positive bacterial meningitis
and the autoimmune disease NMO were independent of IFNAR1. This highlights the specificity of type
I interferon involvement in different diseases of the CNS.
Overall, this thesis shows that type I interferons are important regulators of microglial responses to
CNS infection and damage. Upon recognition of harmful threats by different TLRs, microglia are potent
producers of several type I interferons. At the same time, they are targeted by these immunomodulatory
molecules in order to regulate the outcome of their immune responses, including chemokine production
and subsequent recruitment of peripheral immune cells. The regulatory effect on different TLR systems
is mediated by individual signaling pathways, which indicates a heterogeneous organization of microglial
responses and shows the complexity of interferon actions. This understanding of distinct mechanisms
by which type I interferons exert their functions could establish a basis for further unraveling the complex
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González-Navajas, J. M., J. Lee, M. David, and E. Raz (2012). “Immunomodulatory Functions of Type I
Interferons”. In: Nat. Rev. Immunol. 12.2, pp. 125–135.
Gough, D. J., N. L. Messina, C. J. P. Clarke, R. W. Johnstone, and D. E. Levy (2012). “Constitutive Type I
Interferon Modulates Homeostatic Balance through Tonic Signaling”. In: Immunity 36.2, pp. 166–174.
Grafi, G., I. Sela, and G. Galili (1993). “Translational Regulation of Human Beta Interferon mRNA: As-
sociation of the 3’ AU-Rich Sequence with the poly(A) Tail Reduces Translation Efficiency in Vitro”.
In: Mol. Cell. Biol. 13.6, pp. 3487–3493.
Graves, D. T., Y. Jiang, and A. J. Valente (1999). “The Expression of Monocyte Chemoattractant Protein-
1 and Other Chemokines by Osteoblasts”. In: Front. Biosci. 4, pp. D571–580.
Hamilton, J. A., G. A. Whitty, I. Kola, and P. J. Hertzog (1996). “Endogenous IFN-Alpha Beta Suppresses
Colony-Stimulating Factor (CSF)-1-Stimulated Macrophage DNA Synthesis and Mediates Inhibitory
Effects of Lipopolysaccharide and TNF-Alpha”. In: J. Immunol. 156.7, pp. 2553–2557.
Hanisch, U.-K. (2002). “Microglia as a Source and Target of Cytokines”. In: Glia 40.2, pp. 140–155.
Hanisch, U.-K., T. V. Johnson, and J. Kipnis (2008). “Toll-like Receptors: Roles in Neuroprotection?” In:
Trends Neurosci. 31.4, pp. 176–182.
Hanisch, U.-K. and H. Kettenmann (2007). “Microglia: Active Sensor and Versatile Effector Cells in the
Normal and Pathologic Brain”. In: Nat. Neurosci. 10.11, pp. 1387–1394.
Hardy, M. P., C. M. Owczarek, L. S. Jermiin, M. Ejdebäck, and P. J. Hertzog (2004). “Characterization
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Uzé, G., G. Lutfalla, and I. Gresser (1990). “Genetic Transfer of a Functional Human Interferon Alpha
Receptor into Mouse Cells: Cloning and Expression of Its cDNA”. In: Cell 60.2, pp. 225–234.
Valente, A. J., J. F. Xie, M. A. Abramova, U. O. Wenzel, H. E. Abboud, and D. T. Graves (1998). “A Com-
plex Element Regulates IFN-Gamma-Stimulated Monocyte Chemoattractant Protein-1 Gene Tran-
scription”. In: J. Immunol. 161.7, pp. 3719–3728.
Van Rompaey, L., R. Galien, E. M. van der Aar, P. Clement-Lacroix, L. Nelles, B. Smets, L. Lepescheux,
T. Christophe, K. Conrath, N. Vandeghinste, B. Vayssiere, S. De Vos, S. Fletcher, R. Brys, G. van ’t
Klooster, J. H. M. Feyen, and C. Menet (2013). “Preclinical Characterization of GLPG0634, a Selective
Inhibitor of JAK1, for the Treatment of Inflammatory Diseases”. In: J. Immunol. 191.7, pp. 3568–3577.
Van Furth, R. and Z. A. Cohn (1968). “The Origin and Kinetics of Mononuclear Phagocytes”. In: J. Exp.
Med. 128.3, pp. 415–435.
Van Pesch, V., H. Lanaya, J.-C. Renauld, and T. Michiels (2004). “Characterization of the Murine Alpha
Interferon Gene Family”. In: J. Virol. 78.15, pp. 8219–8228.
Velazquez, L., K. E. Mogensen, G. Barbieri, M. Fellous, G. Uzé, and S. Pellegrini (1995). “Distinct
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